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Malaria and tuberculosis are ancient diseases that continue to have a profound impact on 
mankind, 5 millennia after their first documentation. Malaria is endemic in more than 100 
countries and about 50% of the world’s population is at risk of infection. Sub-Saharan Africa 
accounts for nearly 91% of malaria-related deaths annually. Tuberculosis on the other hand 
infects about one third of the world’s population and is the second major cause of death in 
adults worldwide, with about 1.8 million deaths reported annually. The major challenge to the 
control of these diseases has been the rapid emergence of multi-drug resistant strains to the 
currently administered drugs, as such, these exert an enormous pressure on health care 
systems, especially in resource-limited areas. Alleviation of this pressure requires the 
development of highly efficacious new chemical entities (NCEs) to curb or manage these 
pathogens. The main aim of this study was to design NCEs based on the quinoline-, PA-824-, 
and tetrazole-scaffolds, which exhibit in vitro antiplasmodial and antimycobacterial activity. 
A series of quinoline-based compounds bearing the deoxyamodiaquine-, chloroquine-, 
primaquine-, and 4-arylamino quinoline-tetrazole scaffolds were rationally designed, profiled 
in silico and synthesized via the modified TMSN3-Ugi multi-component reaction (MCR) 
strategy. These were then evaluated for antiplasmodial activity against the chloroquine-
resistant (K1 and W2) and chloroquine-sensitive (3D7) strains of P. falciparum, as well as for 
antimycobacterial activity against the drug sensitive H37Rv strain of M. tuberculosis.  
 
In the deoxyamodiaquine series, the designed target compounds were profiled in silico to 
have predicted aqueous solubilities that were comparable to amodiaquine at both pH 5.0 and 
7.5. Furthermore, all the proposed compounds were predicted to have acceptable Caco-2 
permeation and intermediate hepatic metabolic stabilities. The in silico aqueous solubility 
predictions were compared to and/or verified with experimentally determined solubility 












In this series, compounds 3.9a-f, 3.9k and 3.10c (IC50 values ranging from 0.040 to 0.194 
µM) were more potent than amodiaquine in both K1 and W2 strains. Also, compounds 3.9b-c 
and 3.9k exhibited greater in vitro potency than chloroquine in the K1 strain, while only 
compound 3.9k was also more active than chloroquine in the W2 strain. These compounds 
also possessed potent antimycobacterial activity, with compounds 3.9a, 3.9c-f inhibiting over 
90% of the replicating bacteria. Against the non-replicating persistent form of the bacteria, 
compounds 3.9a (MIC90 =118.7 µM), 3.9c (MIC90 = 74 µM) and 3.9k (MIC90 = 15.1 µM) 
were the most active.  
 
In the chloroquine-like series, of the 14 compounds tested against K1 strai , 6 showed greater 
activity than chloroquine, the most active compound, 3.15a5 (IC50 = 0.001 µM), was 36-fold 
more active than the reference drug. Against the W2 strain, almost all the compounds tested 
were more active than chloroquine except compound 3.15a1, which was 1.2 times less active. 
Moreover, compounds 3.15a3-a5 completely inhibited the growth of the replicating bacteria, 
with MIC90 values in the range of 5.6 to 14.3 µM. Additionally, compounds 3.15a3 and 
3.15a4 were also active against the non-replicating bacteria, while also exhibiting better 
activity than two standard TB drugs, isoniazid and moxofloxacin.  
 
Primaquine-based compounds showed modest activity against the K1 strain. The most active 
compound in this series was 3.19d (IC50 = 1.311 µM), which was 2 times less active than 
primaquine. However, none of these compounds showed any (MIC90 >160 µM) activity 
against the M. tuberculosis H37Rv strain.  
 
The 4-arylamino quinoline derivatives did not show significant activity against K1 strain 
except compounds 4.12a (IC50 = 1.310 µM) and 4.12f (IC50 = 1.228 µM). Also, none of these 
compounds inhibited the growth of the W2 strain at the highest concentration (IC50 > 10 µM) 












µM). Furthermore, compounds 4.12b (MIC90 = 123.2 µM) and 4.12d (MIC90 = 92.5 µM) 
were the only ones in this series that exhibited inhibitory activity against the non-replicating 
and replicating M. tuberculosis bacteria, respectively. 
 
The majority of the designed PA-824 derivatives were predicted to have improved aqueous 
solubilities than PA-824 at both pH 5.0 and 7.5. However, some of these derivatives were 
also predicted to have an affinity for binding to proteins and were susceptible to hepatic 
metabolic degradation. In addition, these compounds, including PA-824, were predicted to 
have acceptable Caco-2 permeation. As before, in silico aqueous solubility predictions were 
compared to and/or verified with experimentally determined kinetic solubility studies of key 
compounds. Among the PA-824 derivatives, the PA-824-aminoquinoline hybrids were the 
most active against the K1 strain, with hybrids 4.19d (IC50 = 0.100 µM) and 4.19f (IC50 = 
0.164 µM) being more active than chloroquine. In addition, all the tested hybrids were more 
efficacious than mefloquine. Finally, these PA-824 derivatives exhibited potent 
antimycobacterial activity with MIC90 values between 0.25-125 µM. All these compounds 
were more active than kanamycin and streptomycin, standard TB drugs, in the 7 and 14 day 
assays.  
 
Lastly, a limited number of β-lactams were synthesized via the Staudinger reaction, 
demonstrated activity against K1 strain. The most active compound, 4.22c (IC50 = 0.209 µM), 
had comparable to the activity to chloroquine. Additionally, these β-lactams were inactive 















ACT  Artemisinin Combination Therapy 
ADME(T)  Absorption, Distribution, Metabolism, Excretion (Toxicity) 
BBB  Blood-Brain Barrier 
n-BuLi  n-Butyl lithium 
CaH  Calcium hydride 
CDCl3  Deuterochloroform 
CHCl3  Chloroform 
13
C NMR  Carbon Nuclear Magnetic Resonance 
CYPs  Cytochrome P450 isozymes 
DCM  Dichloromethane 
DFV  Digestive food vacuole 
DMF  Dimethylformamide 
DMPK  Drug Metabolism and Pharmacokinetics 
DMSO  Dimthylsulfoxide 
DNA  Deoxyribonucleic acid 
DOTS  Directly Observed Therapy, Short-course 
ESI  Electron Spray Ionization 
Et3N  Triethylamine 
EtOAc  Ethylacetate 
EtOH  Ethanol 
FGI  Functional group interconversion 
HIV  Human Immunodeficiency Virus 
1
H NMR  Proton Nuclear Magnetic Resonance 
HPLC  High Pressure Liquid Chromatography 
IC50  50% Inhibitory Concentration 
IR  Infrared 
KBr  Potassium bromide 
LORA  Low Oxygen Recovery Assay 
MABA  Microplate Alamar Blue Assay 
MCR  Multi-Component Reaction 
MDR  Multi-drug resistant 
MIC90  90% Minimum Inhibitory Concentration 












MeOH  Methanol 
m.p.  Melting point 
MS  Mass Spectroscopy 
m/z  mass to charge ratio 
NaH  Sodium Hydride 
PB  Protein Binding 
PBr3  Phosphorus tribromide 
PBS  Phosphate buffered saline 
Pgp  P-glycoprotein 
PfCRT  Plasmodium falciparum Chloroquine Resistance Transporter  
Pfcrt  Plasmodium falciparum chloroquine resistance transporter gene 
PfMDR1  Plasmodium falciparum Multi-Drug Resistance-1 Transporter  
Pfmdr1  Plasmodium falciparum multi-drug resistance-1 transporter gene 
PK  Pharmacokinetics 
PM  Plasmepsin 
POBr3  Phosphorus oxy-tribromide 
ppm  Parts per million 
Py.SO3  Pyridine sulphur trioxide 
Rf  Retention factor 
Rt  Retention time 
RI  Resistance Index 
SAR  Structure-Activity Relationships 
TB  Tuberculosis 
TDR  Totally-Drug Resistant 
TMSN3  Trimethylsilane azide 
WHO  World Health Organization 
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1.1.1 Historical overview  
Malaria is an ancient disease that has had a profound impact on the history of mankind for 
over 5000 years.
1
 The first documented evidence of the disease characterized by intermittent 
fevers and enlargement of the spleen dates as far back as 2700 BC in the Chinese medical 
writings, Nei Ching (the canon of medicine), and in the Egyptian, Greek and Hindu texts in 
about 400 BC.
2,3
 For some time malaria fevers were believed to be caused by poisonous 
vapors that arose from swamps and stagnant water. As a result of this ancient belief the word 
malaria derived from a Roman term “mal aria”, which directly translates to “bad air” was 
adopted as the name for this disease. 
 
The search for the cause of malaria intensified in the 19
th
 century resulting in major advances 
and discoveries. In 1847, a German pathologist, Heinrich Meckel observed the presence of 
black-brown granules (Haemozoin) in the blood and spleen of patients who died of fever but 
did not link these observations to malaria.
4
 In 1880 the true cause of malaria was identified to 
be a protozoan parasite by Charles Louis Alphonse Laveran.
2 
Subsequent to this great 
discovery, Ronald Ross and Giovanni Battista Grassi identified the mosquito as the vector for 
both human and bird malaria.
2 
Both Ross and Laveran were awarded the Nobel prize in 1902 
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1.1.2 Global distribution  
Malaria remains one of the most important health and economic burdens facing the 
developing world. The World Health Organization (WHO) estimates malaria to be endemic 
in more than 100 countries and about 50% of the world’s population is at risk of infection 
worldwide.
5
 Although malaria is a global problem, more than 70% of the total morbidity is in 
Africa, followed by some parts of Asia and Latin America (Fig. 1.1 and Table 1.1).
6,7a,7b
 The 
global distribution pattern suggests this disease is centered in the tropical and sub-tropical 
regions where the conditions are conducive for the survival and multiplication of the vector 
mosquitoes. To date, over 255 million new infections and 781 000 deaths are reported 
annually, 91% of which occur in sub-Saharan Africa, mostly to children under the age of 5 
years and pregnant women.
8,9a,9b
 These staggering mortality figures are exacerbated by co-
infection with other opportunistic diseases such as human immunodeficiency virus (HIV) and 
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Table 1.1: Estimated malaria incidence and deaths by region, 2009 (adapted from the US 




WHO Region (No. of 
Endemic Countries) 
Estimated No. (%) of 
Malaria Cases, 2009  
Estimated No. (%) of 
Deaths, 2009 
Global Total (106)  225 million (100%) 781,000 (100%) 
Africa (43) 176 million (78%) 709,000 (91%) 
South-East Asia (10) 34 million (15%) 49,000 (6%) 
Eastern Mediterranean (12) 12 million (5%) 16,000 (2%) 
Western Pacific (10) 2 million (1%) 5,300 (1%) 
Americas (23) 1 million (<1%) 1,300 (<1%) 
Europe (8) 1 million (<1%) 0 
 
1.2 Malaria vector and Plasmodium falciparum 
Malaria is a parasitic blood infection caused by the intracellular-protozoan parasite belonging 
to the genus Plasmodium. It is transmitted from one human to another by the blood-feeding 
female Anopheles mosquitoes.
3,11
 There are currently 41 known Anopheles mosquito species 
and sub-species complex worldwide that are implicated as vectors of Plasmodium falciparum 
malaria, Anopheles gambiae being the most important and efficient.
12
 This species feeds 
predominantly on humans and has a longer life span compared to other mosquitoes. The 
genome sequence of the Anopheles gambiae was recently completed by Holt et al.,
13
 in 2002. 
 
The Plasmodium genus is comprised of unicellular protozoan parasites and currently there are 
156 different known species, and among these, P. falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi are the only known species able to cause human malaria.
14
 P. falciparum is 





1.2.1 Life cycle of the Plasmodium falciparum  
The understanding of malaria parasite biochemistry and molecular biology over the last two 
decades increased extensively. The highlight of which was the full disclosure of P. 
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mechanisms that the parasite uses during host-cell invasion.
16,17
 The life cycle of the 
Plasmodium parasite alternates between a human host (asexual reproduction) and the 








Asexual reproduction: When an infected Anopheles female mosquito feeds on humans it 
injects saliva containing infective worm-like, unicellular organelles called sporozoites into 
the bloodstream (1, Fig. 1.2). These sporozoites rapidly migrate to the liver where they 
invade hepatocytes. Here they undergo replication that results in the production of 
uninucleate merozoites (2-3 and 4, Fig. 1.2). At this stage, the pre-erythrocytic stage, the 
human host is asymptomatic. After a period of about 9-16 days (depending on the infecting 
species), the hepatocytes burst releasing merozoites into the bloodstream where they invade 
red-blood cells and initiate the second phase of asexual multiplication (erythrocytic 
schizogony) (5, Fig. 1.2).
14
 The merozoites undergo differentiation into early trophozoites 
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The erythrocyte cytoplasm is ingested and haemoglobin digested to form multinucleated 
schizonts. Haeme, the by-product of this haemoglobin digestion, is toxic to the parasite and 
as a result the parasite has developed a detoxification mechanism of converting the toxic 
material to an insoluble non-toxic haemozoin. The rupture of the schizont-containing 
erythrocyte releases merozoites into the bloodstream, which invade other red blood cells or 
differentiate into gametocytes, the male and female sexual forms (6-7, Fig. 1.2). The human 




Sexual reproduction: The gametocytes circulating in the bloodstream are taken up by 
another female mosquito feeding on an infected human (8, Fig. 1.2). Upon entering the 
stomach of the mosquito, the parasite receives environmental signals such as temperature 
drop and pH increase, which indicate a switch from a warm-blooded host to an insect 
vector.
19
 The gametocytes mature into male and female gametes. Fertilization occurs forming 
zygotes and then ookinetes which penetrate the gut wall to become oocysts (9-10, Fig. 1.2).
20
 
The mature oocysts in the body cavity of the mosquito rupture to release infectious 
sporozoites, which migrate to and infect the mosquito salivary gland. Release of sporozoites 
in the next blood meal restarts the cycle (11, Fig. 1.2). 
 
1.3 Targets for Antimalarial Chemotherapy 
Certain phases of the parasite life cycle reveal various critical biological processes that are 
essential for the survival and development of the parasite. Mapping of the P. falciparum 
genome has contributed considerably in the identification and elucidation of these processes 
as potential drug targets. Many of these have been validated and shown to be localized inside 




 the acidic 
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1.3.1 Biochemistry of the parasite digestive food vacuole (DFV) 
The digestive, lysosomal food vacuole is an acidic (pH 5.2-5.8) single-membrane organelle 
that is unique to the genus Plasmodium.
26,27
 Electron microscopy (EM) studies suggest that 
the formation of the DFV occurs immediately after the erythrocyte invasion through the 
coalescing of several cytostomic-derived vesicles, sometimes known as small vacuoles.
27,28,29
 
The formation of these cytostomic-derived vacuoles is mediated by the double-membrane 
endocytic invagination called the cytostome.
29
 This cytostome is in turn made from the 
merozoite surface protein 1 (MSP1) of the parasitophorous vacuolar membrane.
30,31
 
Merozoite surface proteins protect the infective merozoites from attack by the host’s immune 
system while they are circulating in the bloodstream. In addition, these merozoite surface 
proteins also play a significant role in the initial recognition and attachment to the red-blood 
cells.
14
   
 
The digestive food vacuole of the malaria parasite is a site for a number of biochemical 
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are haemoglobin degradation and haeme polymerization, only the former will be discussed in 
this report. 
 
1.3.2 Haemoglobin degradation 
The malaria parasite has a limited ability to synthesize its own amino acids for proliferation.
32
 
During the intraerythrocytic stage of its life cycle the parasite degrades about 80% of the host 
haemoglobin to create space for growth, as a source of amino acids required for protein 
synthesis and in maintaining osmotic stability.
28,30,33
 Haemoglobin degradation is believed to 
be a semi-ordered sequence of proteolytic events involving various DFV-residing protease 
enzymes such as: (i) the aspartic plasmepsin (PM) proteases [PM-I, PM-II and PM-IV and 
five others, and closely related histo-aspartic protease],
34a,34b,34c
 (ii) cysteine falcipain (FP) 
proteases [FP-2, FP-2’ and FP-3],
35,36a,36b
 (iii) metalloprotease [falcilysin],
35
 and (iv) 






The P. falciparum genome project has identified a family of ten aspartic plasmepsin protease 
enzymes that play an important role in the degradation of the erythrocyte haemoglobin.
16
 PM-
I and II initiate the degradation of the native hemoglobin by hydrolyzing the peptide-bond 
between Phe-33 and Leu-34 to generate acid denatured-globin fragments and haeme (Fig 
1.4).
38
 The globin fragments are further broken down by a second set of enzymes, PM-IV to 
PM-10, histo-aspartic protease and cysteine falcipain proteases (FP-2, FP-2’ and FP-3) into 
peptides containing no more than 20 amino acids.
35,37a
 The resulting peptides are hydrolyzed 
further into smaller peptides or oligopeptides of 6-8 amino acids by the metalloprotease 
(falcilysin) and dipeptidyl aminopeptidase which are thought to act downstream in the 
degradation pathway. These oligopeptides are then pumped out of the DFV into the 
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Unlike plasmepsin I-IV, plasmepsin V (PM-V) is not localized to the DFV, but is restricted to 
the endoplasmic reticulum (ER) membrane.
39 
Plasmepsin V is responsible for cleaving the 
Plasmodium Export Element (PEXEL) sequence motif, which is essential for the export of 
200-300 PEXEL-containing parasite proteins into the erythrocyte cytosol.
40,41 
This export of 
parasite proteins allow the parasite to remodel the host cell functions, such as nutrient 
permeation pathway, adhesion to endothelial cells and mechanical stability, and as such PM-




Interruption and/or inhibition of these proteolytic events could have detrimental effects on the 
parasite development and proliferation, thus these present important targets for antimalarial 
chemotherapy. 
 
1.4 The battle for malaria control  
Malaria is complex and difficult to control largely due to the political and socioeconomic 
circumstances of the malaria endemic countries, as well as the highly adaptable nature of the 
Anopheles mosquito and the malaria parasite.
43 
For over half a century the battle for malaria 
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control has been highly successful and is being achieved through reduction and/or eradication 
of the mosquito breeding sites using insecticides.
44,45
 However, given the increase in 
mosquito resistance to most of the currently administered insecticides, there is an urgent need 




In the recent past there have been positive developments in the malaria vaccine research. The 
most encouraging and significant of these developments came from the largest malaria 
vaccine study ever undertaken. RTS,S/AS01, the most advanced vaccine candidate, currently 
undergoing phase III clinical trials showed up to 50% protection against both clinical and 
severe malaria in children between the ages of 5 and 17 months during the 12 months after 
vaccination.
46a,46b 
In addition, this vaccine exhibited acceptable side-effect profiles and could 
be administered safely with other childhood vaccines.
46b 
Although the study is far from being 
concluded, this vaccine has the potential to play a very important role on the burden of 
malaria in young children residing in malaria endemic regions. However, chemoprophylaxis 
and chemotherapy are still the major players in combating malaria infections and will 
continue to be for the foreseeable future. This role is, however, compromised by the limited 
number of the available antimalarial drugs currently in use and the relentless emergence and 
spread of parasite strains that are resistant to these drugs. 
 
1.4.1 Antimalarial chemotherapy  
The majority of the antimalarial drugs currently available today have been in use for over 
three decades and they act on the intra-erythrocytic stage of development.
47
 Many of these 
drugs were not rationally developed, but rather were serendipitously discovered from natural 
products with inherent antimalarial activity.
48
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possessing certain characteristics such as activity against multi-drug resistant parasite strains, 
minimal toxicity and affordability.  
 
1.4.2 Classification of antimalarial drugs 
The majority of the antimalarial drugs in use today can be classified according to the three 
main categories; (i) life-cycle stage upon which they act, (ii) their mode of action and (iii) 
their structural features. 
 
1.4.2.1 Classification according to the life cycle stage  
Antimalarial drugs can be classified as blood schizonticides, tissue schizonticides, 
hypnozointicides and sporontocides or gametocytocides depending on which stage of the life 
cycle they target.
49,50,51 
Blood schizonticides act on the asexual blood form of the parasite by 
inhibiting asexual growth within erythrocytes, whereas tissue schizonticides act on the 
primary tissue of the P. falciparum by killing hepatic schizonts and preventing erythrocyte 
invasion. The “radical cure of malaria”, eradication of both the exo-erythrocytic and intra-
erythrocytic stages of malaria infection, uses both the blood and tissue schizonticidal drugs in 
clearing the parasitaemia caused by P. vivax and P. ovale.
52 
Hypnozointicides kill the 
persistent intrahepatic parasitic forms thus preventing a malaria relapse from the dormant 
parasite. Gametocytocides and sporontocides function by destroying the intra-erythrocytic 
sexual forms of the parasites in the infected human blood and by inhibiting the development 




1.4.2.2 Classification according to their mode of action  
Antimalarial drugs can also be classified according to their mode of action as compounds 
acting on haeme-detoxification, inhibitors of nucleic acids and DNA synthesis, inhibitors of 
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1.4.2.3 Classification according to their structural features 
Structurally, antimalarial drugs can be broadly classified into two groups, namely, “nitrogen-
and “non-nitrogen containing heterocyclic compounds”.
54
 In the following discussion 
antimalarial drugs are grouped according to this classification. 
 
1.4.2.3.1 Nitrogen containing heterocyclic compounds  
This subclass of compounds contains many of the common antimalarial drugs and can further 
be subdivided into two groups, (A) the aminoquinoline and arylamino alcohols, and (B) 
antifolates. 
 
A: Aminoquinoline and arylamino alcohols  
The majority of the aminoquinoline and arylamino alcohols exert their activity during the 
blood stages of the P. falciparum by interfering with the detoxification of haeme, while a few 
of these are also believed to target the hepatic stage.
55,56 
Quinine, chloroquine, amodiaquine, 
piperaquine, primaquine, halofantrine, mefloquine, pyronaridine, lumefantrine and 
tafenoquine are some of the known aminoquinoline and arylamino alcohol drugs (Fig. 1.5).   
 
Chloroquine and amodiaquine are the most common and widely used of all the 4-
aminoquinoline drugs. These blood schizonticidal drugs are effective for the treatment and 
prophylaxis of malaria.
50
 Chloroquine is effective against the erythrocytic forms of all the 
plasmodial species and together with amodiaquine they are believed to act by inhibiting 
haeme dimerization (through the formation of double protonated species in the DVF) and 
haeme-dependent parasitic protein synthesis, although their exact mechanism of action is still 
debated.
54 
The attractive features of chloroquine are its mild side-effects and affordability, 
while its use is hampered by the spread of drug-resistant strains of the parasite. Amodiaquine, 










Chapter 1: Introduction                                                                    
12 
strains of the parasite.
57
 However, their use is restricted because of side effects such as 
hepatotoxicity and agranulocytosis due to amodiaquine, while pyronaridine metabolite causes 
toxicity to neutrophils.
54,58 
Other safety concerns with the 4-aminoquinolines include 
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Figure 1.5: Chemical structures of aminoquinoline and arylamino alcohol compounds. 
The 8-aminoquinoline family of compounds consists of primaquine and tafenoquine, the 
former being the most widely used. Primaquine is the only tissue schizonticidal drug 
currently available for the treatment of P. vivax and it acts by inhibiting the maturation of the 
fertile gametocytes.
8,59 
Primaquine is also used as a chemoprophylactic but its use is 
compromised by its association with hemolytic anaemia in people with glucose-6-phosphate 
dehydrogenase (G6PD) deficiency.
54,57
 Consequently, a less toxic and more active 
primaquine analogue, tafenoquine, was synthesized. Tafenoquine is currently undergoing 
phase (III) clinical trials and has demonstrated activity against all parasitic forms of 
malaria.
54,60 
It is hoped that tafenoquine will someday replace primaquine as the antimalarial 
drug of choice against relapsing malaria. 
 
Another major class of antimalarial drugs is the arylamino alcohol family which can be sub-
divided into quinoline containing, i.e. quinoline-methanols (quinine and mefloquine) and 
non-quinoline-containing (halofantrine and lumefantrine) arylamino alcohols. Quinine and its 
diastereomer, quinidine, originally extracted from the bark of the Peruvian Cinchona tree, 
were the first antimalarial drugs to be used for treating malaria about 400 years ago.
60,61 
The 
schizonticidal quinine drug is still widely used today for the treatment of uncomplicated and 
severe malaria because of the availability of its intravenous preparation.
50,54
 Quinine is 
associated with multiple side-effects such as hypoglycemia and α-adrenergic blocking effect, 




The emergence of the multi-drug resistant strains of the malaria parasite to quinine 
necessitated the development of mefloquine, its synthetic analogue, by the Walter Reed Army 
Institute of Research in 1971.
8
 Mefloquine and halofantrine are both active against 














However, the use of mefloquine is linked to adverse events such as 
sleep and seizure disorders, insomnia and gastro-intestinal disorders.
8,50,57 
Currently, 
mefloquine is used as part of combination therapy with artesunate due to the rapid spread of 
mefloquine-resistance. 
 
B: Antifolate-based drugs 
This class of drugs act by inhibiting the enzymes involved in the folate metabolic pathway of 
the parasite.
26,56 
In addition, the antifolate drugs are thought to inhibit the early phases of the 
parasite liver stage as well as the development of the infective stages in the mosquito.
60
 The 
antifolate drugs include pyrimethamine, proguanil, chlorproguanil, sulphadoxine and dapsone 
(Fig. 1.6). These drugs are usually administered as part of a combination therapy due to the 
rapid emergence and spread of parasite resistance to these drugs.
50,60
 Development of 





Figure 1.6: Chemical structures of antifolate drugs. 
 
Pyrimethamine and sulfadoxine (SP) combination therapy has played a pivotal role in the 
fight against malaria mainly because of its affordability and effectiveness against the drug-
susceptible strains of P. falciparum. However, the use of this combination therapy has been 
limited by the development of the parasite resistance.
8,63 
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1.4.2.3.2. Non-nitrogen containing heterocyclic compounds  
This subclass of antimalarial drugs can also be subdivided into two groups, (A) sesquiterpene 
endoperoxide lactones (artemisinins) and (B) naphthoquinones and antibiotics.  
 
A: Sesquiterpene endoperoxide lactones 
This class of compounds is unique and structurally different from all the other known 
antimalarial drugs, an attractive feature for circumventing resistance and cross-resistance. 
Artemisinin, also known as Qinghaosu, is a sesquiterpene endoperoxide lactone that 
originates from the Chinese herb Artemisia Annua, whose use in China as an antipyretic 
remedy dates as far back as 2000 years ago.
8,54,64
Artemisinin was first isolated in 1971, used 
as an antimalarial a year later in China, and its active principle was identified to be the 1,2,4-
trioxane moiety or the endoperoxide bridge.
50
 The low bioavailability of artemisinin has 
necessitated the development of a number of its synthetic analogues such as the water soluble 
artesunate and lipid soluble dihydroatermisinin, artemether and arteether (Fig. 1.7). All these 
are active against all stages of the P. falciparum life cycle and multi-drug resistant strains.
47,51
 
The one disadvantage of these derivatives is their short half-lives which are associated with 
the high levels of recrudescence following artemisinin-based monotherapy. As such these 
drugs are used as part of the artemisinin-based combination therapy (ACT) with other drugs 
that have longer half-lives and possibly different modes of action to artemisinins in an 
attempt to reduce recrudescence and resistance development.
55 
Although resistance to this 
class of compounds is yet to be observed, there are indications that reveal reduced sensitivity 
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Figure 1.7: Artemisinin-based drugs. 
 
Despite their importance in the fight against malaria, the exact mode of action of artemisinin-
based compounds is still not well understood. However, a number of putative modes of action 
have been reported and in some cases contradicted. The majority of these, however, concur 
that the formation of the C-centred radicals from hemolytic cleavage of the intact 
endoperoxide bridge in the presence of Fe
2+ 
plays an important role.
8,67a,67b,68 
These radicals 
are believed to be involved in the formation of haeme-artemisinin adducts that inhibit 
haemozoin formation.
69
 In addition, these radicals are also postulated to be involved in 
protein alkylation, parasite membrane damage, interference with the mitochondria, inhibition 
of food vacuole cysteinyl proteases and PfATP6, a homologue of the mammalian 
sarco/endoplasmic reticulum Ca
2+
-dependent ATPase (SERCA), resulting in the death of the 
parasite.
8,50,64,68
 Neurotoxicity seem to be the major side-effect of these drugs although this is 




B: Naphthoquinones and antibiotics 
Naphthoquinones (atovaquone and hydrolapachol) is another promising class of antimalarial 
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compounds when they inhibited the growth of P. vivae.
9b
 Atovaquone, initially marketed for 
Pneumocsytis pneumonia,
63
 is active against the multi-drug resistant strains of the malaria 
parasite. It is known to inhibit the parasite mitochondrial respiratory system through the 
mitochondrial electron transport chain.
8
 As a result this interferes with the mitochondrial 
membrane potential.
8,50 
Due to the rapid emergence of resistance to this class of compounds, 
atovaquone is used in combination with other drugs such as proguanil to target the liver stage 
of the parasite.
8,9b
 Rash, fever, vomiting and abdominal pains are some of the side-effects 





Figure 1.8: Naphthoquinones and antibiotics. 
 
Several antibacterial agents are known to possess considerable activity against the eukaryotic 
P. falciparum parasite and as such they represent another interesting class of antimalarial 
drugs. Antibiotics with antimalarial activity such as tetracycline, doxycycline, clindamycin 
and azithromycin have been used to treat multi-drug resistant strains of the malaria parasite 
for over thirty years (Fig. 1.8).
70 
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immediate killing effect during the first intracellular asexual replication cycle of the parasite, 





Tetracycline, a secondary metabolite from Stremptomyces actinobacteria, is believed to act 
against the mitochondrion by inhibiting protein synthesis while its derivative, doxycycline, 
acts by blocking the expression of apicoplast genes.
8,50 
Because of their slow acting effect, 
these antibiotics can be used prophylactically as a single agent or in combination with the fast 
acting antimalarial drugs.
50,72 
Azithromycin and clindamycin are known to have excellent 
safety profiles in pregnant women and they target the 50S ribosomal subunits of the 
apicoplast and further inhibit the polypeptide development, and subsequently protein 
synthesis.
8,72
 However, the use of tetracycline and doxycycline is impaired by side-effects 





1.5 Antimalarial drug resistance  
Drug resistance, including multi-drug resistance, has been highlighted as one of the major 
contributing factors to malaria resurgence and malaria-induced morbidity and mortality.
49
 
Antimalarial drug resistance is defined as the “ability of the parasite strain to survive and/or 
multiply despite the administration or adsorption of a drug given in doses equal to or higher 
than the usually recommended; but within tolerance of the subject”.
54 
The drug in question 
must “gain access to the parasite or the infected red blood-cell for the duration of the time 
that is necessary for its action”.
73 
Malaria parasite resistance arises as a result of overuse of 
antimalarial drugs for prophylaxis, inadequate or incomplete therapeutic treatments of active 
infections, high level of parasite adaptability at the genetic or metabolic levels, and the 














Resistance to all currently available antimalarial drugs emerged during 
the last three decades, the exception being the artemisinin derivatives although there have 
been reports of reduced in vitro susceptibility to artemether.
65
 The exact molecular 
mechanism of resistance has been a matter of debate, thus the following discussion will be 
limited to the universally accepted mechanisms of resistance to the aminoquinoline and 
arylamino alcohols only  
 
1.5.1 Mechanism of resistance of aminoquinolines and arylamino alcohols 
Development of resistance of the malaria parasite to quinoline-based antimalarial drugs was 
first observed in 1910 to quinine then in 1957 to chloroquine in Thailand, by 1988 it had 
spread to the major parts of the sub-Saharan Africa.
74 
As early as the 1960s, it was observed 
that chloroquine resistant parasites exhibit lower levels of drug inside the digestive food 
vacuole (DFV) when compared to their sensitive counterparts.
55
 This is an indication that the 
parasite is capable of either accumulating less drug or increasing its efflux.
 
This ability of the 
parasite to accumulate low drug concentrations inside the DFV is facilitated by three major 
genes; P. falciparum chloroquine resistant transporter (pfcrt), P. falciparum multi-drug 




 exchanger (pfnhe) genes which are located in 




Parasites with the point mutation at position 76 of the pfcrt gene have been shown to expel 
chloroquine at a much higher rate than those without.
68
 The PfCRT protein is a ten 
transmembrane-domain transporter that belongs to the superfamily of transporters called drug 
and metabolite transporters (DMT), located in the membrane of the DFV of the parasite.
77 
Recent studies pointed out that mutations in the pfcrt gene alone are insufficient for 
chloroquine resistance and as such mutations in the pfdmr1 and pfnhe genes were also 
implicated, suggesting a multi-genic process.
55,78 
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membrane transporter protein known as the P. falciparum multi-drug resistance-1 transporter 
(PfMDR1) which is linked to the overexpression and/or presence of the P-glycoprotein 
homologue 1 that resemble the mammalian Pgp.
51,75
 Mammalian Pgp are suspected of 
“pumping out” a number of drugs in chemo-resistant mammalian cell-lines resulting in drug 
resistance.
55 
Amplification of the pfdmr1 gene is implicated as one of the major modulators of 
resistance for the arylamino alcohols and for the reduced sensitivity of artemisinins.
50,75 
Lastly, the gene pfnhe, also known to play a crucial role in the resistance of quinoline 




 exchanger (NHE), the second 




1.5.2 Strategies used to avert and manage drug resistance 
The 17
th
 meeting of the Roll back Malaria (RBM) consortium devised the following 
strategies in counteracting the emergence and spread of antimalarial drug resistance; (i) use 
of combination therapy, (ii) use of parasite-resistance reversers, (iii) drug-repositioning, and 
(iv) rationally designing analogues of the currently administered drugs in such a way that 
cross-resistance is circumvented.
63,80 
The rationale behind the use of combination therapy is 
well documented in the treatment of other diseases such as HIV and Tuberculosis.
54
 This 
concept is based on the synergistic or additive potentials of two or more drugs with different 
modes of action, different mechanisms of resistance and acting on different targets of a 
particular disease.
54,68 
In 2001 the WHO issued guidelines for the treatment of malaria, and 
among these was the recommendation of using artemisinin-based combination therapy (ACT) 
to treat uncomplicated P. falciparum malaria.
48,81 
ACT increases the rate of clinical and 
parasitological cure, and also reduces the probability of drug resistance development.
68 
However, the emergence of resistance to some ACT combinations is posing a big threat to 













Chapter 1: Introduction                                                                    
21 
Another interesting approach that has recently garnered support is the use of previously 
effective antimalarial drugs in combination with compounds that are known to reverse 
parasite resistance to those drugs.
75
 This strategy uses compounds with weak antimalarial 
activity such as calcium channel blockers, antidepressants drugs (e.g. desipramine), 





1.6 Tuberculosis  
Tuberculosis (TB) is a curable and preventable ancient disease that has plagued humankind 
throughout history. The earliest recorded evidence of this disease comes from the 9000 year-
old skeletal fossils found in the Neolithic settlements of the Eastern Mediterranean.
82 
TB is 
associated with skeletal abnormalities (Pott’s disease) and has long been found in Egyptian 
mummies dating back as far as 5000 years.
83 
In addition, early texts found in India and China 
depicting a disease with TB characteristics suggests the disease occurred around these parts 




1.6.1 A Global Epidemic 
One third of the world population harbour the latent form of TB and this poses a risk of 
disease reactivation in immunocompromised individuals such as those co-infected with the 
human immunodeficiency virus (HIV).
84
 TB is the second major cause of death due to an 
infectious disease in adults worldwide, most severely felt in poverty stricken areas such as 
Asia and Africa.
85
 This airborne disease is spread through sneezing and coughing, and it 
predominantly affects the lungs (pulmonary TB) but it can also affect other parts of the body 
(extrapulmonary TB). The 2011 WHO report estimates 9.2 million new cases of TB and 1.8 
million deaths among HIV-negative people and an additional 0.35 million from HIV-assisted 
TB deaths annually (Fig. 1.9).
86
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Saharan Africa, accounting for 79% of the worldwide disease burden and more noticeably 
25% of these are found in South Africa alone.
87 
In 1993, the WHO declared TB a global 
emergence and in an attempt to stem the tide on drug-susceptible TB, the directly observed 
therapy, short-course (DOTS) was launched in 1994. In this therapy patients are observed 
taking the drugs until completion of the course.
88 
However, despite the adoption of DOTS 
strategy, treatment success in some areas remains low due to poor management of TB control 
programs and patient non-compliance.
88                   
 
 




The burden of TB is not only compounded by its synergy with HIV/AIDS but also by the 
widespread emergence of multi-drug resistant (MDR), extensive-drug resistant (XDR) and 
totally drug-resistant (TDR) strains of the disease.
85
 MDR-TB is defined as the TB infection 
caused by the strain of the disease that is resistant to at least two (i.e. isoniazid and 
rifampicin) powerful first-line anti-TB drugs while XDR-TB denotes MDR-TB with 
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drugs (kanamycin, amikacin, etc).
89 
In 2010 there were 650 000 estimated cases of MDR-TB 
and its current treatment (DOTS-plus strategy) can take anything from 1.5 to 2.5 years while 




1.6.1.1 Mycobacterium tuberculosis 
Tuberculosis (TB) is caused by a group of closely related bacterial species belonging to the 
genus Mycobacterium and to the family of Mycobacteriaceae.
91
 There are currently 85 
species known to belong to this genus; Mycobacterium tuberculosis is responsible for the 
majority of all TB cases but other species such as Mycobacterium bovis, Mycobacterium 
africanum, Mycobacterium microtti and Mycobacterium canetti are also known to cause TB 
but this is not common.
92,93,94 
Discovered in 1882 by Robert Koch, Mycobacterium 
tuberculosis is a slow-growing rod-shaped intracellular organism enclosed by a 
mycobacterial cell envelope.
95 
This envelope is composed of a cell wall, a capsule-like layer 
and the cytoplasmic membrane which accommodates enzymes required for metabolic 
processes including energy generation.
91 
The cytoplasmic membrane is surrounded by a cell 
wall that protects cell contents, provides mechanical support and is responsible for the 
characteristic shape of the bact rium.
96
 The cell wall consists of a capsule, a core and an inner 
membrane (Figure 1.10).
97 
The capsule is made up of free lipids and mycolates 
(phosphatidylinosistol, PIMs, and lipoarabinomannan, LAM), while the core is composed of 
N-glycolylated peptidoglycan linked to a heteropolyscharide, the D-arabino-D-galactan, 





In addition, the core also contains porin proteins which are responsible for passive diffusion 
of aqueous solute through the mycolic acid layer .
91,96
 The majority of TB drugs target the 
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1.6.2 Current status of chemotherapy and biological targets 
TB is one of the most challenging infectious diseases to treat mainly due to the long treatment 
term prone to patients’ non-compliance and subsequently, the emergence of MDR-TB and 
XDR-TB.
92
 The DOTS strategy used to treat drug-susceptible Mycobacterium tuberculosis is 
initiated by taking a multidrug therapy consisting of the four first line drug combinations 
(isoniazid, pyrazinamide, ethambutol and rifampicin or streptomycin) over a period of 2 
months (Fig. 1.11). These drugs target and act on the replicating and the semi-dormant 
infective bacilli and in the process reduce the bacterial population by about 95%, thereby 
decreasing the potential for TB transmision.
99
 This phase is followed by a further 4 months of 





Isoniazid, the most powerful mycobactericidal drug, exerts its activity by inhibiting mycolic 
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bacterial RNA polymerase enzyme.
85,100
 Pyrazinamide functions by lowering the pH of the 
intracellular environment thus inactivating the fatty acid synthase enzyme, while ethambutol 
inhibits arabinosyl transferase involved in the cell wall synthesis.
100
 Streptomycin on the 





Figure 1.11. Chemical structur s of the first-line anti-TB drugs. 
 
The first-line anti-TB drug therapy is inadequate against MDR-TB and as such effective 
second-line drugs were introduced (Figure 1.12).
94
 Although these second-line drugs are used 
to treat MDR-TB for a period of up to 2 years, they are less effective, toxic and more 
expensive compared to the first–line drugs.
92
 Cycloserine inhibits cell wall biosynthesis, 
ethionamide inhibits lipid biosynthesis and cell wall assembly, and fluoroquinolones 
(moxifloxacin, gatifloxacin and levofloxacin) act by inhibiting DNA topoisomerase and DNA 
gyrase enzymes which are responsible for DNA replication.
92,94 
p-Aminosalicylic acid is 
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Campreomycin inhibits protein synthesis while aminoglycosides (kanamycin and amikacin) 
inhibit protein synthesis by binding to the 16S rRNA of the bacterial 30S ribosomal subunit, 
resulting in mycobacterial cell death.
85,102
 Although difficult to treat, XDR-TB can be 
successfully managed using the third-line anti-TB drugs, the cure rate currently ranges from 
30 to 75%.
85
 Third-line drugs are currently poorly understood since few in vivo human 





Figure 1.12. Chemical structures of the second-line anti-TB drugs. 
 
TB chemotherapy has its shortcomings and the four widely accepted primary objectives for 
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(ii) improving treatment efficacy, safety and duration for drug-resistant TB, (iii) avoiding 
drug-drug interactions and improving the safety of co-therapy for TB patients co-infected 




There are currently a number of different classes of compounds undergoing clinical 
development with the aim of addressing the four primary objectives mentioned above. These 
include nitroimidazooxazines (lead compound; PA-824),
103
 diaryquinolines (lead compound; 
TMC207),
104
 oxazolidinones (lead compounds; eperezolid and linezolid),
105 
and 
ethylenediamines (lead compound; SQ109) (Fig. 1.13).
97 
Nitroimidazooxazines inhibit cell 
wall lipids and protein synthesis and diarylquinolines are active against drug-resistant strains 
and they inhibit membrane bound ATP synthase.
85,93
 Oxazolidinones inhibit protein synthesis 
by binding to bacterial 20S rRNA of the 50S ribosomal subunits, and ethylenediamines target 
cell wall synthesis.
99  
   
 
 













Chapter 1: Introduction                                                                    
28 
1.6.3 Mechanism of drug resistance  
The emergence of anti-TB drug resistance is a serious problem for TB control programs and 
is attributed to two factors; (i) erroneous prescribing practices by clinicians, and (ii) 
inappropriate and irregular intake of medication by patients.
105 
In 2008, a global project for 
anti-TB drug resistance surveillance reported prevalence of drug resistance of more than 10% 
in 30 countries and also identified 14 countries with prevalence for MDR-TB strains.
106,107 
The majority of resistance towards isoniazid and rifampicin is thought to occur primarily 
through point mutations in the katG or inhA genes and in the 81bp region of the RNA 
polymerase β-subunit (rpoB) gene.
85,102 
Toxic side-effects associated with the use of isoniazid 
and rifampicin include mild influenza, hepatotoxicity and hepatic enzyme abnormalities 
which lead to hepatitis.
108
 Resistance to streptomycin is a result of mutation in the 16S rRNA 
genes, rrs and rpsL, that encode ribosomal protein S12 and the associated side-effects are 




Resistance to flouroquinolones is due to specific mutation in the gyrA and gyrB genes that 
encode for DNA gyrase A and subunits, while resistance in ethionamide is acquired through 





The injectable aminoglycosides’ (kanamycin and amikacin) resistance is similar to that of 
streptomycin and is due to mutation in the rrs gene encoding for 16S rRNA.
88 
Common side-
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1.7 Rationale for research undertaken  
Development of multi-drug resistant (MDR) and extensive-drug resistant (XDR) strains of 
Plasmodium falciparum and Mycobacterium tuberculosis has reduced the efficacy of the 
currently administered drugs. Thus, there is an urgent need for new chemical entities (NCE) 
with novel modes of action that will provide maximal anti-infective activity against these 
infectious diseases. Our interest in discovering new anti-infective agents is focused primarily 
on the quinoline-based compounds that can exert their activity against P. falciparum and 
Mycobacterium tuberculosis. This approach is supported by the fact that the quinoline 












The fact that quinoline-based antimalarial drugs such as quinine, chloroquine, mefloquine, 
primaquine and amodiaquine, have been shown to possess moderate activity against 
Mycobacterium tuberculosis further supports the choice of using the quinoline 
nucleus.
115,116,117
 Another important reason for searching for new chemical entities (NCE) 
based on the quinoline nucleus is the diarylquinoline TMC207 which is in phase IIB clinical 
trials for TB.
118 
This compound is active against drug-sensitive and drug-resistant 
Mycobacterium tuberculosis, and has bactericidal effect against the dormant bacilli.
119 
Furthermore, this compound possesses a new mechanism of action by inhibiting ATP 
synthase subunit C, an energy source for the bacterium.
120
 The enzyme, ATP synthase, is an 
attractive target since there is limited similarity between the mycobacterial and human AtpE 
protein sequence.
121,122 
As such TMC207 is a viable alternative for the treatment of multi-
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Multi-component reactions and DMPK/ADMET 
 
2.0 General introduction 
Diversity-orientated synthesis (DOS) continues to grow as an area of importance in drug 
discovery. The introduction of structural diversity in a focused library of potential therapeutic 
compounds is believed to have a greater chance of delivering positive hits.
1,2 
The majority of 
potential therapeutics are natural products or drug-like molecules that often contain a 
heterocyclic ring.
3 
The chemistry of heterocyclic compounds has attracted a great deal of 
interest in recent times due to the increasing importance of the heterocyclic scaffold in 
pharmaceuticals. However, the range of easily accessible and suitable functionalized 
heterocyclic building blocks for the synthesis of structurally diverse libraries of therapeutics 
is somehow limited.
4 
Therefore, the development of simple, elegant and facile methodologies 
towards focused libraries of such compounds is one of the most important aspects of drug 
discovery.
5 
The multi-component reaction (MCR) strategy is arguably the most efficient 
method for rapid synthesis of heterocyclic compounds.
4 
Large libraries of MCR heterocyclic 
products are particularly attractive for drug discovery efforts because they provide rapid 
access to complex molecules for biological evaluation. 
 
2.1 Multi-component reactions (MCRs) 
The synthesis of an α-aminonitrile (2.4) from the reaction of ammonia (2.1) and hydrogen 
cyanide (2.2) in the presence of a carbonyl compound (2.3) was reported by Strecker in 1850, 
and is considered to be the first MCR (Scheme 2.1).
6 
Multi-component reactions are chemical 
reactions that combine three or more different starting materials in a one-pot synthesis to 
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starting materials do not all react simultaneously in one step but rather proceed in a series of 
ordered steps.
7 
Multi-component reactions can be grouped into three basic types,
7 










Scheme 2.1: Strecker three-component reaction.  
 





Multi-component reactions in which starting materials, intermediates and product are in 
dynamic equilibrium is classified as type I. In this case yields range between 0 and 100% 
depending on the state of balance that prevails. In most cases type I reactions do not go to 
completion, have a greater chance of side product formation and desired products are usually 
difficult to isolate because they occur as mixtures with intermediates and/or starting 
materials. This is not an ideal type of MCR and an example is the Strecker reaction (Scheme 
2.1).  
 
Multi-component reactions whose elementary reactions are in reversible equilibria and the 
only irreversible step being the product forming step belong to type II. These reactions are 
advantageous in that they are high yielding due to the total equilibrium shift towards the 
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in drug discovery programs where rapid generation of a library of compounds is of utmost 


















2.5 2.6 2.7 2.8
 
Scheme 2.2: Biginelli three-component reaction.  
 
Multi-component reactions of type III consist of a sequence of irreversible elementary 
reactions that rarely occur in preparative chemistry, but found mostly in biochemical 
reactions of living organisms. 
 









 and Ugi (1959)
7
 
reactions came to light after Strecker’s discovery.
 
Many different variations of these reactions 
are known and some utilize as many as seven different starting materials. An example of this 
is the Dömling-Ugi seven-component reaction.
15 
To date more than 400 different Multi-
component reactions are known, 20-25% of them utilize isocyanides as one of the starting 
materials.
16 
Isocyanide-based multi-component reactions are by far the most important and 
widely used of all the MCRs. In addition, the isocyanide based MCRs have been extensively 
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2.1.1 Isocyanide-based multi-component reaction 
In 1921, Passerini synthesized a carbamoylmethyl ester (2.12) from a three-component 
reaction of a carboxylic acid (2.9), an isocyanide (2.11) and a carbonyl compound (2.10), and 














2.9 2.10 2.11 2.12
R3
 
Scheme 2.3: Passerini three-component reaction.  
 
After forty years of non-activity on isocyanide-based MCRs, Ugi discovered an aza version 
of the Passerini reaction in 1959 and this reaction became known as the Ugi reaction.
6
 This 
reaction is discussed further in section 2.1.1.2. The advantages of using these reactions 
include; (i) high efficiency and versatility, (ii) functional group tolerance, and (iii) high levels 
of chemoselectivity, regioselectivity and stereoselectivity often observed.
12
 In addition, both 
these reactions serve as a powerful tool for the production of a diverse array of biologically 
active compounds with high atom economy from readily accessible or easily prepared 
starting materials.
8a,17 
Furthermore, isocyanide-based MCRs are being employed in the 






Isocyanides, formerly known as isonitriles, are a class of compounds containing an unusually 
extraordinary functional group whose structure and reactivity have been discussed for over 
one and a half century.
7
 The majority of isocyanides or compounds containing an isocyano 
functional group are largely found in marine species.
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was isolated from Penicillium notatum Westling by Rothe in 1950 and was later used as an 
antibiotic, Xanthocillin (2.13) (Fig. 2.1).
8a,19 
A larger number of simple and volatile 
isocyanides are characterized by an extremely unpleasant “odor” and the majority are only 
slightly toxic except for a select few.
20 
However, prolonged exposure and inhalation of 









Figure 2.1: Xanthocillin, a naturally occurring isocyanide.  
 
Isocyanides are the only class of stable organic compounds with a formally divalent carbon 
(C
II
) capable of undergoing oxidation to a tetravalent carbon (C
IV
) under mild reaction 
conditions.
7 
In addition, the divalent carbon has a unique ability to react with both 
nucleophiles and electrophiles to give rise to α-adducts.
8a
 The structural representation of 
isocyanides is depicted in Figure 2.2 and conformer I has been shown to contributes 
significantly more than II to the overall isocyanide structure.
21 
 





Figure 2.2: Resonance structures of isocyanides. 
 
Carbenes and carbon monoxide are the only organic compounds with a divalent carbon and 
by virtue of this are structurally related to isocyanides. Reactivity of isocyanides is 
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The first synthetic isocyanide, allyl isocyanide (2.16), was accidentally made by Lieke in 
1859 from the reaction of allyl iodide (2.14) and silver cyanide (2.15) (Scheme 2.4).
19 
In the 
original synthesis Lieke believed he had formed nitriles only to be surprised in obtaining 
formamides instead of carboxylic acids when he tried to hydrolyze his product.
7
 
Unfortunately Lieke had to abandon his experiments as a result of the awful smell of 
isocyanides.
7
 Eight years later Gauntier and Hoffman independently described the isomeric 













Scheme 2.4: Lieke synthesis of allyl isocyanide.  
 
Currently there are dozens of methods reported in literature for the synthesis of isocyanides 
but the method of choice involves dehydrating N-formamides (2.18) (Scheme 2.5).
8a
  Various 











 among others have been used to great 
effect in dehydrating formamides. Generally, dehydration of N-formamides is associated with 
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2.1.1.2 The Ugi multi-component reaction 
In 1959, Ugi described the synthesis of an α-acylamino amide (2.21) from the reaction of a 
carboxylic acid (2.9) with an aldehyde (2.10) and an isocyanide (2.11) in the presence of an 
amine (2.20), and this reaction became known as the Ugi four-component reaction (Scheme 
2.6).
26 
Many variations of this reaction that are known today were discovered in a matter of 
weeks after this disclosure in 1959.
7
 From the early 1990s until today, this reaction in 
conjunction with the enabling technologies such as high-throughput screening became one of 
























Scheme 2.6: Ugi four-component reaction (U4CR).  
 
The reaction mechanism of the Ugi four-component reaction begins with the formation of a 
imine (2.22A) from the condensation of an amine (2.20) with the aldehyde (2.10) as depicted 
in Scheme 2.7. Protonation of the Schiff base nitrogen by the carboxylic acid (2.9) increases 
the electrophilicity of the C=N bond, thereby generating an activated iminium ion (2.22B). 
Addition of the isocyanide (2.11) to the activated imminium ion and subsequent nucleophilic 
addition of the carboxylate ion generates an α-adduct (2.22D), which is analogues to an acid 
anhydride via an intermediate nitrilium ion (2.22C). Irreversible intramolecular acylation, 
also known as the Mumm rearrangement, generates a hydroxyimine-amide (2.22E) which 
subsequently undergoes rearrangement and proton transfer to form a stable Ugi adduct (2.21). 
All the intermediate steps of this reaction sequence are equilibria. However, the acyl transfer 
and the rearrangement step lie exclusively on the product side, characteristic of type II 














) to the amide tetravalent carbon (C
IV
). In the course of this reaction, one C-C and 
































































Scheme 2.7: Ugi four-component reaction (U4CR) mechanisms. 
 
Reactivity series studies as a function of solvent and concentration established that this 
reaction is mainly influenced by inductive and mesomeric effects, and to a lesser extent by 
steric effects.
7 
Conducti g this reaction in polar aprotic solvents or in low-molecular weight 
alcohols has been found to be advantageous. However, the concentration of the reactants is 
postulated to be the most important factor.
12 
The main drawbacks of this reaction are poor 
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2.2 Application of the Ugi MCR in drug discovery 
2.2.1 Drugs already in the market 
The increasing demand for rapid synthesis of biologically active compounds in the 
pharmaceutical industry has encouraged the use of MCRs in drug discovery and generic drug 
synthesis.
29 
In addition, the possibility of performing post-condensation modifications on Ugi 
products gives access to new biologically relevant molecules. Furthermore, the fact that this 
reaction enables automated parallel synthesis further highlights its importance in the drug 
discovery process.
30 
Application of the Ugi reaction in the synthesis of marketed drugs is 
exemplified by the following: The first application of the Ugi reaction was in the synthesis of 
Xylocain
®












2.23 2.24 2.25 2.26
 




Secondly, the Ugi reaction was also used in the modified synthesis of known marketed drugs 
such as Plavix
® 
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Lastly, scientists at Merck & Co utilized the Ugi four-component reaction in synthesizing the 
core fragment (2.35) of an HIV-1 protease inhibitor, Crixivan
®













































1. H2, Chiral catalyst
2. NH2NH2
 





2.2.2 Application in early drug discovery programs 
A number of compounds obtained via the Ugi multi-component reaction have found 
successful use in lead discovery and lead optimization stages of drug discovery programs. As 
such, various research institutes and academic research labs are also utilizing Ugi multi-
component reactions in search of biologically active molecules for screening purposes in “hit 
to lead” campaigns. The following three examples illustrate the application of Ugi multi-




 functionalized a quinoline pharmacophore found in a number of 
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using the “Ugi 3-component 4-centre multi-component reaction” (Scheme 2.11). In addition, 
these γ- and δ-lactams showed activity against a chloroquine-resistant strain of the P. 





















Scheme 2.11: Application of the Ugi MCR in the synthesis of 4-aminoquinoline γ- and δ-
lactams.   
 
In 2007 Dömling and co-workes at Morphochem disclosed the Ugi four-component synthesis 
of novel anti-TB agents (2.45) based on the isoniazid and pyrazineamide pharmacophores 
(Scheme 2.12).
34
 These anti-TB agents possessed activity against the H37Rv drug-sensitive 
strain of Mycobacterium tuberculosis. 
2.452.44 2.11
N
















Scheme 2.12: Application of the Ugi MCR in the synthesis of novel anti-TB agents.  
 
Scientists from the Korean’s Institute of Science and Technology synthesized potent 
morpholin-2-one based T-type Ca
2+
-ion channel blockers via the Ugi five-centre three-




































Scheme 2.13: Application of the Ugi MCR in the synthesis of novel Ca
2+
-channel blockers.  
 
In addition, some of the products synthesized using the Ugi multi-component reactions 











2.3 Tetrazoles as biologically relevant heterocycles 
The tetrazole moiety is a doubly unsaturated heterocyclic five-membered ring system 
consisting of one carbon atom and four nitrogen atoms. Tetrazoles have not been found in 
nature and they exist as 1H- (A) and 2H-tetrazole (B) tautomers, the latter being more stable 
in the gas phase (Fig. 2.3).
40
 They usually possess a significantly high acidic and weak basic 
characteristics, and as such, many of their physical, chemical, physico-chemical, and 
biological properties are linked to this amphoteric character.
41 
Tetrazole-based compounds 
have found a wide range of applications in explosives, in photography, in agriculture, in 
medicine, and information recording and imaging systems.
42 
In addition, tetrazoles are 
normally used in synthetic chemical transformations as building blocks or derivatizing agents 
and as ligands in coordination chemistry.
43,44 
This latter property has been successfully 
exploited by analytical chemists in removing heavy metal ions from liquids and chemical 



































Figure 2.3: General representation of tetrazoles.  
 
 
Tetrazoles belong to the family of biologically active compounds known as the “azole 
pharmacophoric compounds” which include imidazoles, thiazoles and triazoles among 
others.
46
 The majority of medical applications of tetrazole-based compounds are a result of 
the acidic property of the tetrazole ring. Medicinal chemists are interested in the tetrazole 
moiety due to the fact that this scaffold possesses excellent physico-chemical properties and 
thus is used as a bioisostere for carboxylic acids in biologically active molecules.
48,49
 The 
tetrazolic acid fragment has similar acidity to carboxylic acids but is more metabolically 
stable at physiological pH and has been shown to be at least ten times more lipophilic than 
the corresponding carboxylate.
50
 Lipophilicity is an important drug property as this is a 
measure of how effectively a particular drug will pass through the cell membrane. Isosteric 
replacement of functional groups is of particular interest in drug discovery efforts because it 
allows one to alter unfavourable ADME (Absoprtion, Distribution, Metabolism and 





Tetrazoles are found in a number of marketed pharmaceutical agents particularly the 
angiotensin II antagonists such as Losartan (2.49) and its analogues; Irbesartan (2.50) and 
Valsartan (2.51) (Fig. 2.4).
52
 On the other hand, several tetrazole derivatives have been 



































































Figure 2.4: Drugs on the market with the tetrazole scaffold. 
 
2.3.1 Synthesis of tetrazoles  
Various methods for preparing tetrazoles, especially 1,5-disubstituted tetrazoles, are widely 
reported in literature and these include; (i) amides reacting with PCl5 or triflic anhydride or 
HN3 or NaN3,
60
 (ii) thioamides with trimethylsilyl azide,
61
 (iii) imidoyl chlorides with 
NaN3,
62
 (iv) ketones with NaN3 or trimethylsilyl azides,
63
 (v) oximes with HN3,
64
 (vi) nitriles 
with alkyl chlorides and trimethylsilyl azide or alkyl azide,
65
 (vii) nitrillium triflate with 
NaN3,
66




The majority of these 
methods suffer from drawbacks such as long reactions times, use of toxic and/or explosive 
reagents, tedious work-up and low yields, use of dangerously high temperatures, and use of 
uncommon starting materials among others.
68,69
 Isocyanide based multi-component reactions, 
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convenient alternative method for synthesizing 1,5-disubstituted tetrazoles from readily 

















































Scheme 2.14: Various methods for synthesizing 1,5-disubstituted tetrazole (Adapted from 
ref. 68) 
 
2.3.1.1 Synthesis of tetrazoles from isocyanide-based MCRs 
For the first time Nixely et al.,
58c
 utilized the modified TMSN3-Passerini reaction to 
synthesize norstatine tetrazoles as a new class of HIV-1 protease inhibitors in 2002. They 
achieved this by replacing the standard carboxylic acid input in the classical Passerini 
reaction with TMSN3. The N-Boc-α-aminoaldehydes (2.53) were reacted with an isocyanide 
(2.11) in the presence of TMSN3 (2.54) to furnish protected tetrazoles (2.55) (Scheme 2.15). 
Subsequent deprotection and N-capping with 2.56 gave the desired cis-constrained norstatine-


















































Scheme 2.15: Synthesis of tetrazoles using the modified TMSN3-Passerini reaction. 
 
In 1960 Ugi accomplished the synthesis of tetrazoles (2.58) by replacing the carboxylic acid 
with hydrazoic acid. The modified reaction involved reacting aldehydes with amines in the 
presence of isocyanides and hydrazoic acid (Scheme 2.16).
70 
The main problem with this 























Scheme 2.16: Synthesis of tetrazoles using the HN3 based Ugi reaction.  
 
The drawbacks of using HN3 prompted the research into alternative reagents such as TMSN3. 
Mayer et al.,
72
 and Dömling et al.,
48
 have synthesized a number of tetrazoles (2.61) using the 
modified TMSN3-Ugi reaction in conjunction with cleavable isocyanides (Scheme 2.17). 




















































Scheme 2.17: Synthesis of tetrazoles using the TMSN3 modified Ugi reaction. 
 
2.4 DMPK/ADMET  
A large numbers of new chemical entities (NCEs) are developed in drug discovery programs, 
thus the understanding of drug-metabolism and pharmacokinetic (DMPK) properties 
involved in the absorption, distribution, metabolism, excretion and toxicity (ADMET) of such 
NCEs is of utmost importance. Prior to the year 2000 the major reason for the high failure 
rate of drugs in clinical development was largely due to the DMPK related issues, with rates 
around 40%.
73,74
 The incorporation of DMPK in early drug discovery dropped this rate to 
below 10% from the year 2000 onwards (Fig. 2.5). 
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Drug metabolism (DM) comprises of biological processes that are involved in the conversion 
of potential drugs into toxic or non-toxic metabolites before and after they reach their site of 
action in the body.
75
 Most of these processes are enzyme-catalyzed; uridine-diphosphate-
glucuronosyl-transferases, cytochrome P-450 and carboxylesterases are some of the drug-
metabolizing enzymes.
75,76 
DM is dived into two phases, oxidative (phase I) and conjugative 
(phase II) metabolism, and predominantly takes place in the liver, gastrointestinal tract, 
kidneys, lungs and the plasma through a series of reactions.
77 
The establishment of the in 
vitro and in vivo ADMET technologies has resulted in a better understanding of the DM 
properties of potential drug candidates. Pharmacokinetics (PK) is the study of the rate at 
which a potential drug is transported to its site of action in sufficient concentrations and in 
long enough time to course a significant pharmacological response.
78,79
 PK encapsulate the 
efficiency of drug absorption, the rate of drug metabolism, rate of distribution, and the rate of 
excretion by measuring the amount of drug concentration in the blood or plasma.
77,80,81,82
 The 
role of DMPK in early drug discovery is to identify and eliminate compounds exhibiting poor 
metabolic and/or pharmacokinetic properties that would reduce their chances of successful 




2.4.1 Physico-chemical properties affecting ADME  
Much of the work on drug metabolism and pharmacokinetics (DMPK) within drug discovery 
programs is mainly concerned with the oral delivery of drugs.
84 
An orally administered drug 
will first dissolve in the gastrointestinal tract and followed by one of the two processes; the 
drug will either (i) be excreted without modification or (ii) some of it will be absorbed 
through the gut wall, modified by first pass metabolism (phase I) and distributed to the liver 
(Fig. 2.6).
85
 Once it reaches the liver, the drug will be metabolized further (phase II), 
distributed in systematic circulation to tissues, organs, and finally, to its molecular target. The 
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Dosage form, dissolution, permeation through the gastrointestinal tract, and metabolic 
stability are some of the factors that influence drug bioavailability.
84,86
 In addition, these 
factors are largely dependent on physico-chemical properties of drugs such as lipophilicity, 
solubility and permeability among others. 
 





Lipophilicity represents an affinity of a molecule or moiety to partition in the oily phase or 
biological membrane (lipophilic environment).
87 
This is expressed as the logarithm of 
partition coefficient or distribution coefficient (log P or log D) of a drug in an octanol/water 
system. This physico-chemical property greatly affects solubility, dissolution and absorption 
of drugs. Poor aqueous solubility and slow dissolution of drugs can lead to poor oral 





Solubility measures the ability of a drug or drug candidate to dissolve and remain in aqueous 
or other physiological media. Low solubility is detrimental to good or complete oral 
absorption and/or bioavailability. As such early measurements of this parameter are of great 
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2.4.2.3 Permeability 
Permeability is an ability of a drug or drug candidate to pass through biological membranes 
after dissolution in the gastrointestinal tract.
 
Permeability can occur via transcellular 
diffusion, paracellular diffusion, and transporter mediated-mechanism.
88 
Permeability of 
compounds through Caco-2 cells is used to model human intestine absorption and this 
approach is commonly referred to as the membrane-interaction quantitative structure-activity 
relationship (MI-QSAR).
89
 This physico-chemical property is influenced largely by the 
molecular weight of compounds because as molecules increase in size their ability to 




The majority of these physico-chemical properties can be predicted by in silico tools such as 
Moka, Volsurf+, and MetaSite among others.
91 
In silico predictions are advantageous in that 
they utilize a virtual library of compounds and generate ADME data to assess which 
compounds to prioritise in synthesis. This approach reduces the cost and time involved in 
discovering new compounds which have high potential to be positive hits. However, such 
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2.5 Objective, Hypothesis and Aims  
Objective 
The overall objective of this research program is to identify and develop bi-therapeutic 
chemically hybridized new anti-infective agents in a quest to overcome or delay drug 
resistance in malaria and tuberculosis.  
 
Hypothesis 
The questions to be addressed at the conclusion of this project are two-fold: 
- Using MCR, is it possible to identify single agents that provide inhibition of multiple 
disease-causing organisms or cells?   
- Is it possible to improve the physico-chemical and DMPK properties of antiplasmodial and 
anti-mycobacterium tuberculosis pharmacophores or bioactiphores? 
 
Specific aims 
Specific aims include: 
- The synthesis new tetrazole-based compounds as potential anti-malaria and anti-
tuberculosis agents via Multi-Component Reaction (MCR) strategies. 
- Pharmacological evaluation of synthesized compounds, In silico ADME profiling of the most 
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Design, synthesis and biological evaluation of novel 
tetrazole-based aminoquinoline derivatives 
 
3.1 Preface 
This chapter describes the design, synthesis and biological evaluation of a series of novel 
tetrazole-based aminoquinoline derivatives. Specifically, these derivatives are based on the 
deoxyamodiaquine, 4-amino-7-chloroquinoline and primaquine scaffolds. Prior to synthesis, 
in silico prediction tools were utilized in selecting a small number of compounds predicted to 
possess favourable ADME properties (solubility and metabolic stability). The multi-
component reaction (MCR) strategy was then used to synthesize these target compounds, 
which were all fully characterized by spectroscopic methods. The synthesized compounds 
were all evaluated in vitro for antiplasmodial and antimycobacterial activity.  
 
3.2 General overview 
Aminoquinoline-based antimalarial drugs have been the most important class of compounds 
used for treating malaria over the years. This was largely due to their excellent clinical 
efficacy, limited host toxicity, ease of use and most importantly, their simple and cost-
effective synthesis.
1 
The precise mode of action of aminoquinolines is believed to involve Π-
stacking of the quinoline ring to the porphyrin units of the haeme-moiety, resulting in the 
accumulation of the “free-haeme” inside the parasite digestive food vacuole, and 
subsequently death of the parasite.
2,3
 Although aminoquinoline-based drugs are useful in 
treating and managing malaria, their use has been limited by the emergence of drug-resistant 
strains of the parasite.
4 
Thus, the search for new and improved aminoquinoline derivatives 
that will be equally effective against both the sensitive and resistant P. falciparum strains is 
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One good starting point in antimalarial drug discovery is an existing antimalarial drug in 
which the validated chemical scaffold critical for inhibition of the parasite growth, at least in 




3.3 General rationale 
The general rationale used in designing target compounds is illustrated by the generic 
rationale representation in Figure 3.1. Based on the design, the tetrazole scaffold is fused with 
one or two known biologically active bioactiphores that will form part of the inputs envisaged 
for the MCR. The choice of the tetrazole R’ substituent was deliberately limited to two 
convertible isocyanides, namely, 4-ethylmorpholine- and the tert-butyl isocyanide, whose 
resulting product would lend themselves to post MCR modification if desired. The tetrazole 
moiety was chosen as an integral part of this design mainly for three reasons. First, this 
scaffold possesses excellent physico-chemical/ADME properties.
6
 Second, it is found in a 
number of synthetic biologically active compounds.
7
 Third, molecules containing this 
scaffold are known to exhibit excellent activity against infectious disease-causing organisms 
(Chapter 2, section 2.3).
8,9,10
 There are various methods reported in literature for synthesizing 
substituted tetrazoles but the MCR strategy appears to be the most convenient because of its 
high efficiency and versatility, functional group tolerance, and use of non-toxic and readily 









R'= tBu, 4-ethylmorpholine, H
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3.4 Deoxyamodiaquine-based tetrazole compounds  
Amodiaquine (AQ) (3.1) is a Mannich base derivative that was first synthesized by 
Burckhalter in 1948 as an alternative to quinine (Fig. 3.2).
11,12 
Amodiaquine possesses 
excellent activity against a variety of chloroquine-resistant strains of P. falciparum. In the 
1980s the use of amodiaquine was discouraged as a result of its association with adverse 
effects such as hepatotoxicity and agranulocytosis in people taking the drug 
prophylactically.
13
 However, following wide-spread development of resistance to 
chloroquine, the use of amodiaquine was reconsidered in the 1990s. Currently, the WHO 
recommends the use of amodiaquine in combination with artesunate or with 








Figure 3.2: Amodiaquine, an antimalarial drug.  
 
Amodiaquine is rapidly metabolized by the hepatic CYP2C8 enzyme into N-
desethylamodiaquine (DEAQ) metabolite, which has a longer half-life and is three-times less 
active than the parent drug.
14
 Toxic episodes of amodiaquine are manifested by in vivo 
biotransformation of its p-aminophenol moiety into an electrophilic metabolite, amodiaquine 
quinoneimine (ADQI) (3.2A) (Scheme 3.1).
15,16 
This CYP450-mediated biotransformation is 
accompanied by the expression of drug-related antigens on the cell surface caused by the 
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Scheme 3.1: CYP450 mediated biotransformation of amodiaquine and subsequent protein 
binding. 
 
Recently, another metabolite (aldehyde, 3.2B) of amodiaquine was identified from in vitro 
incubation studies of amodiaquine with recombinant human CYP1A1 and CYP1B1 
enzymes.
18
 Subsequent trapping of metabolite 3.2B with N-acetyl cysteine revealed that this 
metabolite undergoes further oxidation into an aldehyde quinoneimine intermediate (3.2C) 
(Scheme 3.1), as evidenced by the formation of 3.3B and 3.3C. The formation of 
intermediate 3.2C implies that aldehyde 3.2B also has the potential to cause type II 
hypersensitivity reaction. However, no in vivo studies have so far been performed in order to 
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Various strategies for improving the toxicity profile of amodiaquine while retaining and/or 
bettering its activity involved modification of the Mannich base side-chain,
17,19
 blockade of 
the biotransformation pathways,
20,21 
and total replacement of the phenyl moiety.
22
 
Modification of the Mannich base side-chain with cyclic amines or with a tert-butylamino 
group resulted in compounds that were more active in vivo against P. beghei than 
amodiaquine. Moreover, interchanging the Mannich base side-chain and the hydroxyl group 
of the phenyl moiety of amodiaquine resulted in more metabolically stable compounds that 
had comparable activity to amodiaquine. Unfortunately, replacement of the phenyl ring has 
thus far not yielded any lead compound that is more active than amodiaquine.  
 
Judging from various studies undertaken on amodiaquine, it appears that the blockade of the 
biotransformation pathway is a method of choice in developing new amodiaquine analogues, 
one of which is isoquine (also known as GSK369796) (3.4) (Fig. 3.3).
23 
However, in 2008 the 
development of isoquine by Medicine for Malaria Venture (MMV), in partnership with 











Figure 3.3: Isoquine, also known as GSK 369796.  
 
Other modifications that have been performed on amodiaquine include replacement of the 
metabolically susceptible p-hydroxyl group with a fluorine (fluoroamodiaquines) or hydrogen 
atom (deoxyamodiaquines) in order to circumvent the formation of the quinoneimine 
metabolite.
25 
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to amodiaquine but their observed IC50 remain stable across all chloroquine-reistant strains. 
Recently, Chibale et al.,
26
 utilized the deoxyamodiaquine scaffold fused with chalcones in 
developing potent inhibitors of Plasmodial and tumor growth. This suggests that fusion of 
deoxyamodiaquine scaffold “to appropriate moieties” could potentially deliver potent 
deoxyamodiaquine analogues. As such, the rationale adopted in this project involved the 
incorporation of a tetrazole moiety and protonatable nitrogen into the deoxyamodiaquine 
scaffold (Fig. 3.4). The substituent on the phenyl ring, which consists of the tetrazole and the 
tertiary amine, was varied between the ortho-, meta- and para-positions. Furthermore, the 
choice of the tertiary amine R-groups was based on favourable in silico ADME (Absorption, 














Figure 3.4: Rationale for the tetrazole-based deoxyamodiaquine target compounds. 
 
3.4.1 In Silico profiling 
Drug discovery programs have traditionally relied on identifying potential drug candidates 
through in vitro and/or in vivo screening, followed by optimization for potency and 
specificity for molecular targets while optimization of ADME parameters was reserved for 
clinical development.
27,28
 However, this approach led to high attrition rates of drug candidates 
in late stages of development due to poor pharmacokinetic and ADME properties, which 
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circumvent and/or reduce such attrition rates, in silico prediction tools are being utilized in 
selecting and eliminating compounds with ADME liabilities before any substantial resources 
are invested.
29,30 
Thus, in silico ADME prediction models and tools complement in vitro and 
in vivo ADME experiments by facilitating the characterization of compounds prior to their 




Models for predicting ADME parameters are usually based on empirical approaches such as 
quantitative structure-activity relationship (QSAR)
33
 and/or quantitative structure-
permeability relationship (QSPR)
27
. Chemometric methods such as multi-linear regression 
(MLR),
33 
principal compact analysis (PCA),
35
 and partial least square (PLS)
36
 analysis are 
used in constructing QSAR/QSPR models. These models are often employed in programs 
such as Volsurf+
37,38
 in predicting physico-chemical properties from molecular structures. 
Volsurf+ is an automated procedure for the conversion of 3D molecular interaction fields 
(MIFs) into simple physico-chemically relevant molecular descriptors.
39,40
 A number of these 
descriptors are based on models of solubility, permeability, blood-brain barrier (BBB) and 
metabolic stability among others.  
 
Bioavailability of an orally administered drug largely depends on solubility, permeability and 
metabolic stability.
41 
In this study in silico prediction tools were applied in the ADME 
profiling of a focused library of proposed tetrazole-based deoxyamodiaquine compounds 
(Fig. 3.5). It is important to note that these predictions were merely used as a guide in these 
studies. The predicted Volsurf+ parameters were aqueous solubility at two pHs (5.0 and 7.5), 
Caco-2 permeability and metabolic stability of the proposed compounds. The style and 
format of the presentation of in silico results reported by Guantai et al.,
41
 was followed and 
adopted in profiling the proposed compounds. In addition, amodiaquine was selected as a 























































R= tBu (3.9a) (TK1)
R= H (3.10a) (TK1B3)
R= Ethylmorpholine (3.9g) (TK7)
R= tBu (3.9b) (TK2)
R= H (3.10b) (TK2B3)
R= tBu (3.9c) (TK3)
R= H (3.10c) (TK3B3)
R= Ethylmorpholine (3.9i) (TK9)
R= tBu (3.9d) (TK4)
R= H (3.10d) (TK4B3)
R= tBu (3.9f) (TK6)
R= H (3.10f) (TK6B3)
3.9j (TK10) 3.9k (TK11)
Figure 3.5: Structures of the proposed tetrazole-based deoxyamodiaquine compounds. 
 
The majority of the proposed compounds had predicted aqueous solubilities that were 
comparable to that of the reference drug, amodiaquine, at both pH 5.0 and 7.5. However, two 
compounds, 3.9g and 3.9i, exhibited significantly superior predicted solubility compared to 
amodiaquine and other test compounds at pH 5.0 (Fig. 3.6A). This observation might be due 
to the fact that both these compounds contain an additional protonatable morpholine nitrogen 
attached to the tetrazole side-chain when compared to the other test compounds, and this is 
postulated to be aiding the ionization of these compounds at low pHs. Also not surprisingly, 
the free tetrazole-based compounds (grey) had a slightly superior predicted aqueous solubility 
compared to the protected analogues (yellow) at both pHs, except for compounds 3.9g and 
3.9i at pH5.0. This is anticipated because the free tetrazole moiety usually possess a 
significantly high acidic and weak basic characteristics, an amphoteric character, and as such 
these would be ionized at both pHs, thus facilitating the solubility of the free tetrazole-based 
analogues.
42 
The conclusion that can be drawn from this exercise is that the predicted aqueous 
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The prediction of the Caco-2 permeability and metabolic stability were qualitative. The study 
sets of compounds were projected onto the inbuilt two-dimensional PLS scores plot to 
generate the Caco-2 permeation model. All the test compounds, including amodiaquine, 
showed acceptable predicted Caco-2 permeation, falling within the permeation (Blue) zone of 
the plot, indicating an efficacious permeation of intestinal epithelium cells (Fig. 3.6B).  
 
 
Figure 3.6: A: Plots of predicted solubility (log S) against predicted n-Octanol-water 
partition coefficient (log D) at pH 5.0 and 7.5; B: Plots showing the proposed compounds 
projected onto PLS models used to predict Caco-2 permeability and metabolic stability- the 
black dots represent compounds comprising the models’ training data sets while the yellow 
and white dots represent the test compounds. The blue regions indicate acceptable predicted 
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In addition, the free tetrazole-based compounds (yellow) were predicted to have an 
intermediate but acceptable metabolic stability that is comparable to amodiaquine, while the 
protected tetrazole (white) were shown to be less metabolically stable (red region) (Fig. 
3.6B). To get a better picture of the metabolic pathway of the proposed compounds, 
MetaSite
43,44 
was used to predict the site of metabolism (SOM). The site of metabolism refers 
to the part of the molecule where the metabolic reaction is predicted to occurs. MetaSite is a 
computational tool that is able to predict human cytochrome P450 (CYP450) mediated 
metabolism using only the 3D structure of the proposed compounds to generate the probable 
site of metabolism.
44
 Furthermore, these 3D structures are automatically generated by the 
software in the cytochrome enzyme cavity from the 2D input structures. 
 
Figure 3.7 shows the probable hepatic metabolic positions on each proposed compound as 
suggested by MetaSite; the blue circles indicate highest probable site of metabolism. For 
compounds 3.9a, 3.10a, 3.9g, 3.9b and 3.10b the main routes of metabolism is predicted to 
be N-dealkylation of the tertiary amine of the alkyl side-chain, similar to amodiaquine. This 
predicted route of metabolism for amodiaquine is in agreement with the reported 
experimental observations, where the N-desethylamodiaquine is identified as the major 
metabolite.
14,45 
In addition, N-oxidation of the quinoline moiety is also predicted to be another 
major route of metabolism for amodiaquine. However, this route is not favoured.
41
 The 
protected tetrazole analogues contain an extra group (i.e. the t-butyl or the 4-ethylmorpholine 
group) that is predicted to be susceptible to metabolism, and this may partly explain why 
these are predicted to be less stable than the free tetrazole analogues.  
 
In conclusion, at pH 7.5 the free tetrazole compounds were profiled to have predicted 
aqueous solubility that is similar to amodiaquine but superior to the other analogues. 
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for compounds 3.9g, 3.9i and amodiaquine, which had better solubilities. Furthermore, all the 
proposed compounds were predicted to have acceptable permeation on Caco-2 cells. The 
metabolic stability of the free tetrazole-based compounds was predicted to be superior on 
both Volsurf+ and MetaSite packages than the protected analogues. Overall, the free tetrazole 
analogues were predicted to have better physico-chemical properties than the protected ones.  
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3.4.2 Synthesis of tetrazole-based deoxyamodiaquine derivatives 
3.4.2.1 Retrosynthetic analysis 
The synthesis of the target compounds (3.10) was envisaged as achievable from the de-tert-
butylation of compounds (3.9) which in turn can be prepared from the modified TMSN3-Ugi 
reaction. Intermediates 3.8 can be obtained from oxidation of benzyl alcohols (3.7) that 
would be synthesized from a nucleophilic aromatic substitution reaction of commercially 





















































Scheme 3.2: Retrosynthesis of tetrazole-based deoxyamodiaquine compounds. 
 
3.4.2.2 Synthesis 
3.4.2.2.1 Synthesis of 4-aminoquinoline benzaldehydes 
The procedure followed for the synthesis of the intermediate compounds (3.8a-c) was 
previously reported in our research group
26,46
 and commenced with the preparation of 4-
aminoquinoline benzyl alcohols (3.7a-c) in reasonable yields from the nucleophilic aromatic 
substitution reaction of aminobenzyl alcohols (3.5a-c) with 4,7-dichloroquinoline (3.6) in 
refluxing EtOH (Scheme 3.3). The ortho- and meta-quinoline-4-aminobenzyl alcohols (3.7a-
b) were obtained as precipitates after 3 hrs of refluxing while the para analogue (3.7c) was 
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the low yields observed for the para-analogue (3.7c) might be due to the rapid 
polymerization of the commercially available 4-aminobenzyl alcohol
47
 at room temperature. 
Evidence of the correct products was confirmed by 
1
H NMR spectra which had the 
characteristic singlet, or a doublet in some instances (due to coupling with the hydroxyl 

















Scheme 3.3: Reagents and conditions: (i) EtOH, reflux at 85-90 °C, 3 hrs to 18hrs; (ii) 
SO3.Py (2.0 eq), Et3N (4.0 eq), DMSO, 26 °C, 3 days. 
 
The quinoline-4-aminobenzaldehydes (3.8a-c) were then obtained in modest yields from the 
Parikh-Doering
48
 oxidation of the primary quinoline-4-aminobenzyl alcohols (3.7a-c) 
(Scheme 3.3, Table 3.1). This reaction is analogous to the Swern oxidation
49 
except that the 
oxayl chloride used to oxidise alcohols in the Swern reaction is replaced with a milder 
reagent, Py.SO3. Complete oxidation was furnished after three days of stirring at 26 °C in 
anhydrous DMSO-Et3N mixture. The main drawback of this reaction is the long reaction 
times required for the reaction to go to completion and the awful smell that results from the 
production of dimethylsulfide. The presence of the desired aldehydes (3.8a-c) was confirmed 




C) and mass spectrometry. Using compounds 3.8b and 
precursor alcohol 3.7b as an example, the disappearance of the key benzylic methylene 
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signal at approximately 10.0 ppm in the 
1
H NMR spectra serve as confirmation of the 
oxidation of the alcohols (Fig. 3.8). 
 
Table 3.1: Percentage yields of the intermediate products. 
 Entry 3.7 Yield/[%] 3.8 Yield/[%] 
     a 2-CH2OH 25 2-CHO 87 
     b 3-CH2OH 88 3-CHO 84 




Figure 3.8: Superimposed 400 MHz 
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3.4.2.2.2 Synthesis of tetrazole-based deoxyamodiaquine 
The synthesis of the novel tetrazole-based deoxyamodiaquine derivatives was achieved using 
the multi-component reaction strategy. Following the modified TMSN3-Ugi procedure 
described by Dömling et al.,
50
 and Mayer et al.,
51
 quinoline-4-aminobenzaldehydes (3.8a-c) 
were allowed to react at ambient temperature with various commercially available secondary 
amines and tert-butyl isocyanide or the 4-(2-isocyanoethyl)morpholine, in the presence of 
TMSN3 in anhydrous MeOH for a period of 24 hrs. The reaction progress was monitored by 
thin layer chromatography (TLC). On completion of the reaction, the novel tetrazole-based 
deoxyamodiaquine compounds (3.9a-k) were obtained in moderate to good yields after 
purification by column chromatography (Scheme 3.4, Table 3.2). In addition, these 
compounds were further purified by high pressure liquid chromatography (HPLC) to give 

















Scheme 3.4:. Reagents and conditions: (i) TMSN3 (2.0 eq to the aldehyde and 1.0 eq to the 
other reagents used), MeOH, 25 °C, 24 hrs. 
 
The generalized mechanism for the formation of target compounds (3.9a-k) is shown in 
Scheme 3.5. The reaction is initiated by the condensation of the aldehyde with the secondary 
amine to give rise to an intermediate (A), iminium ion, in situ. This iminium ion then reacts 
with an isocyanide via a nucleophilic addition reaction to form a key intermediate (B), the 
nitrilium ion. Azide trapping of this nitrilium ion produces intermediate (C), which undergoes 
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    R’ Position Code Product R 







meta TK1 3.9a N
 
86 99.5 
“ TK2 3.9b N
 
25 98.7 
“ TK3 3.9c N
 
87 99.0 















“ TK7 3.9g N
 
35 97.5 
“ TK8 3.9h N
 
32 98.9 




ortho TK10 3.9j N
 
12 98.2 





















































Scheme 3.5: Mechanism for the synthesis of tetrazole using TMSN3-modified Ugi reaction.  
 









C NMR spectra of 
representative compound 3.9a. The absence of the characteristic aldehyde peak at 
approximately 10.0 ppm in the 
1
H NMR spectrum served to confirm that the reaction did 
occur, and the singlets at 1.68, 2.27 and 5.50 ppm correspond to the H-14 t-butyl methyl, H-
15 methyl, and H-13 methine protons, respectively (Fig. 3.9). These signals represent the new 
structural motifs that had been incorporated into the starting 4-aminoquinoline 
benzaldehydes. The C-13 is the newly created stereogenic centre in the final products. The 
signals resonating at 1.18, 2.00 and 4.04 ppm are due to the solvent peaks, i.e. ethyl acetate 
residual peaks. In Figure 3.10, the carbon peaks at 29.9, 40.2, 61.3 and 62.8 ppm correspond 
to these new structural features that are incorporated into the final product, while the rest of 

















Figure 3.9: 400 MHz 
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Figure 3.10: 100 MHz 
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3.4.2.2.3 Post MCR modification of previously synthesized target compounds 
The next phase in the synthesis involved the deprotection of the tetrazole moiety in 
compounds synthesized in section 3.4.2.2.2. It is important to note that only the tert-butylated 
tetrazoles were deprotected in this study mainly due to the feasibility of the de-tert-butylation 
reactions. Furthermore, only the meta-substituted compounds (3.9a-f) were intentionally 
deprotected to provide representative compounds. 
 
There are various methods reported in literature for the de-tert-butylation of the tetrazole 
ring. The majority of these methods use harsh reaction conditions such as refluxing strong 
mineral acids like hydrobromic acid (HBr)
53
, sulphuric acid (H2SO4)
54
, methanolic-
hydrochloric acid (mixture of methanol and HCl gas)
55
 etc, at high temperatures and long 
reaction times. However, in our study it was observed that the use of hydrobromic acid (40%) 
and sulphuric acid (98%) resulted in the destruction of the starting material as suggested by 
the complex TLC and 
1
H NMR of the crude reaction mixture. It was also noted that when a 
“milder” methanolic-hydrochloric acid was used, no reaction occurred. This was evidenced 
by the recovery of starting material in the reaction flask. Thus, there was a need to find 
reaction conditions that fitted between these two extremes. The method that worked 
efficiently in our case involved heating the starting materials (3.9a-f) at 120 °C for 4 to 8 
hours in neat hydrochloric acid (32%) (Scheme 3.6). Upon cooling and neutralization of the 
reaction mixture, the intended product (3.10a-f) precipitated in reasonable yields after 
standing overnight in the fume hood (Table 3.3). These compounds were then purified by 





























Scheme 3.6: Reagents and conditions: (i) neat 32% HCl (excess), 120 °C, 4 to 8 hrs. 
 
















3.10a  TK1B3 N
 
59 98 174-176 
3.10b  TK2B3 N
 
40 95.7 185-187 
3.10c TK3B3 N
 
55 99.4 189-192 
3.10d  TK4B3 N
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Scheme 3.7 shows a simplified mechanism for thermally induced de-tert-butylation of the 
tetrazole ring.
56
 The initial phase of the mechanism is protonation of one of the tetrazole 
nitrogens (I). This then leads to the formation of a partially protonated tetrazole ring (II). The 
positive charge of the partially protonated tetrazole ring is subsequently delocalized around 
the ring due to the resonance effect from the neighbouring nitrogens, thus leading to a fully 
protonated and positively charged ring (III). This delocalization of the positive charge on the 
tetrazole ring facilitates the cleavage (or de-tert-butylation) of a relatively stable tert-butyl 
carbocation to form a free tetrazole ring system (IV). This “carbenium” further reacts 
spontaneously with the chloride ions in situ to form a colourless, volatile and flammable 























Scheme 3.7: Proposed mechanism for de-tert-butylation of tetrazoles. 
 





C) and mass spectrometry. Figure 3.11 shows superimposed 
1
H NMR spectra of 
product 3.10a, the desired de-tert-butylated product, and 3.9a, the parent compound. The 
absence of the singlet at 1.68 ppm corresponding to the tert-butyl group (H-14) in the 
spectrum of compound 3.10a when compared to that of compound 3.9a is evident, thus 














Figure 3.11: Superimposed 400 MHz 
1
H NMR spectra of products 3.9a and 3.10a in DMSO-
d6. 
 
3.4.3 Experimental determination of solubility 
Aqueous solubility was determined using a high-throughput plate-based kinetic solubility 
assay. This method measures the onset of precipitation of any given compound by absorbance 
change. Precipitation occurs when the maximum aqueous solubility level is reached, and 
solubility is measured using LC-UV spectrophotometry at 620 nm and the mass of the 
compound is confirmed by MS spectrometry. 
 
Concentrations of 10mM stock solutions of test compounds were prepared in 100% DMSO, 
followed by dilution with phosphate buffered saline (PBS), pH 7.0 (and in some case pH 7.4), 
to 200 µM solutions. These dilutions were effected such that the final DMSO concentration 
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orbital shaker and filtered, and the filtrate used to determine kinetic solubility. Aqueous 
solubility of each compound was ranked according to the following criteria: <5 µM = 
insoluble; 5- 50 µM = partially soluble; 50- 100 µM = soluble; and > 100 µM = highly 
soluble. 
 
Experimentally determined kinetic solubility results at pH 7.0 of selected key compounds are 
shown in Table 3.4. These results corroborated the trend observed in the in silico solubility 
predictions described in section 3.4.1. The de-tert-butylated compounds were found to be 
highly soluble while the protected analogues varied from being insoluble to partially soluble.  
 
Table 3.4: Results for experimentally determined kinetic solubility at pH 7.0 
Code Product Solubility at pH 7.0 (µM) Conclusion 
TK1 3.9a 83.8 ± 2.97 soluble 
TK2 3.9b 27.8 ± 0.86 Partially soluble 
TK3 3.9c 1.70 ± 0.14 Insoluble 
TK4 3.9d 2.31 ± 0.15 Insoluble 
TK1B3 3.10a 65.5 ± 6.08 soluble 
TK2B3 3.10b 207 ± 6.08 Highly soluble 
TK3B3 3.10c 191 ± 1.66 Highly soluble 
TK4B3 3.10d 207 ± 3.48 Highly soluble 




Tested at pH 7.4. 
 
3.5 Chloroquine-based tetrazole compounds 
Chloroquine (3.11) (Fig. 3.12), a 4-aminoquinoline drug, has a long history of being a first 
choice antimalarial drug. However, widespread resistance to chloroquine and other quinoline-
based antimalarials has exacerbated the problem of endemic malaria. Various researchers 
have postulated and shown that lengthening or shortening the chloroquine alkyl side chain 
leads to compounds which are effective against drug-resistant strains.
59
 However, recently 
Roepe et al.,
60 
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diethyl substituetnt on the terminal nitrogen. Although, there is still some debate among 
researchers regarding the influnce that result from the modification of the alkyl side-chain 
length, they all however agree that these modifications do not improve the metabolic stability 
of these chloroquine derivatives, especially N-dealkylation at the terminal tertiary amine that 
is normally observed in chloroquine and/or amodiaquine. This N-dealkylation at the terminal 
tertiary amine has been shown to be the cause of a reduced lipid solubility of these drugs, and 
as such it increases the potential for cross-resistance with chloroquine.
61
 As a result of this 
observation, Stocks et al.,
62
 and Madrid et al.,
63
 suggested and showed that substitutions on 
the terminal tertiary amine by a bulkier group increased the in vivo efficacy and decreased the 
potential for emergency of cross-resistance, presumably by circumventing metabolic N-
dealkylation. The mode of action of chloroquine is believed to involve the inhibition of 








Figure 3.12: Chloroquine, an antimalarial drug. 
 
Considering the facts highlighted above, the rationale for the design of the target compounds 
included an attempt to circumvent metabolic N-dealkylation of the tertiary amine by 
incorporating bulkier substituents such as the aromatic and tetrazole rings, while varying the 
length of the 4-amino alkyl side-chain in the proposed target compounds (Fig. 3.13). With the 
incorporation of the tetrazole ring, it was hypothesized that this would also significantly 

























Substituents on the aromatic ring
selected from in silico profiling
 
Figure 3.13: Rationale design for chloroquine-based target compounds. 
 
3.5.1 In Silico profiling 
In light of the rationale given above, the aim of performing in silico profiling in this sections 
was to get a sense of the metabolic degradation of the designed compounds. During the 
design, emphasis was placed specifically on circumventing N-dealkylation of the terminal 
amine found in 4-aminoquinoline alkyl side-chain by introducing bulkier substituents. Thus, 
the discussion in this section will only focus on this aspect of in silico profiling. Figure 3.14 
shows a series of 14 chloroquine-based tetrazole compounds that were profiled in silico for 
metabolic stability. In addition, the route of metabolism was also investigated via the in silico 

















































R= tBu 3.15a (TK900A)





R= tBu 3.15b (TK900B)
R= H  3.16b (TK900BB3)
R= tBu 3.15c (TK900C)
R= H  3.16c (TK900CB3)
R= tBu 3.15d (TK900D)
R= H  3.16d (TK900DB3)
R= tBu 3.15e (TK900E)
R= H  3.16e (TK900EB3)
R= tBu 3.15f (TK910)
R= H  3.16f (TK910B3)
R= tBu 3.15g (TK920)
R= H  3.16g (TK920B3)
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Chloroquine (3.11) was selected as a reference compound and compared to the designed 
chloroquine-based tetrazole compounds. The metabolic stability trend observed on the 
deoxyamodiaquine analogues (section 3.4.1) was also evident in this class of compounds, and 
this is to be expected since all these are 4-aminoquinoline-based compounds. The free 
tetrazole compounds (white) were predicted to have acceptable metabolic stabilities which 
were comparable to and in some instances better than chloroquine, while the protected 
tetrazoles (yellow) were shown to be metabolically unstable (red region) (Fig. 3.15). 
 
Figure 3.15: Plot of the proposed compounds projected onto metabolic stability PLS models.  
 
As mentioned earlier the route of metabolism of these compounds was investigated by 
MetaSite. Again, the software predicted correctly the experimentally observed metabolite of 
chloroquine, N-desethylchloroquine (Fig. 3.16).
62,65,66 
N-oxidation of the quinoline moiety 
was predicted to be the major route of metabolism for most of these compounds, except for 
3.15b and 3.16b, which were predicted to undergo O-demethylation of the para-methoxy 
group of the phenyl ring. In addition to the above mentioned likely sites of metabolism, p-
hydroxylation of the phenyl ring was predicted to be another possible route of metabolism for 
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oxidation was predicted to be another likely route of metabolism for compounds 3.15c and 
3.16c. Similar to the deoxyamodiaquine series, the protected tetrazole compounds were 
predicted to be less stable than the unprotected compounds. In summary, these predictions 
appear to suggest that N-dealkylation of the terminal amine alkyl side-chain is not a major 
route of metabolism in these proposed compounds.  
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3.5.2 Synthesis of chloroquine-based tetrazole derivatives 
3.5.2.1 Synthesis of precursor quinoline diamines 
The synthesis of the precursor quinoline diamines (3.13a-c) was achieved following known 
standard procedures reported in literature.
67,68,69
 A nucleophilic substitution reaction 
involving excess diamines (3.12a-c) (5.0 equivalents) and 4,7-dichloroquine (3.6) in neat 
reflux gave the desired quinoline diamines (3.13a-c) in good yields (Scheme 3.8, Table 3.5). 




C) and by 


















Scheme 3.8: Reagents and conditions: (i) Neat reflux 80 °C, 1 hrs, then 135 °C, 4 hrs.  
 






Compound n Yield/[%] 




3.13a 1 65 138-140 137-139 
3.13b 2 66 120-122 124-127 
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3.5.2.1.1 Mechanistic comments  
Before one can fully appreciate the mechanism of this nucleophilic substitution reaction, 
reactivity of the quinoline ring towards nucleophiles needs to be explained first; Quinoline (I) 
is a fused benzo[b]pyridine heterocyclic system, and as such its reactivity can be likened to 
that of benzene towards nucleophiles, and to that of pyridine towards electrophiles. The 
quinoline nitrogen atom causes the ring to be π-electron deficient through mesomeric and 
inductive effects, which are largely felt at the C-2 and C-4 positions due to their close 
proximity to the nitrogen atom (Fig. 3.17).
70
 Thus, these two positions are susceptible to 
nucleophilic attack and their reactivity is further enhanced by the presence of electron-
withdrawing substituents such as halogens in the ring. In the mechanism, nucleophilic attack 
at position C-4 by the amine (nucleophile) is facilitated by the nitrogen atom’s ability to act 
as an electron ‘sink’, and by resonance effect, which drives the observed regioselectivity 
(Scheme 3.18). 
 



































Chapter 3: Design, synthesis and biological evaluation of novel tetrazole-based aminoquinoline derivatives 
92 
3.5.2.2 Synthesis of the target compounds 
The quinoline diamines (3.13a-c) were then reacted with various aromatic aldehydes (3.14) 
following a similar procedure used in the synthesis of deoxyamodiaquine-based target 
compounds, except these reactions were conducted at 40 °C instead of 26 °C. Target 
compounds (3.15a1-a5, 3.15b and 3.15c) were obtained in poor to moderate yields after 
purification by column chromatography (Scheme 3.9, Table 3.6). Thereafter, these 
compounds were deprotected by refluxing at 120 °C in neat hydrochloric acid over a period 
of 8 hours to give the free tetrazole-based target compounds (3.16a1-a5, 3.16b and 3.16c), 
also in low to moderate yields (Scheme 3.9, Table 3.6). All the synthesized compounds were 
purified to acceptable levels of purity by HPLC. In addition, characterization was achieved 











































Scheme 3.9: Reagents and conditions: (i) TMSN3 (1.0 eq), t-Butyl isocyanide (1.0 eq), 
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Compound Code n R’’ R’ R Yield/[%] 
HPLC 
Purity/[%] 
3.15a1 TK900A 1 
t
Bu H H 65 98.5 
3.15a2 TK900B 1 
t
Bu H OCH3 57 99.0 
3.15a3 TK900C 1 
t
Bu H CH3 61 99.5 
3.15a4 TK900D 1 
t
Bu Cl Cl 11 99.2 
3.15a5 TK900E 1 
t
Bu H Cl 28 99.5 
3.15b TK910 2 
t
Bu H H 51 96.5 
3.15c TK920 3 
t
Bu H H 57 95.9 
3.16a1 TK900AB3 1 H H H 8 99.0 
3.16a2 TK900BB3 1 H H OCH3 38 97.4 
3.16a3 TK900CB3 1 H H CH3 31 98 
3.16a4 TK900DB3 1 H Cl Cl 58 99 
3.16a5 TK900EB3 1 H H Cl 27 99.2 
3.16b TK910B3 2 H H H 52 98.3 
















H NMR spectra confirming the presence of the desired products 3.15a1, 
3.15b and 3.15c is shown in Figure 3.19. The main differences between the spectra of these 
compounds are the extra signals due to the methylene and twice the methylene protons for 
compounds 3.15b and 3.15c, respectively, when compared to the spectrum of compound 
3.15a1. Since all the other inputs were constant in the synthesis of these compounds, the 
aromatic region is similar in all cases. Furthermore, the observed singlets resonating at 
approximately 5.3- 5.6 ppm are due to the protons of the newly created stereogenic centre, 
thus confirm the presence of the desired products. 
 
Figure 3.19: Superimposed 400 MHz 
1
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Confirmation of the deprotected compounds is exemplified by the superimposed 
1
H NMR 
spectra of compounds 3.15a2 and 3.16a2 (Fig. 3.20). It is important to note that the two 
compounds were analyzed in two different solvents (CDCl3 and DMSO-d6). However, the 
spectra suffice in terms of comparison purposes. From the 
1
H NMR spectrum of compound 
3.16a2, the absence of a singlet resonating at 1.62 ppm which corresponds to the three methyl 
protons of the tert-butyl group when compared to that of compound 3.15a2 confirms the de-
tert-butylation of the tetrazole ring. Furthermore, all the other signals are accounted for and 
appear to be similar in both spectra as expected since the only difference between the two 
compounds is the absence of the tert-butyl group in compound 3.16a2.  
 
 
Figure 3.20: Superimposed 400 MHz 
1
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3.5.3 Experimental determination of solubility 
Similar to the deoxyamodiaquine-based compounds, the de-tert-butylated chloroquine-like 
compounds exhibited superior aqueous solubility than the protected analogues (Table 3.7). 
However, the majority of compounds in this series had acceptable solubilities, with 3.16a5 
(207 ± 4.08 µM) being the most soluble at pH 7.0 while 3.15a4 (30.3 ± 0.47 µM) was the 
least soluble. Also, compounds 3.15b and 3.15c were found to be insoluble (< 5 µM). 
Commercially available chloroquine diphosphate was not determined because it was 
insoluble in 100% DMSO. 
 
Table 3.7: Results for experimentally determined solubility at pH 7.0 
Code Product Solubility at pH 7.0 (µM) Conclusion 
TK900A 3.15a1 181 ± 4.76 Highly soluble 
TK900C 3.15a3 110 ± 2.25 Highly soluble 
TK900D 3.15a4 30.3 ± 0.47 partially soluble 







TK900DB3 3.16a4 143 ± 2.77 Highly soluble 
TK900EB3 3.16a5 207 ± 4.08 Highly soluble 
TK910B3 3.16b 157.23
a
 Highly soluble 
TK920B3 3.16ac 196.12
a
 Highly soluble 




 Kinetic solubility performed at pH 7.4 
 
3.6 Primaquine-based target compounds 
Primaquine (3.17), an 8-aminoquinoline derivative, is currently the only available 
antimalarial drug that is active against both Plasmodium vivax and Plasmodium ovale latent 
liver forms of relapsing malaria.
71
 Primaquine is also the only available transmission-
blocking (from human host to mosquitoes) antimalarial drug which is active against the 














 Recently, for the first time Lougheed et al.,
73
 observed anti-
tuberculosis activity of primaquine and suggested that this scaffold could represent a new 
class of anti-TB drugs with a novel mode of action against the M. tuberculosis pathogen. On 
this basis it may be hypothesized that primaquine and its analogues could potentially find use 
in killing the dormant forms of M. tuberculosis bacteria given their activity against the 
dormant liver forms of the malaria parasite. However, this speculation remains to be proven 
experimentally. As effective as primaquine is, its clinical use is impaired by toxic side effects 
such as its implication in hemolytic anaemia in humans who are glucose-6-phosphate 
dehydrogenase (G6PD) deficient, a genetic condition commonly associated with African 
males, and intravascular hemolysis in pregnant women.
74
 Primaquine is rapidly metabolized 
via deamination into its inactive but toxic metabolite, carboxyprimaquine (3.18), which 
causes blood toxicity as a result of an induced oxidation of oxyhemoglobin to 
methemoglobin.
63
 Thus, there is a dire need for the design and synthesis of novel primaquine 
derivatives which are devoid of the formation of 3.18, but exert the same or improved 
efficacy against all forms of the human malaria parasite and M. tuberculosis without the 











Figure 3.21: Primaquine, an antimalarial drug and its metabolite, carboxyprimaquine. 
 
The rationale used in the design of primaquine-based target compounds is shown in Figure 
3.22. Similar to chloroquine-based compounds in section 3.4, a bulky moiety (consisting of a 
tetrazole and various aromatic rings) is introduced at the terminal amine. The aim of this 
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metabolism at that site while keeping the primaquine backbone intact. In addition, this was 
done in order to exploit the efficacy of primaquine while simultaneously limiting the 















Figure 3.22: Rationale behind the design of primaquine-based compounds. 
 
3.6.1 Synthesis of the target compounds 
The first step in the synthesis of primaquine-based target compounds (3.19a-e) was 
neutralization of a commercially available primaquine diphosphate salt (3.17) using 
triethylamine as a base, followed by the MCR strategy similar to that used in the synthesis of 
chloroquine-based target compounds (Scheme 3.10). The desired compounds 3.19a-e were 
obtained as racemic diastereomeric mixtures (1:1) in poor to moderate yields after 
purification (Table 3.8). Varying the mobile phase gradient and pH were undertaken in 
attempting to separate and/or resolve the diastereomers without success, and Figure 3.23 
shows an HPLC chromatogram of a diastereomeric mixture of compound 3.19a. From Figure 
3.23 it is evident that the diastereomers coalesce into a single sharp peak and this complicates 
matters when trying to separate these. Perhaps the best option of separating these 
diastereomeric mixtures would be to use a chiral column or chiral resolving agent. Due to 
time constraints, the use of superior separating methods on these distereomeric mixtures were 



































Scheme 3.20: Reagents and conditions: (i) TMSN3 (1.0 eq to the aldehyde and primaquine 
salt), t-Butyl isocyanide (1.0 eq), Et3N (4.0 eq), MeOH, 40 °C, 24 hrs. 
 











Compound Code R’ R Yield/[%] HPLC Purity/[%] 
3.19a TK1000A H H 21 99.3 
3.19b TK1000B H OCH3 40 99.5 
3.19c TK1000C H CH3 50 99.4 
3.19d TK1000D Cl Cl 17 99.5 
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C and mass spectrometry). 
Figure 3.24 shows a typical 
1
H NMR of one of the desired target compounds (3.19c). The 
important signals to note in this spectrum are the two sets of overlapping singlets between 
1.54 and 1.56 ppm, and between 5.20 and 5.23 ppm, which correspond to the tert-butyl 
protons and the H14 methine proton of each diastereomer in the racemic mixture. The 
appearance of these signals as overlapping singlets is a clear confirmation of the 
diastereomeric mixture of the target compound, and this is to be expected because of the 
presence of two stereogenic centres. The appearance of signals at 20.5, 30.0 and 47.9 ppm 
corresponding to carbons C10, C18 and C19, respectively, as multiplets in the 
13
C NMR 
spectrum (Fig. 3.25) also confirm the presence of a diastereomeric mixture.  
 
 
Figure 3.24: 400 MHz 
1
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Figure 3.25: 100 MHz 
13
C NMR spectrum of product 3.19c in CDCl3. 
 
3.7 Biological results and discussion 
In vitro antiplasmodial and antimycobacterial evaluation of all synthesized compounds were 
conducted in collaboration with: (i) London School of Hygiene and Tropical Medicine, 
University of London (LSHTM) (3D7 and K1); (ii) Department of Medicine, San Francisco 
General Hospital, University of San Francisco (W2); (iii) Swiss Tropical and Public Health 
Institute, Switzerland (STPH) (K1); (iv) Institute of Tuberculosis Research, College of 
Pharmacy, University of Illinois at Chicago (MABA and LORA assays); and (v) Institute of 
Infectious Disease and Molecular Medicine (IIDMM), University of Cape Town (7 and 14 
days MABA experiments).  
 
In all antiplasmodial assays, chloroquine, amodiaquine and primaquine were used as 
reference drugs for growth inhibition of P.falciparum chloroquine-sensitive (3D7) and 
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50% inhibitory concentration (IC50), and this describes the concentration of a drug necessary 
to cause 50% inhibition of growth or activity in the test sample. In antimycobacterial 
evaluation, the MABA (Microplate Alamar Blue Assay) and LORA (Low Oxygen Recovery 
Assay) were conducted and antimycobacterial activities are expressed as minimum inhibitory 
concentration (MIC90). Furthermore, streptomycin (SM), kanamycin (KAN), rifampin 
(RMP), isoniazid (INH), and PA-824 were used as controls. Cytotoxicity testing of selected 
compounds were conducted in Vero cell-lines (Institute of Tuberculosis Research, University 
of Chicago), in Chinese Hamster ovarian (CHO) cell-lines, using emetine as a reference drug 
in the standard MTT assay, which was used to measure cellular growth and chemosensitivity 
(Department of Pharmacology, University of Cape Town), and in L6 mammalian cell-lines, 
using podophylotoxin as a reference drug (STPH). Experimental details pertaining the assays 
can be found in the experimental section (Chapter 6). 
 
3.7.1 In vitro antiplasmodial evaluation of the target compounds 
3.7.1.1. Antiplasmodial activity of deoxyamodiaquine-based compounds 
The antiplasmodial activities of compounds 3.9a-3.10f against 3D7, K1 and W2 strains were 
determined and the results are shown in Table 3.9. This data revealed that most of these 
compounds had in vitro antiplasmodial activity against all three strains of the parasite, and 
the protected tetrazole-based compounds were generally more active than the deprotected 
analogues. Compounds 3.9b-c and 3.9k showed greater activity in the K1-resistant strain 
(IC50 ranging from 0.006 to 0.012 µM) than both reference drugs, i.e. amodiaquine and 
chloroquine. In fact, these compounds were 2- to 5-fold more active than amodiaquine, and 
3- to 6-fold more active than chloroquine, while compounds 3.10b-c had comparable activity 
to these reference drugs. The least active compound in this series against the K1 strain was 
3.10a (IC50 = 2.979 µM), which was about 80-fold less active than both drugs. Furthermore, 
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strain, while only compound 3.9k was more active than chloroquine in this strain. In addition, 
compound 3.10b had comparable activity to that of amodiaquine but was less active than 
chloroquine on the W2 strain.  
 
The differences in these antiplasmodial results between these two resistant strains (K1 and 
W2), although not too significant, might be due to the assay conditions used in the two 
experiments which were carried out at two independent laboratories. For instance, in the K1 
assays, only 0.5% parasitemia and 2.5% hematocrit were used, whereas in the W2 assays, 1% 
parasitemia and 2% hematocrit were used. Thus, the parasitemia load in the W2 assays was 
two times higher than the one used in the K1 assays. This might in some way explain why the 
tested compounds appeared to be more active in the K1 assays than they were in the W2 
assays.  
 
Generally, the reference drugs were more active than all the deoxyamodiaquine analogues in 
the 3D7-sensitive strain, the most active compound identified against this strain is 3.9c (IC50 
= 0.10 µM), which was 2-fold less active than chloroquine and 12-fold less active than 
amodiaquine. From the structural point of view, the para-compound 3.9k (IC50 values of 
0.012 and 0.040 µM on K1 and W2, respectively) exhibited superior activity than both the 
meta- 3.9a (IC50 values of 0.150 and 0.0227 µM on K1 and W2, respectively) and ortho- 3.9j 
(IC50 values of 3.51and 3.51 µM on K1 and W2, respectively) analogues on both resistant 
strains. Furthermore, on close inspection of the data in Table 3.7, there is no obvious trend in 
terms of the nature of the tertiary amine of each compound, but it appears that the majority of 
compounds that have an acyclic tertiary amine are generally more active than the 
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    R’ Position Code Product R 
P. falciparum IC50 (µM) Cytotox. 
(µM) 3D7 K1 W2 
 
meta TK1 3.9a N
 
0.052 0.150 0.227 64.8
a
 
“ TK2 3.9b N
 
0.100 0.006 0.066 110.8
b
 
“ TK3 3.9c N
 
0.010 0.0096 0.077 116.6
b
 
“ TK4 3.9d N
 
0.050 0.170 0.082 90.4
a
 
“ TK6 3.9f ON
 
0.099 1.29 0.195 46.8
a
 
ortho TK10 3.9j N
 
3.51 3.51 3.385 ND* 
para TK11 3.9k N
 




meta TK7 3.9g N
 
0.379 1.288 0.195 ND 
“ TK8 3.9h N
 
0.030 0.245 0.194 ND 
“ TK9 3.9i N
 
0.220 0.310 3.39 ND 
H  
“ TK1B3 3.10a N
 
0.487 2.979 1.168 ND 
“ TK2B3 3.10b N
 
0.164 0.054 0.475 ND 
“ TK3B3 3.10c N
 
1.097 0.049 0.181 ND 
“ TK4B3 3.10d N
 
0.286 1.264 0.487 ND 
“ TK6B3 3.10f ON
 











0.0360 0.0591 ND 




 Vero cells; 
b
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The in vitro cytotoxicity studies were conducted on the few selected compounds using Vero 
and Chinese Hamster Ovarian (CHO) mammalian cell-lines. Among the five compounds 
tested, compounds 3.9a (IC50 = 64.8 µM) and 3.9f (IC50 = 46.8 µM) were moderately 
cytotoxic while the other compounds exhibited no cytotoxicity with IC50 values greater than 
100 µM. However, the selective indices of all these compounds [3.9a (1246), 3.9b (1108), 
3.9c (11660) 3.9d (1808) and 3.9f (472), calculated from the IC50 (mammalian cell-line)/ IC50 
(3D7)] suggest that they are more selective towards the chloroquine-sensitive parasite than 
the mammalian cell-lines. Similar, selective indices on the two resistant strains (not shown) 
are also acceptable, suggesting that these compounds had overall acceptable cytotoxicity 
when viewed in terms of their selective indices. 
 
3.7.1.2 Antiplasmodial activity of chloroquine-based compounds 
The chloroquine-based compounds were also evaluated for antiplasmodial activity against the 
3D7, K1 and W2 strains, and were further assessed for cytotoxicity against L6 and CHO 
mammalian cell-lines (Table 3.10). It is important to note that the results for K1-resistant 
strain were obtained from two independent experiments (LSHTM and STPH), the 
chloroquine IC50 ranged from 0.036 to 0.220 µM, and these are indicated as such in Table 
3.10. The tert-butylated compounds 3.15a3-3.15c (highlighted in bold) were all more active 
than chloroquine on all tested strains of the parasite. More specifically, 6 out of the 7 
compounds tested against the 3D7 strain possessed greater activity than chloroquine, with 
compound 3.15a4 being the most potent while 3.15a2 was the least active. None of the de-
tert-butylated compounds were tested against the 3D7 strain. On the other hand, 6 (3.15a1, 
3.12a3- 3.15a7) out of the 14 compounds tested against K1 strain showed greater activity 
than chloroquine. Among the protected compounds, 3.15a5 (IC50 = 0.001 µM) was the most 
active on this strain, exhibiting 36-fold improvement in activity over chloroquine, while the 
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Product Code n R’’ R’ R 




(µg/mL)] 3D7 K1 W2 
3.15a1 TK900A 1 
t






Bu H OCH3 
3.821 0.155 0.046 ND 
3.15a3 TK900C 1 
t
Bu H CH3 0.001 0.002 0.0311 185.1 (83.3)
b
 
3.15a4 TK900D 1 
t
Bu Cl Cl 0.0004 0.008 0.0305 10.5 (5.30)
b
 
3.15a5 TK900E 1 
t
Bu H Cl 0.002 0.001 0.0255 97.8 (46.0)
b
 
3.15b TK910 2 
t
Bu H H 0.002 0.027 0.039 ND 
3.15c TK920 3 
t
Bu H H 0.002 0.008 0.020 ND 
3.16a1 TK900AB3 
1 H H H 
ND 14.9 (5.67)
ǂ
 ND 132.16 (50.2)
a
 
3.16a2 TK900BB3 1 H H OCH3 
ND 13.2 (5.42)
ǂ




1 H H CH3 
ND 17.4 (6.86)
ǂ




1 H Cl Cl 
ND 4.39 (1.97)
ǂ




1 H H Cl 
ND 2.38 (0.987)
ǂ




2 H H H 
ND 14.26 (5.62)
ǂ




3 H H H 
ND 6.849 (2.79)
ǂ
 ND 142.43 (58.1)
a
 
Chloroquine - 0.0052 0.036 0.059 - 
Chloroquineǂ - - 0.220 (0.11)ǂ - - 
Amodiaquine - 0.0086 0.0262 0.401 - 
Podophyllotoxin - - - - 0.0193 (0.008) 
Emertine  - - - 0.129b 
ǂ
Antiplasmodial testing done at STPH; 
a
L6 mammalian cell-lines; 
b
CHO mammalian cell-lines. 
 
The de-tert-butylated compounds were all less efficacious than chloroquine on this strain, 
their activities ranging from 10 to 80-fold less active than chloroquine. Against the W2-
resistant strain, almost all the compounds were more active than chloroquine, except 
compound 3.15a1 (IC50 = 0.069 µM) which was 1.2 times less active than chloroquine. 
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chloroquine. In terms of structure-activity relationships, the compound with the shortest 
ethylene spacer, 3.15a1, was less efficacious than compounds 3.15b (IC50 = 0.039 µM) and 
3.15c with longer carbon spacers on all strains tested. There is no obvious trend in terms 
antiplasmodial activity based on the nature of the substituents on the phenyl ring. However, a 
substituted phenyl ring appears to be favoured relative to the unsubstituted one. 
 
Almost all the compounds showed acceptable cytotoxicity on mammalian cell-lines, most 
having cytotoxicity values closer to or greater than 100 µM, except for compounds 3.15a1 
(IC50 = 7.54 µM) and 3.15a4 (IC50 = 10.5 µM). Furthermore, all these compounds have 
favourable selectivity indices (Table 3.11), indicating that these compounds are much more 
cytotoxic towards the parasite than the mammalian cell-lines. 
 
Table 3.11: Resistance indices of some chloroquine-based compounds. 
Product Code Resistance indices Selective index 
A
γ B§ 3D7 K1 W2 
3.15a1 TK900A 7.6 13.8 1508 198 109 
3.15a2 TK900B 0.041 0.012 - - - 
3.15a3 TK900C 2 31 185000 92550 5951 
3.15a4 TK900D 20 75 26250 1275 344 
3.15a5 TK900E 0.5 12.5 48900 97800 3835 
3.15b TK910 13.5 19.5  - - 
3.15c TK920 4 10  - - 
- Chloroquine 6.9 11.3  - - 
γ
Resistance index IC50(KI)/IC50 (3D7); 
§
 Resistance index IC50(W2)/IC50(3D7) 
 
Resistance indices of these chloroquine-based compounds are shown in Table 3.11. 
Resistance index is defined as the IC50 ratio of the chloroquine-resistant and chloroquine-
sensitive strains. This serves as an indication of the difference in activity of the synthesized 
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(or not) those compounds have potential to develop cross-resistance with chloroquine. 
Ideally, for favourable antimalarial compounds, resistance indices should be unity or closer. 
From the table, it is apparent that the majority of these compounds have high resistance 
indices, many of them higher than that of chloroquine. In this regard the most favourable 
compounds were 3.15a2, 3.15a3, 3.15a5, and 3.15c against the K1 strain, while for W2 strain 
only compounds 3.15a2 and 3.15c were favourable. Compounds 3.15a4 and 3.15b had the 
least favourable resistance index, suggesting that these have a potential to develop cross-
resistance with chloroquine. 
 
3.7.1.3 Antiprotozoan activity of primaquine-based compounds 
Table 3.12 shows the results obtained for primaquine-based compounds against chloroquine-
resistant strain (K1) and against cultured T. b. brucei parasite. Briefly, T. b. brucei is an 
extracellular protozoan parasite and a causative agent for Human African Trypanosomiases 
(HAT), or sleeping sickness, in about 300 000 to 500 000 people in Sub-Saharan Africa.
74
 A 
person becomes infected when bitten by an infected vector, a tsetse fly, and if this remains 
untreated it can lead to a coma or worse, death. The parasite multiplies in the skin before 
invading the hemolymphatic system where it develops into elongated trypomastigotes.
75 
Currently there is no vaccine for treating HAT, and there are two strategies that are employed 
in combating the disease; (i) vector control through use of insecticides, and (ii) prophylactic 
and therapeutic measures.
76 
However, drugs (e.g. melarsoprol) used for treating HAT are 
generally associated with toxic episodes. Thus, there is an urgent need for the development of 
novel drugs that will urgently address this disease. 
 
Reference drugs used for comparison purposes were primaquine for antiplasmodial and 
melarsoprol for T. b. brucei, and their in vitro IC50 values are shown in Table 3.12. All the 
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activity than primaquine. The most active compound in this series was 3.19d (IC50 = 1.311 
µM), which was 2-fold less active than primaquine. In addition, these compounds did not 
exhibit appreciable activity against T. b. brucei, the most active compound, 3.19b (IC50 = 
14.16 µM), was 1880-fold less active than melasorprol. Furthermore, these compounds 
showed unfavourable cytotoxicity profile towards the L6 mammalian cells, with 3.19a (IC50 
= 10.77 µM), 3.19c (IC50 = 12.94 µM), and 3.19e (IC50 = 31.30 µM) being the most 
cytotoxic. 
 












Entry Code R’’ R’ R 
P. falciparum 
IC50 µM (µg/mL) 









Bu H H 2.470 (1.17) 18.10 (8.57) 10.77 (5.10) 
3.19b TK1000B 
t
Bu H OCH3 1.979 (0.997) 14.16 (7.13) 75.45 (38) 
3.19c TK1000C 
t
Bu H CH3 1.573 (0.767) 18.54 (9.04) 12.94 (6.31) 
3.19d TK1000D 
t
Bu Cl Cl 1.311 (0.711) 18.30 (9.93) 87.93 (47.70) 
3.19e TK1000E 
t
Bu H Cl 1.799 (0.914) 21.45 (10.9) 31.30 (15.9) 
Primaquine - 0.615 (0.280) - - 
Melarsoprol - - 0.0075 (0.003) - 
Podophyllotoxin - - - 0.0193 (0.008) 
 
3.7.2 In vitro Antimycobacterial evaluation of the target compounds 
All the synthesized compounds were screened against drug-sensitive M. tuberculosis H37Rv 




 assays. MABA is non-toxic, uses a thermally stable 
reagent and shows good correlation with the radiometric BACTEC method.
80 
Briefly, MABA 
is a non-radiometric assay which uses an Alamar blue dye as an indicator of cellular growth. 
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allowing for growth measurements to be made. On the other hand, LORA is a luminescence-
based low oxygen adapted culture of recombinant M. tuberculosis H37Rv. This technique is 
used to evaluate the non-replicating persistent phenotype. In this section, MABA experiments 
were carried out at the Institute of Infectious Diseases and Molecular Medicine (UCT) and at 
the Tuberculosis Research Institute, (UIC). 
 
3.7.2.1 Antimycobacterial activity of deoxyamodiaquine-based compounds 
In vitro activities of the final compounds are shown in Table 3.13, and several compounds 
were found to inhibit the growth of both the replicating and non-replicating M. tuberculosis 
after 7 days of incubation. Compounds 3.9a, 3.9c-f inhibited over 90% of the replicating 
bacteria with MABA MICs ranging from 14.1 to 63.7 µM, with compound 3.9d (MIC90 14.1 
µM) being the most active among these. However, the most potent of all these compounds, 
3.9k (MIC90 = 7.6 µM), inhibited only 10% of the replicating bacteria. For comparison 
purposes, two of these deoxyamodiaquine compounds, 3.9d and 3.9k, had greater MICs than 
amodiaquine (MIC90 56.9 µM). The MICs of all the de-protected analogues were above the 
highest concentration (MIC90 > 128 µM) tested. 
 
Compounds 3.9a, 3.9c and 3.9k seemed to retain their activity in the LORA assay, and all 
had over 70% inhibitory effect on the non-replicating bacteria. Compound 3.9k, the most 
potent on LORA, inhibited about 96% of the non-replicating bacteria with a MIC90 value of 
15.1 µM. In addition, three compounds [3.9a (MIC90 = 118.7 µM), 3.9c (MIC90 = 74.0 µM) 
and 3.9k (MIC90 = 15.1 µM)] had MICs greater than that of a standard drug isoniazid (MIC90 
>128 µM) and amodiaquine (MIC90 = 125 µM) in the LORA assay. In summation, three 
compounds (3.9a, 3.9c and 3.9k) exhibited activity against both forms of the bacteria, while 
none of the deprotected analogues showed any activity at the highest concentration tested 
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    R’ Position Code Product R 
MABA (µM) LORA (µM) 
%Inh MIC90 %Inh MIC90 
 
meta TK1 3.9a N
 
97 63.7 79 118.7 
“ TK2 3.9b N
 
58 >128 37 >128 
“ TK3 3.9c N
 
99 59.3 91 74.0 
“ TK4 3.9d N
 
98 14.1 65 >128 
“ TK6 3.9f ON
 
97 59.1 72 >128 
ortho TK10 3.9j N
 
27 >128 26 >128 
para TK11 3.9k N
 




meta TK7 3.9g N
 
4 >128 -27 >128 
“ TK8 3.9h N
 
62 >128 40 >128 
“ TK9 3.9i N
 
70 >128 21 >128 
H  
“ TK1B3 3.10a N
 
-5 >128 9 >128 
“ TK2B3 3.10b N
 
13 >128 23 >128 
“ TK3B3 3.10c N
 
10 >128 13 >128 
“ TK4B3 3.10d N
 
6 >128 7 >128 
“ TK6B3 3.10f ON
 




99 56.9 92 125 
RMP 100 0.05 98 1.93 
INH 92 0.23 64 >128 
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The observable trends that could be delineated from these results are; (i) the para-substituted 
compound 3.9k (MABA and LORA MIC90 = 7.6 and 15.1 µM, respectively) possessed 
superior efficacy than the meta 3.9a (MABA and LORA MIC90 = 63.7 and 118.7 µM, 
respectively) and ortho 3.9j (both MABA and LORA MIC90 > 128) analogues on both the 
MABA and LORA assays; (ii) the t-butyl substitution on the tetrazole ring appears to be 
highly favoured compared to the ethylmorpholine moiety and when there is no substitution. 
Lastly, antimycobacterial activity is greatly influenced by solubility, similar to the 
antiplasmodial activity. Compounds that are less soluble (protected analogues) are 
substantially more active than the highly soluble (de-tert-butylated) analogues on both the 
replicating and non-replicating bacteria.  
 
3.7.2.2 Antimycobacterial activity of chloroquine-based compounds 
The in vitro MABA assays used to screen these chloroquine-based compounds were 
conducted at two different laboratories. The 7 day MABA (and LORA) experiments were 
conducted at the Tuberculosis Research Institute, University of Illinois at Chicago, while the 
7 and 14 day experiments were performed at the Institute of Infectious Disease and Molecular 
Medicine (IIDMM), University of Cape Town. Several compounds were found to effectively 
inhibit the growth of both replicating and non-replicating M. tuberculosis with reasonable 
MICs (Table 3.14). The para-substituted phenyl ring is highly preferred in the MABA assay; 
compounds 3.15a3-a5, all para-substituted, completely inhibited the growth of the bacteria, 
with MICs in the low micromolar range (5.6 to 14.3 µM). In addition, another para-
substituted phenyl-based compound, 3.15a2, possessed an MIC90 of 40.4 µM. Furthermore, 
the disubstituted phenyl ring was more efficacious than the mono- and the un-substituted 
rings. Elongation of the alkyl side-chain, going from n=1 to n=3, reduced the activity by 2-
fold; 3.15a1 (n=1, MIC90 = 20.9 µM), 3.15b (n=2, MIC90 = 29.0 µM) and 3.15c (n=3, MIC90 
= 47.8 µM). Compound 3.15a1 had a two-fold decrease in activity on the 14
th
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80 µM) of incubation compared to the 7
th
 day (MIC90 = 40 µM), possibly due to degradation. 
Similar to the trend observed with deoxyamodiaquines, the deprotected tetrazoles did not 





 day experiments. 
 














%Inh MIC90 %Inh MIC90 7days 14days 
3.15a1 TK900A 1 
t
Bu H H 10 20.9 99 57.6 40 80 
3.15a2 TK900B 1 
t
Bu H OCH3 10 40.4 100 57.2 ND ND 
3.15a3 TK900C 1 
t
Bu H CH3 99 14.3 100 29.7 ND ND 
3.15a4 TK900D 1 
t
Bu Cl Cl 100 5.6 99 13.5 ND ND 
3.15a5 TK900E 1 
t
Bu H Cl 100 6.7 100 24.0 ND ND 
3.15b TK910 2 
t
Bu H H 100 29.0 100 52.1 ND ND 
3.15c TK920 3 
t
Bu H H 99 47.8 100 60.2 ND ND 
3.16a1 TK900AB3 1 H H H ND ND ND ND >160 >160 
3.16a2 TK900BB3 1 H H OCH3 ND ND ND ND >160 >160 
3.16a3 TK900CB3 1 H H CH3 ND ND ND ND >160 >160 
3.16a4 TK900DB3 1 H Cl Cl ND ND ND ND >160 >160 
3.16a5 TK900EB3 1 H H Cl ND ND ND ND >160 >160 
3.16b TK910B3 2 H H H ND ND ND ND >160 >160 
3.16c TK920B3 3 H H H ND ND ND ND >160 >160 
RMP - 100 0.05 98 1.93 0.002 ND 
INH - 92 0.23 64 >128 - - 
PA-824 - 99 0.12 100 3.78 - - 
Moxifloxacin  100 0.29 88 31.1   
Kanamycin  - - - - 3.125 3.125 
Streptomycin  - - - - 0.4 0.4 
ǂ 
Experiments conducted at Tuberculosis Research institute (UIC); 
§ 
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Regarding the LORA results, the para-substituted phenyl-based compounds also exhibited 
superior antimycobacterial activity than the unsubstituted analogues, as in the MABA assay. 
There is no clear trend that could be deduced from these results regarding the elongation of 
the alkyl side-chain. Compounds 3.15a3 (MIC90 = 13.5 µM) and 3.15a4 (MIC90 = 24.0 µM) 
were more potent than the two standard drugs isoniazid (MIC90 >128 µM) and moxifloxacin 
(MIC90 = 31.1 µM). Furthermore, compound 3.15a4 was the most active in this series with 
significant MICs (MABA, 5.6 µM and LORA, 13.5 µM) on both bacterial forms. 
 
Similar to the deoxyamodiaquine series, compounds that were experimentally determined to 
be less soluble (protected analogues) were more active than the highly soluble (de-tert-
butylated) analogues on both bacterial forms.  
 
3.7.2.3 Antimycobacterial activity of primaquine-based compounds 
















3.19a TK1000A tBu H H >160 >160 
3.19b TK1000B t
Bu H OCH3 
>160 >160 
3.19c TK1000C tBu H CH3 >160 >160 
3.19d TK1000D tBu Cl Cl >160 >160 
3.19e TK1000E tBu H Cl >160 >160 
Primaquine - 80 80 
RMP - 0.002 ND 
Kanamycin - 3.125 3.125 
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These 7 and 14 day in vitro antimycobacterial assays were conducted at the Institute of 
Infectious Disease and Molecular Medicine (IIDMM), University of Cape Town. All the 
primaquine-based compounds were tested as (1:1) diastereomeric mixture and the results are 
shown in Table 3.15. None of these compounds showed any antimycobacterial activity at the 
highest tested concentration (MIC90 >160 µM), while primaquine exhibited modest activity 
with an MIC90 value of 80 µM on both the 7 and 14 day assay. The complete loss of activity 
observed on these primaquine derivatives was unexpected, however, the antimycobacterial 





In conclusion, a focused small library of compounds based on the deoxyamodiaquine, 
chloroquine and primaquine scaffolds were evaluated for their antiplasmodial and 
antimycobacterial activity. In the deoxyamodiaquine series, protected-tetrazole based 
compounds 3.9b-c and 3.9k (IC50 ranging from 0.006 to 0.012 µM) showed superior 
antiplasmodial activity than both amodiaquine (IC50 = 0.02689 µM) and chloroquine (IC50 = 
0.0360 µM) in the K1-resistant strain. In addition, two deprotected compounds 3.10b (IC50 = 
0.054µM) and 3.10c (IC50 = 0.049 µM) exhibited comparable activities to those of the 
reference drugs. Similarly, compounds 3.9a-f, 3.9k and 3.10c (IC50 ranging from 0.040 to 
0.194 µM) were all more potent than amodiaquine (IC50 = 0.4007 µM ) in the W2-resistant 
strain, while only compound 3.9k (IC50 = 0.040 µM) was more active than chloroquine (IC50 
= 0.0591 µM ) on the same strain. In the chloroquine-sensitive strain (3D7), none of the 
synthesized compounds were more potent than the reference drugs. Compound 3.9c (IC50 = 
0.10 µM) was the most active, but was 2-fold less active than chloroquine and 12-fold less 
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Similarly, some of these compounds also exhibited encouraging activity against drug-
sensitive H37Rv M. tuberculosis strain. Compounds 3.9a, 3.9c-f inhibited over 90% of the 
replicating bacteria (MICs ranging from 14.1 to 63.7 µM), with compound 3.9d (MIC90 = 
14.1 µM) being the most active among these. The most potent compound of all the 
deoxyamodiaquines was 3.9k with a MIC90 value of 7.6 µM, but this compound barely 
inhibited (10%) the replicating bacteria. In addition, compounds 3.9d and 3.9k were more 
efficacious than amodiaquine (MIC90 = 56.9 µM), while the de-protected analogues did not 
exhibit any activity. Against the non-replicating bacteria, compounds 3.9a (MIC90 = 118.7 
µM), 3.9c (MIC90 = 74 µM) and 3.9k (MIC90 = 15.1 µM) were the most active, and all had 
over 70% inhibitory effect on the bacteria. Compound 3.9k was the most potent against the 
non-replicating bacteria, with 96% inhibition and an MIC90 of 15.1 µM. Furthermore, 
compounds 3.9c and 3.9k possessed MICs greater than that of a standard drug isoniazid 
(MIC90 >128 µM), and in addition to 3.9a, they had superior efficacy than amodiaquine. 
Lastly, all these compounds showed acceptable cytotoxicity profiles, indicating that they are 
more selective towards the parasite or bacteria than they are towards the mammalian cells 
evaluated.  
 
The chloroquine-based compounds were also assessed for antiplasmodial activity; 6 out of 
the 7 compounds tested against the 3D7 strain possessed activity greater than that of 
chloroquine. Compound 3.15a4 (IC50 = 0.0004 µM), the most potent, was 13-fold more 
active than chloroquine (IC50 = 0.0052 µM), while 3.15a2 (IC50 = 3.821 µM) was the least 
active and was 732-fold less active than chloroquine. Of the 14 compounds tested against K1- 
strain 6 compounds showed greater activity than chloroquine. Compound 3.15a5 (IC50 = 
0.001 µM) was the most active exhibiting a 36-fold improved activity over chloroquine (IC50 
= 0.036 µM), and the least active was 3.15a2 (IC50 = 0.155 µM). Against the W2 strain, 
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except compound 3.15a1 (IC50 = 0.069 µM) which was 1.2 times less active. Compound 
3.15c (IC50 = 0.020 µM) was the most active with a 3-fold superior activity over chloroquine. 
In addition, the compound with the shortest ethylene spacer, 3.15a1, was less efficacious than 
those with the longer carbon spacers, 3.15b and 3.15c, on all strains tested.  
 
Furthermore, compounds 3.15a3-a5 completely inhibited the growth of the replicating 
bacteria, with MICs in the range 5.6 to 14.3 µM, and the most active being 3.15a4 (MIC90 = 
5.6 µM). Structurally, the para-substituted phenyl-based compound were more efficacious 
than the mono- and the un-substituted. Contrary to antiplasmodial evaluation, the elongation 
of the alkyl side-chain had detrimental effect on activity, reducing it by 2-fold going from 
n=1 to n=3. With regards to the non-replicating bacteria, the para-substituted phenyl-based 
compounds also demonstrated superior activity when compared to the unsubstituted variants. 
Compounds 3.15a3 (MIC90 = 13.5 µM) and 3.15a4 (MIC90 = 24.0 µM) were the most potent 
in this assay and they were also more active than the two standard drugs used, isoniazid 
(MIC90 >128 µM) and moxifloxacin (MIC90 = 31.1 µM). In addition, compound 3.15a4 
showed encouraging MICs (MABA, 5.6 µM and LORA, 13.5 µM) on both mycobacterial 
forms. All the synthesized compounds showed acceptable cytotoxicity on the Vero and CHO 
cell lines, the majority having cytotoxicity values closer to or greater than 100 and excellent 
selective indices.  
 
The primaquine-based compounds also possessed antiplasmodial activity albeit not as good 
as the reference drug, primaquine. The most active compound in this series was 3.19d (IC50 = 
1.311 µM), which was 2-fold less active than primaquine (IC50 = 0.615 µM), while the least 
active, 3.19a (IC50 = 2.470 µM), was 4-fold less active than primaquine. In addition, none of 
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the MIC90 values. Furthermore, these compounds showed unfavourable cytotoxicity profile 
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Synthesis and biological evaluation of 4-arylamino 
quinoline- and PA-824-tetrazoles, and β-Lactams 
 
4.1 Preface 
Encouraged by some of the results obtained from the deoxyamodiaquine and chloroquinoline 
tetrazoles (Chapter 3), the 4-arylamino quinoline and PA-824 scaffolds were utilized in 
designing the next series of compounds. The main objective of this undertaking was to 
generate compounds that will possess improved biological activity and physico-chemical 
properties compared to the parent drugs. Thus, this chapter will describe the synthesis and 
biological evaluation of tetrazoles based on the quinine-, mefloquine- and PA-824 scaffolds. 
In addition, a limited series of β-lactams is also described. In line with our overall goal in this 
project, in silico prediction tools were used in profiling the designed target compounds, 
synthesis of which was achieved through the use of the multi-component and Staudinger 
reactions. Lastly, in vitro antiplasmodial and antimycobacterial activity of the synthesized 
compounds is also disclosed. 
 
4.2 4-Arylamino quinolines 
The arylamino alcohol family of compounds include the 4-quinoline methanols, i.e. quinine 
and mefloquine, and their derivatives (Chapter 1, section 1.4.1.4.1A). About 400 years ago 
quinine’s effectiveness was first documented. However, this drug is still an important 
antimalarial drug today.
1
 Quinine (4.1) (Fig. 4.1) was one of the commonly used antimalarial 
drugs in the 1940s, and it was the first to be used for effectively treating malaria caused by P. 
falciparum.
2 
Since that time, however, quinine has been replaced by other quinoline-based 
antimalarial drugs such as chloroquine, amodiaquine and mefloquine. Despite its limited use, 
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action of quinine is unknown but is believed to exert its effectiveness against the asexual 
blood stage of the parasite because of its interference with the detoxification process of 
haematin.
3
 One drawback of quinine and its stereoisomer, quinidine, is their implication in 

















Figure 4.1: Quinine and Mefloquine, anti-malarial drugs. 
 
Mefloquine (4.2) (Fig. 4.1) was discovered by the Walter Reed Army Institute of Research 
(WRAIR) in the 1960s following widespread resistance to quinine.
5
 Mefloquine is a long-
acting blood schizontocide, which is highly effective against the multi-drug resistant P. 
falciparum.
6
 Mefloquine is also effective against all human malaria causing species, 
including P. Knowles.
7
 The mode of action of mefloquine is not clearly understood but is 
believed to act in a similar way as quinine.
8
 As effective as mefloquine is, its use is limited by 
adverse events such as neuropsychiatric adverse reactions, gastro-intestinal intolerability, and 




As already mentioned, the exact mechanism of action for this class of antimalarial drugs is 
not clearly understood. However, recent studies have proposed that these compounds exert 
their activity through (i) π-stacking with the porphyrin ring of the haeme moiety, (ii) 
coordination with the iron centre of the heme via the alkoxide formation on the benzylic 
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chain of the haeme.
9,10,11 
Furthermore, the most convincing evidence in support of this 
proposed mode of action came from the crystal structure of the complex between halofantrine 





Figure 4.2: (a) Crystal structure of the haeme-halofantrine complex; (b) Highlighted 
halofantrine structural features responsible for the interaction with the haeme (reproduced 
from references 9a and 10).  
 
In the crystal structure, in addition to the π-stacking with the porphyrin ring (green), 
halofantrine is depicted coordinating with the iron centre of the haeme through its benzyl 
alcohol moiety (red), and forming intermolecular hydrogen-bonding with the propionate side-
chain of the haeme through its tertiary amine of the alkyl side-chain (blue). The same group 
expanded the scope of this study by further investigating the coordinating ability of various 
nitrogen donor ligands such as imidazoles, pyridines and amines with the haeme.
9b,10 
From 
this study they discovered that nitrogen donor ligands containing sp
2
 hybridised nitrogen, i.e. 
imidazoles and pyridine ligands, formed strong coordination with the iron centre of the 
haeme. 
 
In our study, we hypothesized that incorporating the tetrazole ring that contains sp
2
 
hybridised nitrogen atoms, and the tertiary amine moiety in the arylamino quinoline core 
should potentially satisfy the three key requirement for activity of this class of compounds. 
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exploited by Roman et al.,
12
 in the design of haeme oxygenase inhibitors, and by Adachi et 
al.,
13
 in ligand binding studies of tetrazole-myoglobin complex. As such, in the design of our 
new analogues, the O-donor hydroxyl group is replaced with the N-donor tetrazole moiety, 
while the bridged six membered heterocyclic ring in quinine (Fig. 4.3A) or the piperidine ring 

































Figure 4.3: Substructure replacement in the design of quinine- and mefloquine-based target 
compounds. 
 
4.2.1 In silico Profiling 
The arylamino quinolines that were profiled in silico for aqueous solubility, metabolic 
stability, and blood-brain barrier (BBB) penetration are shown in Figure 4.4. The inclusion of 
the blood-brain barrier model was due to the fact the mefloquine and its derivatives tend to 
accumulate in the central nervous system (CNS).
14
 Moreover, quinine has also been shown to 














Thus, designing compounds with reduced permeation through the 


























































R= tBu (4.12a) (TK501)
R= H (4.14a) (TK501B3)
R= tBu (4.12b) (TK502)
R= H (4.14b) (TK502B3)
R= tBu (4.12c) (TK503)
R= H (4.14c) (TK503B3)
R= tBu (4.12d) (TK504)
R= H (4.14d) (TK504B3)
R= tBu (4.12e) (TK505)
R= H (4.14e) (TK505B3)
R= tBu (4.12f) (TK506)
R= H (4.14f) (TK506B3)
R'= Me (4.13a) (TK710)
R'= Et (4.13b) (TK720)
 
Figure 4.4: Structures of quinine- and mefloquine derivatives for in silico profiling. 
 
At both pHs 5.0 and 7.5, the designed target compounds exhibited comparable and in some 
instances better predicted aqueous solubility than both reference drugs, quinine and 
mefloquine (Fig. 4.5). At pH 5, the majority of the deprotected quinine derivatives were 
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soluble. The t-butyl protected quinine derivatives showed reduced solubility compared to 
quinine, the least soluble compound in this series being 4.12e. Mefloquine was predicted to 
be more soluble than its derivatives (4.13a and 4.13b) but less soluble than quinine at pH 5. 
This was expected since mefloquine and its derivatives are known to be more lipophilic than 
quinine. 
 
A similar trend to the one observed at pH 5 was also displayed by these target compounds at 
pH 7.5. The deprotected quinine derivatives were predicted to be about 100-fold more soluble 
than quinine, while the t-butyl protected derivatives had similar solubilities to quinine. This 
was also anticipated since the free tetrazoles are known to have strong acidic characteristics, 
hence they are easily ionised in basic conditions. Mefloquine on the other hand was again 
predicted to be more soluble than its analogues. The log D values of these compounds 
appeared to be highly influenced by the different pHs. The t-butyl protected quinine 
derivatives had lower log D values at pH 5 (ranging from 0 to 0.75) than at pH 7.5 (ranging 
from 1.8 to 2.8), while log D variations for the deprotected compounds was not as significant.  
 
Figure 4.5: Plots of predicted aqueous solubility (log S) against n-octanol-water partition 
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Quinine and its derivatives were predicted to have acceptable metabolic stability (they all fall 
in the blue region) (Fig. 4.6). The deprotected derivatives were predicted to be more stable 
than quinine and the t-butyl protected analogues. Metabolic stability of mefloquine and its 
derivatives fell outside the 99% confidence interval, i.e. outside the solid ellipsoid, thus these 
compounds could not be reliably quantified. 
 
Figure 4.6: Plots showing the designed target compounds projected onto PLS models used to 
predict metabolic stability and blood-brain barrier permeation.  
 
In addition, quinine and its t-butyl protected derivatives were predicted to have higher 
permeation through the blood-brain barrier, while the deprotected derivatives were not (Fig. 
4.6). This observation to some extent lends support to the observed dose-related CNS effects 
caused by quinine. Mefloquine was also predicted to cross the blood-brain barrier as expected 
since this drug accumulates in the CNS. However, its two derivatives were predicted to have 
a reduced affinity for crossing the blood-brain barrier. It is important to note that these 
models were merely used as guide and indicator of potential physico-chemical properties 
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4.2.2 Synthesis of quinine and mefloquine derivatives 
4.2.2.1 Synthesis of quinine and mefloquine nuclei 
The first step in the synthesis of quinine and mefloquine derivatives involved the synthesis of 
quinine and mefloquine nuclei, i.e. 6-methoxyquinoline-4-carbaldehyde (4.8) and 2,8-
bis(trifluoromethyl)quinoline-4-carbaldehyde (4.11). In synthesizing the quinine nucleus, 
procedures described by Daines et al.,
16
 and Mao et al.,
17
 were followed. Initially, the 
Meldrum’s acid (4.4) was refluxed in ethanol with triethyl orthorformate to give an 
intermediate, methoxyethylene Meldrum’s acid, in situ. This intermediate was then 
condensed with p-anisidine (4.3) via the addition-elimination reaction to yield an ene-amine 
intermediate 4.5, which was subsequently used without further purification (Scheme 4.1).
18
 
Intermediate 4.5 undergoes intramolecular thermal cyclisation when refluxed in Dowtherm A 
to form the 6-methoxyquinolin-4-ol (4.6) in good yields upon cooling and subsequent 
precipitation with diethyl ether. Thereafter, the 6-methoxyquinolin-4-ol was brominated at 
room temperature by the slow addition of phosphorus tribromide under inert nitrogen 
atmosphere to give the 4-bromo-6-methoxyquinoline (4.6) in reasonable yields. The quinine 
nucleus then formed via the n-BuLi mediated formylation of 4-bromoquinoline in good 
yields.  
 
The mefloquine nucleus was synthesized following a procedure described by Milner et al.
14
 
The commercially available 2,8-bis(trifluoromethyl)quinoline-4-ol (4.9) was melted with 
phosphorus oxybromide at 75 to 150 °C to give rise to the 4-bromo-2, 8-
bis(trifluoromethyl)quinoline (4.10) in reasonable yields (Scheme 4.2). The mefloquine 
nucleus, 2,8-bis(trifluoromethyl)quinoline-4-carbaldehyde (4.11), was also obtained via the 
n-BuLi mediated formylation of 4-bromo-2,8-bis(trifluoromethyl)quinoline in low yields, and 







































Scheme 4.1: Reagents and conditions: (i) triethyl orthorformate (1.0 eq), EtOH, reflux, 4 hrs, 
80%; (ii) Dowtherm A, 250 °C, 20 min, 90 %; (iii) PBr3 (1.2 eq), DMF, N2, 2 hrs, rt, 55%; 



















Scheme 4.2: Reagents and conditions: (i) POBr3 (8.0 eq), 75 
o
C to 150 
o
C, 2 hrs, 65%; (ii) 
THF, n-BuLi (3.0 eq), DMF, -78 °C, 3 hrs, 29% (crude yield).  
 
4.2.2.2 Mechanistic comments on the synthesis of 6-methoxyquinolin-4-ol (4.6) 
Meldrum’s acid is a highly acidic (pKa 4.97) and versatile synthetic reagent that readily 
undergoes mono- or di-functionalisation at the 5 or (β) position due to its propensity to 
enolize.
19,20 
The mechanism begins when triethyl orthoformate first expels an ethoxide ion 
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the formation of electrophilic oxonium ion (B).
21
 This oxonium ion is then attacked by the 
enolate to give rise to intermediate II (Scheme 4.3). Abstraction of the second acidic proton 
in II results in ethoxymethylene Meldrum’s acid intermediate III, which undergoes a 
Michael addition reaction with the p-anisidine 4.3 to give intermediate IV that rearranges into 
intermediate V, which then form an ene-amine intermediate 4.5.
18 
The nitrogen lone-pair of 
electrons then activates the ortho position of the ring (VI),
22
 and this activated intermediate 
then undergoes intramolecular cyclisation via the elimination of acetone to give intermediate 
VII. Subsequent thermal decarboxylation and proton transfer of intermediate VII results in 



































































Scheme 4.3: Proposed mechanism for the formation of 6-methoxyquinolin-4-ol (4.6). 
 
4.2.2.3 Synthesis of quinine- and mefloquine-based tetrazoles 
With the desired nuclei (4.8 and 4.11) in hand, the modified TMSN3-Ugi MCR procedure 
described in chapter 3, was followed to give the desired target compounds, 4.12a-f and 4.13a-
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Table 4.1). Furthermore, HPLC purity check of the synthesized compounds confirmed purity 























Scheme 4.4: Reagents and conditions: (i) TMSN3 (1.0 eq), MeOH, 26 °C, 24 hrs.  
 






















4.12a  TK501 N
 
OMe H 65 95.2 101-103 
4.12b TK502 N
 
OMe H 80 99 118-121 
4.12c TK503 N
 
OMe H 46 96.6 - 
4.12d TK504 N
 
OMe H 87 95.5 117-119 
4.12e TK505 NMeN
 
OMe H 56 98.9 140-144 
4.12f TK506 ON
 
OMe H 75 93.8 110-112 
4.13a TK710 N
 
H CF3 22 98.9 171-173 
4.13b TK720 N
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Figure 4.7 shows superimposed 
1
H NMR spectra of the representative compounds 4.12a and 
4.13a. Singlets at 1.56, 2.48, 3.99 and 6.12 ppm in the spectrum of 4.12a are due to the nine 
protons of the t-butyl group (H11), six protons of the two methyl groups (H10), methoxy 
protons, and H9 methine proton, respectively. Similarly, in the spectrum of 4.13a, singlets at 
1.60, 2.43, and 6.29 ppm are due to the nine protons of the t-butyl group (H10), six protons of 
the two methyl groups (H9), and H8 methine proton, respectively. Moreover, in both 
compounds protons in the aromatic regions are accounted for, thus these in addition to the 
mass spectrometry confirm the formation of the desired target compounds. 
 
 
Figure 4.7: Superimposed 400 MHz 
1
H NMR spectra of products 4.12a and 4.13a in CDCl3. 
 
4.2.2.4 De-tert-butylation of quinine-based tetrazole compounds 
The de-tert-butylation procedure disclosed in chapter 3 was followed in the synthesis of de-
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mentioning that de-tert-butylation of the mefloquine derivatives was not attempted due to the 



















Scheme 4.5: Reagents and conditions: (i) neat 32% HCl, 120 °C, 8-12 hrs. 
 

















4.14a  TK501B3 N
 
33 95.8 159-162 
4.14b TK502B3 N
 
15 96.7 168-171 
4.14c TK503B3 N
 
13 95.1 211-214 
4.14d TK504B3 N
 
28 95.2 131-134 
4.14e TK505B3 NMeN
 
34 95.6 176-179 
4.14f TK506B3 ON
 
21 99.1 137-140 
 





C) and mass spectrometry. Figure 4.8 shows superimposed 
1
H NMR 
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compound. The main differences between the spectra of the two compounds is the absence of 
a singlet at 1.56 ppm that corresponds to the nine protons of the tert-butyl group (H12) and 
the downfield shift of H3 signal in the spectrum of compound 4.14b when compared to that 
of compound 4.12b.  
 
 
Figure 4.8: Superimposed 400 MHz 
1
H NMR spectra of products 4.12b in CDCl3 and 4.14b 
in DMSO-d6. 
 
4.2.3 Experimental determination of solubility 
Experimentally determined kinetic solubility results of the selected arylamino quinoline 
derivatives at pH 7.4 are shown in Table 4.3. It is important to note that for comparison 
purposes only one of the de-tert-butylated compounds was assayed for solubility. From Table 
4.3 it is clearly evident that all these compounds exhibited high solubility, with values greater 
than 100 µM. Also, as was in the in silico predictions, the de-tert-butylated compound 4.14f 
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Furthermore, quinine (186.68 µM) was more soluble than these compounds except for 
compounds 4.12a (189.45 µM) and 4.14f (201.86 µM), confirming the results of the in silico 
predictions. 
 
Table 4.3: Results for experimentally determined kinetic solubility at pH 7.4 
Code Product Solubility at pH 7.4 (µM) Conclusion 
TK501 4.12a 189.45 Highly soluble 
TK502 4.12b 136.84 Highly soluble 
TK504 4.12d 114.44 Highly soluble 
TK506 4.12f 178.54 Highly soluble 
TK506B3 4.14f 201.86 Highly soluble 




4.3.1 Brief background on nitroimidazooxazines 
Imidazole, a privileged scaffold, is a five-membered heterocyclic system that has a wide 









 and antiviral activity
27
 among others. Nitroimidazoles are a 
special class of compounds that are widely used in the management of anaerobic bacterial 
and protozoan infections.
28
 In addition, nitroimidazoles have been shown to possess activity 




Nitroimidazooxazines are pro-drugs that are highly effective against both the replicating and 
non-replicating persistent forms of M. tuberculosis, a causative agent of TB.
30,31
 Their 
activity is believed to arise as a result of metabolic activation of the nitroimidazole ring, 
which leads to the generation of nitric oxide as an active species.
32
 An example of a 
nitroimidazooxazine-based antitubercular drug is PA-824. This drug is active against the 














 PA-824 is being developed by the Global Alliance for TB Drug Development and 
is currently undergoing phase III clinical trials. From the SAR studies, the key structural 
features that have been identified to be responsible for the activity of PA-824 are the nitro 
group at the 4-position of the imidazole ring, the conformationally rigid bicyclic system, the 
S-configuration of the stereogenic centre, and the lipophilic group at the para-position of the 
phenyl ring (Fig. 4.9).
32,33,34 
Interestingly, the S-enantiomer of PA-824 is at least 100-fold 
more active than the R-enantiomer.
31
 The main drawbacks of this drug are its poor aqueous 
solubility and its propensity to bind to proteins in human plasma.
35,36
 Various strategies have 
been utilized in attempts to address these shortcomings. These include the synthesis of 
biphenyl analogues of PA-824,
37
 the incorporation of the five-membered heterocyclic 
systems in PA-824,
34
 the use of urea, carbamate and amide linkers in the place of the benzyl 
ether,
30
 and hybridisation of PA-824 with oxazolidinone
38
 among others. However, very few 
of these studies managed to improve these shortcomings while simultaneously retaining a 
similar or improved activity than PA-824. Thus, the aim of this study was to design and 
synthesize tetrazole derivatives of PA-824 that would possess improved physico-chemical 
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for rigid conformation
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4.3.2 Rationale behind the design of PA-824 tetrazoles 
The focus of the PA-824-oxazolidinone hybrids mentioned above was to investigate the 
effects of substituting the terminal lipophilic trifluoromethyl ether group in PA-824 (Fig. 
4.10). From these studies, Ding et al.,
38
 discovered that a number of these hybrids had 
improved activity compared to PA-824, and they also possessed a broad spectrum of activity. 
In an analogous manner to these hybrids, our rationale behind the design of PA-824-tetrazole 
derivatives is also depicted in Figure 4.10. It involved replacing the hydrophobic 
trifluoromethyl ether group with a tetrazole moiety and various ionisable tertiary or 















Retain the core structure of PA-824
for antitubercular activity
But
Introduce tetrazole ring for
improved physico-chemical properties
Incoporating ionizable tertiary





















Figure 4.10: Rationale for the design of PA-824-tetrazole derivatives. 
 
4.3.2.1 In silico profiling 
As already mentioned above, the objective of our work on the nitroimidazooxazine was to 
design PA-824 derivatives that would be able to address the shortcomings of the PA-824 (i.e. 
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proposed series of PA-824 derivatives that were profiled in silico for aqueous solubility, 
permeability, metabolic stability, Protein_Binding (PB), and volume of distribution (VD). Hu 
et al.,
36
 showed that 94% of PA-824 was protein bound in human plasma when given orally, 
thus this coupled with poor aqueous solubility of PA-824 have a negative impact on the oral 
bioavailability of this drug. Hence, this necessitated the inclusion of PB and VD models in 
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At pH 5, eight of the ten designed target compounds exhibited improved predicted aqueous 
solubilities than PA-824, the most soluble being compound 4.19e (Fig. 4.12). This was 
anticipated since most of these new compounds contain ionisable centres and would exist 
predominantly in their ionized state at low pH levels. Primaquine-based PA-824 derivatives 
(4.19g and 4.19h) were predicted to be the least soluble at this pH. Similarly at pH 7.5, 
compounds 4.18a-b and 4.19a-c showed superior solubility compared to PA-824, while 
compounds 4.19d-f had comparable solubilities to that of the parent drug. Just like at pH 5, 
primaquine-based PA-824 derivatives (4.19g and 4.19h) were less soluble than PA-824. 
 
Figure 4.12: Plots of predicted aqueous solubility (log S) against n-octanol-water partition 
coefficient (log D) at pH 5.0 and 7.5.  
 
Prediction of Caco-2 permeability, metabolic stability, PB and VD were all qualitative. All 
the designed compounds and PA-824 were predicted to have acceptable Caco-2 permeation 
(Fig. 4.13A). Compounds 4.18a-b and 4.19a-c were predicted to have comparable metabolic 
stability to PA-824, while compounds 4.19d-h had relatively poor metabolic stabilities (Fig. 
4.13B). 
 
Volsurf+ Protein_Binding model reports mainly albumin protein binding values and the 
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from literature and laboratories connected to the creators of the software. When these novel 
PA-824 derivatives were projected onto the two dimensional PLS plot of the database 
compounds used to generate the PB model, compounds 4.18a-b and 4.19a-c showed 
intermediate protein binding similar to PA-824, while compounds 4.19d-h fell outside the 
quantifiable range, thus could not be assigned whether they are protein bound or not (Fig. 
413C). However, due to the lipophilic nature of compounds 4.19d-h, possibly they would 
bind to proteins in human plasma. 
 
Figure 4.13: Plots showing the designed target compounds projected onto PLS models used 
to predict Caco-2 permeability, metabolic stability, protein binding (PB), and volume of 
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In an attempt to get an idea on the distribution profile of these new PA-824 derivatives in the 
body, Volsurf+ volume of distribution model was utilized. This model consists of an inbuilt 
collection of more than 600 compounds from literature. Low VD values indicate low 
distribution to tissues while high VD values mean high distribution to tissues. When these 
new PA-824 derivatives were projected on this model it was found that compounds 4.18a-b 
and 4.19a-c were predicted to be highly distributed to tissues in the plasma, falling within the 
blue region, while compounds 4.19d-h were less distributed to tissues, falling in the red zone. 
The fact that compounds 4.19d-h were predicted to have less distribution to tissues 
corroborates the observation of the PB model, which indicated that these compounds have a 
slight affinity for binding to tissues. 
 
In summary, a number of these novel compounds were predicted to have superior aqueous 
solubility than PA-824 at both physiological pHs. However, some of these appeared to have 
an affinity for binding to proteins and were susceptible to hepatic metabolic degradation. 
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The retrosynthetic pathway towards the PA-824 derived target compounds is illustrated in 
Scheme 4.6. The key intermediates (4.18a-b) in the synthesis of the target compounds were 
obtained from the nucleophilic substitution reaction of alkyl halides (4.16a-c) and the 
commercially available nitroimidazooxazine alcohol (4.17). The benzylbromide aldehydes 
(4.16a-c) were in turn obtained from diisobutyl aluminium hydride (DIBAL-H) mediated 
reduction of the nitrile group.  
 
4.3.2.2.2 Synthesis 
The first step in the synthesis of the target compounds involved synthesizing alky halides 
(4.16a-c) using a known literature method.
39
 The synthesized alkyl halides were then reacted 
with the commercially available nitroimidazooxazine-alcohol (4.17) in the presence of 
sodium hydride to afford the nitroimidazooxazine-aldehydes (4.18a-b) (meta and para) in 
modest to excellent yields (Scheme 4.7).
40
 The ortho nitroimidazooxazine-aldehyde was not 
obtained as evidenced by the recovery of unreacted starting materials from the reaction 
mixture. The failure of the formation of the ortho nitroimidazooxazine-aldehyde is postulated 
to be the result of steric hindrance. The desired target compounds (4.19a-h) were then 
obtained from the MCR in moderate to excellent yields, with complete diastereoselectivity 






























Scheme 4.7: Reagents and conditions: (i) NaH (1.3 eq), DMF, N2, O°C to rt, 12 hrs; (ii) 
MeOH, 40°C, 12 hrs. (in the case of HCl protected amines, diisopropyl ethylamine (2.0 eq) 











































































































4.18a (PA-2A1) 4.18b (PA-2A2)
4.19a (PA-3A)
















Figure 4.14: Yields and structures of the final PA-824 tetrazole derivatives. 
 
Based on the 
1
H NMR, six (4.19a-f) of the eight target compounds were obtained exclusively 
as single diastereomers, while compounds 4.19g and 4.19h were obtained as 1:1 
diastereomeric mixtures. This may suggest that the newly created stereogenic centre favours 
one configuration over the other, i.e. stereochemical discrimination (it is important to note 
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this is surprising considering the fact that the TMSN3-Ugi MCR is known for its poor 
diastereoselectivity.
41
 Thus, this observed complete diastereoselectivity of this reaction is 
unprecedented. In addition, the obtained 1:1 diastereomeric mixtures of compounds 4.19g 





H NMR spectrum of the precursor nitroimidazooxazine aldehyde (4.18a) is 
showed in Figure 4.15. All the signals are accounted for, and the important ones to highlight 
here are the singlets at 9.99 and 8.02 ppm which are due to the characteristic aldehyde proton 
and the H1 methine proton of the nitroimidazole ring, respectively. The doublet of doublets 
resonating at roughly 4.77 ppm is due to the H5 diastereotopic methylene protons, while the 




Figure 4.15: 400 MHz 
1
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Figures 4.16 and 4.17 show 
1
H NMR spectra of products 4.19c and 4.19e, a 
nitroimidazooxazine-quinoline hybrid compound, respectively. In Figure 4.16, the presence 
of the desired product 4.19c was confirmed by the appearance of two singlets resonating at 
1.69 and 5.20 ppm, which are due to the t-butyl group protons and H7 methine proton, 
respectively. Furthermore, signals resonating at 1.76 and 2.35-2.60 ppm are due to the 
pyrrolidine protons, while the rest of the signals are due to the nitroimidazooxazine scaffold. 
Similarly, Figure 4.17 confirms the presence of compound 4.19e. Signals resonating at 1.57 
and 5.30 ppm are due to the t-butyl group and H7 methine protons. Also, signals at 1.92, 
2.75-2.93, and 3.41 ppm are due to the methylene H9, H10 and H8 protons, respectively, 
while the quinoline aromatic protons resonate in the region 6.29 to 8.46 ppm. The rest of the 
signals in figure 4.16 are due to the nitroimidazooxazine scaffold. In Figure 4.18, all the 
carbon signals are duplicated and off equal intensity, an indication of a 1:1 diastereomeric 
mixture of compound 4.19h. 
 
  
Figure 4.16: 400 MHz 
1
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Figure 4.17: 400 MHz 
1
H NMR spectrum of products 4.19e in CDCl3. 
 
 
Figure 4.18: 101 MHz 
13
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4.3.3 Experimental determination of solubility 
As was in the in silico predictions, compounds with commercial amines (4.19a) were more 
soluble than the hybrids (Table 4.4).  
 
Table 4.4: Results for experimentally determined kinetic solubility at pH 7.0 and 7.4. 
Code Product Solubility at pH 7.0 and 7.4 (µM) Conclusion 
PA-3A 4.19a 195.79
a
 Highly soluble 
PA-6A 4.19d 62.9 ± 0.66
b
 soluble 













Kinetic solubility performed at pH 7.4; and 
b
Performed at pH 7.0 
 
Among the hybrids, the PA-824-primaquine hybrids (4.19g and 4.19h) were found to be 
insoluble, with values < 5 µM. On the other hand, solubility of the PA-824-quinoline hybrids 
decreased with an increase in chain length of the alkyl side-chain, with the 2-carbon spacer 
analogue, 4.19d (62.9 µM); being slightly more soluble than the 3-carbon spacer, 4.19e (59.9 




4.4.1 Brief background on β-lactams and Staudinger reaction 
A β-lactam is a four-membered cyclic amide system found mostly in antibiotics such as penicillin 
and cephalosporin. β-lactam antibiotics are potent non-toxic broad-spectrum agents that have 
been a powerful first-line of defence against bacterial infections since their discovery.
42
 The 
biological activity of most antibiotics is largely due to the presence of the β-lactam ring, of which 
once open, the antibiotic loses its antibacterial activity.
43
 The heavy use of antibiotics over the 
years led to the emergence of bacteria that are resistant to β-lactams.
41
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relevant bacterial mechanism of resistance to β-lactams is the production of β-lactamase, a 
bacterial enzyme. This enzyme functions by hydrolyzing the β-lactam into the ring-opened β-
amino acid, and as such inactivating antibiotics or compounds containing the β-lactam ring.
43
 
There are, however, various β-lactam derivatives that are known for inhibiting this enzyme. An 
example of this is the naturally occurring clavulanic acid (4.20) (Fig. 4.19).
44,45
 Apart from their 


















Figure 4.19: Clavulanic acid, a naturally occurring β-lactamase inhibitor. 
 
A number of methods used to synthesize β-lactams are described in literature. However, the 
Staudinger
51
 reaction is generally accepted as a method of choice.
52
 The Staudinger reaction, 
named after its inventor, is a [2+2] imine-ketene cycloaddition reaction that results in the creation 
of a β-lactam ring bearing two stereogenic centres. This reaction was discovered in 1907, and to 
date its exact reaction mechanism is still a matter of debate.
53
 However, it is generally 
acknowledged that this [2+2]-cycloaddition reaction is a stepwise reaction rather than a 
concerted one, and the key intermediate is a zwitterionic species that undergoes ring closure to 
give a final product as a cis-, trans- or a mixture of the two.
54,55
 In this study this reaction was 
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4.4.2 Rationale for the design 
Due to the broad spectrum of biological activity of β-lactams, the rationale behind this section of 
the project involved hybridizing the β-lactam ring with the 4-amino-7-chloroquinoline analogues 









Antimalarial and anti-TB pharmacophore
Substituents selected  based on Toplis 




Figure 4.20: Rationale behind the β-lactam-quinoline hybrids.  
 
The quinoline scaffold is found in a number of potent antimalarial drugs and is also known for 
possessing antitubecular activity.
53
 Furthermore, β-lactam-quinolone hybrids have been shown 
by Miller and co-workers to have potent antitubercular activity.
49
 Thus, it was envisaged that 
hybrid compounds containing these two scaffolds will not only possess a novel mechanism of 
action but will also circumvent metabolic N-dealkylation of the terminal alkyl side-chain of the 
4-aminoquinolines, hence reducing the potential for resistance development. 
 
4.4.3 In silico predictions 
These β-lactam-quinoline hybrids were profiled in silico for aqueous solubility, permeability and 
metabolic stability in relation to chloroquine. At both pH 5.0 and 7.5 chloroquine showed 
significantly superior aqueous solubility than the hybrids (Fig. 4.21). This is expected since these 
β-lactam-quinoline hybrids are more hydrophobic than chloroquine. Furthermore, chloroquine 










Chapter 4: Synthesis and biological evaluation of 4-arylaminoquinoline and PA-824 tetrazoles, and β-Lactams 
152 
Also, these β-lactam-quinoline hybrids showed acceptable predicted Caco-2 permeation that is 
comparable to that of chloroquine (Fig. 4.22). However, these hybrids were predicted to have 
intermediate metabolic stability, similar to that of chloroquine. The compound with the 3,4-di-
chloro substituents on the phenyl ring was predicted to be the least stable in this series.  
In summary, these β-lactam-quinoline hybrids were predicted to have in silico physico-chemical 
properties that were comparable but not better than chloroquine. Low aqueous solubility at both 
physiological pHs was identified to be major limitation of these hybrids. 
 
Figure 4.21: Plots of predicted aqueous solubility (log S) against n-octanol-water partition 
coefficient (log D) at pH 5.0 and 7.5, of β-lactam-quinoline hybrids. 
 
Figure 4.22: Plots showing the designed β-lactam-quinoline hybrids projected onto PLS 
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4.4.4 Synthesis of β-lactam-aminoquinoline hybrids 
The synthesis of these hybrids began with the synthesis of key intermediates, quinoline amines 
3.13a-c, that were described in chapter 3, section 3.5.2.1. These intermediates were subsequently 
reacted at room temperature with various aromatic aldehydes (3.14) over a period of 24 hours to 
give imines 4.21a-g in reasonable crude yields after being dried on the vacuum line for 4 hours 
(Scheme 4.8). No attempt was made in purifying these imines because of their known instability 
properties, hence they were used as such in the next step. The last step in the synthesis of these 
hybrids involved reacting these crude imines with the methoxyacetyl chloride under Staudinger 
reaction conditions to afford exclusively the cis β-lactams (4.22a-g) based on the 
1
H NMR 
spectroscopy (Scheme 4.8). The configurations of these β-lactams were assigned following a 
model proposed by Jiao and co-workers.
56
 The model suggests that when the J-coupling constant 
between the two protons on the adjacent chiral carbon is between 4-6 ppm then the configuration 
of the β-lactam is cis, while between 2-3 ppm indicates trans. The desired compounds were 





mass spectroscopy. In addition, their purity was established by HPLC to be greater than 94% 
(Table 4.5). The reason for the relatively low yields is probably due to the fact that almost all the 
imines used were partially soluble in DCM, thus only a small percentage of these imines were 


























Scheme 4.8: Reagents and conditions: (i) MeOH, rt, 24 hrs; (ii) methoxy acetyl chloride (1.5 eq), 
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4.22a BL1 1 H H 30 142-146 95.6 
4.22b BL2 1 H Cl 14 135-138 99.2 
4.22c BL3 1 Cl Cl 4 152-156 99.5 
4.22d BL4 1 H OCH3 9 144-147 95.6 
4.22e BL5 1 H Me 6 78-82 94.6 
4.22f BL6 2 H H 5 - 97.2 
4.22g BL7 3 H H 9 86-89 98 
 
4.4.4.1 Reaction pathways towards cis- and trans-β-lactams 
As mentioned earlier there is still no consensus among researchers with regards to the exact 
mechanism of this reaction. However, the pathway for the formation of the cis- or trans-β-
lactams is shown in Scheme 4.9.
56
 The relative stereochemistry of the β-lactam is decided by the 
initial approach of the imine (B) to the ketene (A), and by the competition between direct ring 
closure and the isomerisation of the imine in the zwitterionic intermediate.
56,57
 Furthermore, this 
stereochemistry is also influenced by electronic effects of the substitutents on the imine. The 
initial exo attack of the imine to the ketene generates intermediate C. Subsequent direct ring 
closure of this intermediate forms a cis-β-lactam (a to b). However, isomerisation of intermediate 
C to D, followed by direct ring closure gives rise to the trans-β-lactam (a to c and then d). Also 





























































































Scheme 4.9: Pathway for the formation of cis- and trans-isomers, only one enantiomer is shown 
(adapted from reference 55). 
 
Confirmation of the cis-β-lactam-quinoline hybrids was by the presence of the two distinct 
coupling (
3
J 4.3-4.5 Hz) doublets in 
1
H NMR spectra, each integrating for one proton, resonating 





J-coupling constant values indicate the formation of the cis-β-lactams. Also apparent 
in the spectra of these compounds are singlets resonating in the region 3.10-3.45 ppm, which 
correspond to the methoxy group of the acetyl chloride input. This is exemplified by Figure 4.23, 
1
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Figure 4.23: 400 MHz 
1
H NMR spectra of products 4.22b in CDCl3. 
 
4.4.5 Experimental determination of solubility 
Three of these new β-lactam derivatives were profiled in vitro for aqueous solubility (Table 
4.6). All the tested β-lactam derivatives were found to be highly soluble while the 
commercially available chloroquine diphosphate could not be determined due to it being 
insoluble in DMSO. 
 
Table 4.6: Results for experimentally determined kinetic solubility at pH 7.0. 
Code Product Solubility at pH 7.0 (µM) Conclusion 
BL1 4.22a 221 Highly soluble 
BL2 4.22b 222 ± 1.30 Highly soluble 
BL7 4.22g 215 ± 1.87 Highly soluble 
Chloroquine diphosphate Did not dissolve in DMSO - 
 
4.5 Biological results and discussion 
Biological evaluation of compounds in this chapter were conducted in the same laboratories 































δppm Multiplicity 3J (Hz) H# 
4.72 d 4.3 2’ 
4.77 d 4.3 1’ 
7.24 d 8.5 3’ 
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4.5.1 In vitro antiplasmodial evaluation of the target compounds 
4.5.1.1. Antiplasmodial activity of 4-Arylamino quinolines 









4.12a-f, 4.13a-b  







P. falciparum IC50 [µM (µg/mL)] 
3D7 K1 W2 





























Bu 0.980 1.228 >10 
4.14f TK506B3 ON
 


















 (1.1) ND 
Quinine - 0.0007 0.0204 0.0187 
ǂ
Antiplasmodial testing done at STPH. 
 
As clearly evident from Table 4.7, the most active compound [4.12f (IC50 = 1.228 µM)] in 
this series was 60 times less efficacious than quinine in the resistant K1 strain. Also, quinine 
derivatives were more active than the two mefloquine derivatives (4.13a-b). In addition, none 
of the tested compounds exhibited any significant activity against the W2 strain. Furthermore, 
these compounds were more active in the sensitive 3D7 strain than in the two resistant 










Chapter 4: Synthesis and biological evaluation of 4-arylaminoquinoline and PA-824 tetrazoles, and β-Lactams 
158 
quinine. Unfortunately comparison between mefloquine and its derivatives cannot be made 
since the former was not tested.  
 
4.5.1.2. Antiprotozoan activity of PA-824 derivatives 
Based on the results in Table 4.8, the PA-824-aminoquinoline hybrids were the most active 
against the K1 strain in this series. Hybrids 4.19d (IC50 = 0.100 µM) and 4.19f (IC50 = 0.164 
µM) exhibited at least 1- and 4-fold superior activity than both chloroquine (IC50 = 0.213 
µM) and primaquine (IC50 = 0.643 µM), respectively. Also, 4.19d (IC50 = 0.100 µM) showed 
3-fold improved activity than its intermediates 3.13a (IC50 = 0.298 µM) and the 1:1 molar 
combination of the parent compounds (4.18a:3.13a) (IC50 = 0.303 µM). However, the second 
intermediate (4.18a) of this hybrid was unfortunately not tested. This improved activity of 
4.19d over one of its intermediate (3.13a) and the equimolar combination of the individual 
components highlights the benefit of the covalent linkage (hybridization), indicating an 
additive effect. Moreover, the equimolar combination 4.18a:3.13a (IC50 = 0.303 µM) also 
possessed better activity than primaquine. In terms of the SAR, there was no clear trend that 
could be delineated from these results based on the length of the alkyl side-chain of these 
hybrids. However, the 2- and 4-carbon spacers appear to be more favoured.  
 
The two PA-824-primaquine hybrids [4.19g (IC50 = 2.042 µM) and 4.19h (IC50 = 0.985 
µM)], which were tested as 1:1 diastereomeric mixtures, were less active than both 
primaquine (IC50 = 0.643 µM) and chloroquine (IC50 = 0.213 µM) on the K1 strain. 
Compound 4.19h, the most active of the two, showed 1- to 4.6-fold less activity than both 
reference drugs. Furthermore, 4.19h (IC50 = 0.985 µM) was significantly more active than 
one of its intermediate, 4.18b (IC50 = 62.62 µM), but comparable to the 1:1 combination of 
the individual components, 4.18b:Primaquine (IC50 = 0.721 µM). Since the activity of the 
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antagonistic effect is suggested. Lastly, the PA-824 derivatives with commercial amines 
[4.19a (IC50 = 15.79 µM), 4.19b (IC50 = 7.95 µM), and 4.19c (IC50 = 8.70 µM)] did not show 
any significant activity against the K1 strain. 
 






































































4.17 PA-1A - - - >270 (>50) >540 (>100) 330.6 (61.2) - 
4.18a PA-2A1 - para - ND ND ND - 














“ - 8.70 (4.20) 41.65 (20.1) 75.23 (36.3) 8.65 
4.19d PA-6A - “ 1 0.100 (0.064) 3.850 (2.44) 24.64 (15.6) 246 
4.19e PA-7A - “ 2 0.485 (0.314) 4.064 (2.63) 41.52 (26.9) 85 
4.19f PA-8A - “ 3 0.164 (0.109) 6.76 (4.47) 29.34 (19.4) 178 
4.19g PA-9A - “ - 2.042 (1.37) 11.73 (7.87) 75.88 (50.9) 37 
4.19h PA-11A - meta - 0.985 (0.661) 9.929 (6.66) 142.83 (95.8) 145 
3.13a - 
- 
1 0.298 (0.066) 10.49 (2.32) 21.22 (4.69) 71.2 
4.18a:3.13a - 
- 
1 0.303 (0.159) 4.615 (2.42) 20.41 (10.7) 67.4 
4.18a:3.13b - 
- 
2 1.874 (1.01) 3.377 (1.82) 21.89 (11.8) 11.7 
4.18a:3.13c - 
- 
3 2.514 (1.39) 3.562 (1.97) 11.81 (6.53) 4.69 
4.18a:Primaquine - 
- 
- 0.900 (0.683) 2.557 (1.94) 29 (22) 32.2 
4.18b:Primaquine - 
- 
- 0.721 (0.547) 2.992 (2.27) 22.94 (17.4) 31.8 
Chloroquine                -                     
- 
- 
0.213 (0.110) - - - 
Primaquine                - 
- 
- 
0.643 (0.280) - - - 
Melarsoprol                - 
- 
- 
- 0.0075 (0.003) - - 
Podophyllotoxin                - 
- 
- 
- - 0.0193 (0.008) - 
a 
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Most of the compounds in this series showed poor activity against the cultured T. b. brucei 
parasite, only the two PA-824-aminoquinoline hybrids [4.19d (IC50 = 3.850 µM) and 4.19e 
(IC50 = 4.064 µM)] exhibited some notable activity, which decreased with an increase in 
length of the alkyl side-chain. The selective indices of the most active compounds in this 
series were closer to or greater than 100, suggesting that these compounds are more selective 
towards the chloroquine-resistant parasite. 
 
Aqueous solubility of these compounds does not seem to be playing a significant role on 
antiplasmodial activity. This appears so because the two most active compounds in this series 
exhibit contrasting solubilities, with one being highly soluble [4.19d (62.9 ± 0.66 µM)] while 
the other was insoluble [4.19h (< 5 µM)]. Moreover, both the PA-824-primaquine hybrids 
were found to be insoluble (< 5 µM) but one of them possessed potent antiplasmodial activity 
while the other did not. 
 
4.5.1.3. Antiprotozoan activity of β-lactam-aminoquinoline hybrids  
The desired β-lactams were all active against the K1 strain, exhibiting IC50 values in the low 
micromolar range (Table 4.9). Compounds containing chloro substituted phenyl rings [di-
chloro substituted 4.22c (IC50 = 0.209 µM) and mono-chloro substituted 4.22b (IC50 = 0.304 
µM)] showed comparable activity to chloroquine (IC50 = 0.213 µM) and intermediate 3.13a 
(IC50 = 0.298 µM). On the other hand, the least active compound in this series, 4.22d (IC50 = 
0.617 µM), was 3-fold less active than the reference drug. In terms of SAR, there was no 
obvious trend with regards to the length of the alkyl side-chain on antiplasmodial activity. 
However, similar to the PA-824-aminoquinoline hybrids, compounds with the 2- and 4-
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However, none of these β-lactams showed any significant inhibitory activity against the 
cultured T. b. brucei parasite. The most active compound 4.22b (IC50 = 7.005 µM) in this 
series was 934 times less active than melarsoprol (IC50 = 0.0075 µM), a reference drug.  
 
All these compounds except 4.22a and 4.22e showed notable cytotoxicity against the L6 
mammalian cell-line. Compound 4.22g (IC50 = 2.87 µM) was the most cytotoxic in this 
series, followed by compound 4.22c (IC50 = 8.54 µM). This cytotoxicity profile exhibited by 
these β-lactams potentially limits their chances for further development.  
 











code Product n R’ R’’ 
K1 IC50 [µM 
(µg/mL)] 






4.22a BL1 1 H H 0.466 (0.178) 53.16 (20.3) 98.47 (37.6) 
4.22b BL2 1 H Cl 0.304 (0.127) 7.005 (2.94) 11.62 (4.84) 
4.22c BL3 1 Cl Cl 0.209 (0.094) 18.99 (8.54) 8.54 (3.85) 
4.22d BL4 1 H OMe 0.617 (0.254) 52.93 (21.8) 20.37 (8.39) 
4.22e BL5 1 H Me 0.581 (0.23) 52.54 (20.8) 92.70 (36.7) 
4.22f BL6 2 H H 0.568 (0.225) 16.09 (6.37) 14.40 (5.7) 
4.22g BL7 3 H H 0.309 (0.127) 20.00 (8.2) 2.87 (1.18) 
3.13a 1           - 0.298 (0.066) 10.49 (2.32) 21.22 (4.69) 
Chloroquine - 0.220 (0.100) - - 
Melarsoprol - - 0.0075 (0.003) - 
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4.5.2 In vitro Antimycobacterial evaluation of the target compounds 
4.5.2.1 Antimycobacterial activity of 4-Arylamino quinolines 
 









4.12a-f, 4.13a-b  







MABA (µM) LORA (µM) 
H37Rv MIC90 
(µM) 


































Bu o >128 32 >128 - - 
4.14f TK506B3 ON
 
OMe H H 0 >128 1 >128 - - 
4.13a TK710 










Bu - - - - >160 >160 
Quinine - 95 119.7 98 122.0 - - 
Mefloquine  - - - - 10 20 
RMP - 100 0.05 98 1.93 - - 
INH - 92 0.23 64 >128 - - 
PA-824 - 99 0.12 100 3.78 - - 
Kanamycin - - - - - 3.125 3.125 
Streptomycin - - - - - 0.4 0.4 
 
Generally, the target compounds (Table 4.10) had MICs greater than the highest tested 
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bacteria, with the exception of two compounds, 412b and 4.12d. Compound 4.12b inhibited 
83 and 94% bacterial growth of the replicating and non-replicating bacteria, respectively. 
Also, this compound had an MIC90 of 123.2 µM against the non-replicating bacteria. In 
addition, compound 4.12d (MIC90 = 92.5 µM) inhibited 98% of the replicating bacteria 
However, this compound only showed weak inhibition of the non-replicating bacteria. This 
lack of activity exhibited by the majority of these compounds is not surprising considering 
the fact that Kozikowski et al.,
58
 observed in their SAR studies that the replacement of the 
hydroxyl group of the 4-quinoline methanols was accompanied by the complete loss of 
activity. Thus, it maybe postulated that perhaps the abolished activity of these target 
compounds was largely due to the replacement of the hydroxyl group.  
 
4.5.2.2 Antimycobacterial activity of PA-824 derivatives 
All the PA-824 derivatives showed potent antimycobacterial activity against the replicating 
M. tuberculosis drug sensitive H37Rv strain during the 7 and 14 day assays (Table 4.11). The 
MICs of all the target compounds ranged between 0.25 and 1.25 µM, except for the PA-824-
primaquine diastereomeric mixture 4.19h. All these compounds were more active than the 
standard TB drug, Kanamycin (MIC90 = 3.125 µM), and the two antimalarial drugs, 
chloroquine (MIC90 > 160 µM) and primaquine (MIC90 = 80 µM). In addition, the three 
equimolar combinations [4.18a:3.13a, 4.18a:3.13b and 4.18a:3.13c, all had MIC90 of 0.25 
µM] were more efficacious than Streptomycin (MIC90 = 0.4 µM), while four compounds, 
4.18a (MIC90 = 0.25 µM), 4.19b (MIC90 = 0.313 µM), 4.19c (MIC90 = 0.313 µM) and 4.19d 
(MIC90 = 0.4 µM), had comparable activity to this standard TB drug in the 7 day assay. 
Intermediate 4.18a showed superior activity than all the target compounds in the 7 day assay, 
while it had the same activity as both 4.19b and 4.19d in the 14 day experiment. However, 
the majority of these compounds appeared to lose their 7 day efficacy when incubated for 
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Reasons for this loss in activity are unknown at this stage, perhaps degradation and 
precipitation in the assay media might have potentially influenced this observation. However, 
this postulation will have to be verified experimentally.  
 
























































Code Product R Position n 
H37Rv MIC90 (µM) 
7 days 14 days 
4.17 PA-1A - - - 40 40 
4.18a PA-2A1 - para - 0.25 0.313 
4.18b PA-2A2 - meta - 0.625 1.25 
4.19a PA-3A N
 
para - 0.625 1.25 
4.19b PA-4A N
 
“ - 0.313 0.313 
4.19c PA-5A N
 
“ - 0.313 0.625 
4.19d PA-6A - “ 1 0.4 0.313 
4.19e PA-7A - “ 2 ND ND 
4.19f PA-8A - “ 3 0.625 1.25 
4.19g PA-9A - “ - 0.625 1.25 
4.19h PA-11A - meta - 5 20 
3.13a - 1 160 >160 
3.13b - 2 >160 >160 
3.13c - 3 >160 >160 
4.18a:3.13a - 
- 
1 0.25 <0.156 
4.18a:3.13b - 
- 
2 0.25 <0.156 
4.18a:3.13c - 
- 
3 0.25 <0.156 
4.18a:Primaquine - - 0.4 <0.156 
4.18b:Primaquine - - 0.625 0.625 
Chloroquine                   - >160 >160 
Primaquine                   - 80 80 
Kanamycin                   - 3.125 3.125 
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Contrary to the antiplasmodial data, compounds containing commercial amines (4.19a, 
4.19b, and 4.19c) possessed better antimycobacterial activity than the PA-824-
aminoquinoline hybrids, with compounds 4.19b and 4.19c having MICs in the range of 
0.313-0.625 µM. An increase in the length of the alkyl side-chain of the PA-824-
aminoquinoline hybrids was accompanied by reduction in activity in both assays. Also 
apparent from this data was that the para-analogues were more active than their meta 
counterparts. This is exemplified by intermediate 4.18a compared to 4.18b, and by the 
primaquine-based diastereomeric mixtures 4.19g and 4.19h.  
 
From the data it appears that the MICs of the physically mixed equimolar combinations are 
approximately equal to the MIC90 of the most active corresponding parent compound. This is 
to be expected since the 4-aminoquinolines (3.13a-c) completely lack activity at the highest 
tested concentration (MIC > 160 µM). Also, all the equimolar combinations were more active 
than the corresponding hybrids in both assays. The PA-824-aminoquinoline hybrids (4.19d-f) 
were less active than the nitroimidazooxazine 4.18a intermediate while they were 
significantly more active than their corresponding 4-aminoquinoline (MIC90 > 160 µM) 
intermediate. Similarly, the PA-824-primaquine (4.19g-h) hybrids showed the same trend, 
where the nitroimidazooxazine 4.18a-b intermediates showed superior activity to the 
corresponding hybrids while the primaquine (MIC90 = 80 µM) intermediate was less so. 
Thus, hybridisation in both cases indicates an antagonistic effect, suggesting that 
administering these intermediates in equimolar combinations is much more advantageous 
than covalently linking them. 
 
Unlike in the antiplasmodial data, aqueous solubility appears to be playing a minor role on 
antimycobacterial activity. Among the PA-824-aminoquinoline hybrids, antimycobacterial 
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better solubility (62.9 ± 0.66 µM) than the other hybrid 4.19f (< 5 µM). Furthermore, 
compounds with commercial amines had better activity and solubility than the hybrids. 
However, the role of solubility on the PA-824-primaquine hybrids is less clear because one of 
these hybrids is significantly more active than the other although both of them had similar 
solubilities (< 5 µM). 
 
4.5.2.3 Antimycobacterial activity of β-lactam-aminoquinoline hybrids 
 

















code Product n R’ R’’ 
H37Rv MIC90 (µM) 
7 days 14 days 
4.22a BL1 1 H H >160 >160 
4.22b BL2 1 H Cl 160 >160 
4.22c BL3 1 Cl Cl 80 160 
4.22d BL4 1 H OCH3 >160 >160 
4.22e BL5 1 H Me >160 >160 
4.22f BL6 2 H H >160 >160 
4.22g BL7 3 H H >160 >160 
3.13a     1             - 160 >160 
3.13b     2             - >160 >160 
3.13c     3             - >160 >160 










Almost all the tested compounds were inactive against the replicating bacteria in both assays 
at the highest concentration (MIC90 > 160 µM) tested, the exception being 4.22c which had 
an MIC of 80 µM in the 7 day assay (Table 4.12). Similar, the intermediates (3.13a-c) of 
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160 µM). The lack of activity observed in these β-lactam-aminoquinoline hybrids is in stark 
contrast to the documented antitubercular activity of β-lactams and quinoline-based
53,54 




In conclusion a number of the synthesized target compounds exhibited better antiplasmodial 
and antimycobacterial activity than the used reference drugs. Most notable, the two PA-824-
aminoquinoline hybrids 4.19d (IC50 = 0.100 µM) and 4.19f (IC50 = 0.164 µM) were slightly 
more active than chloroquine (IC50 = 0.213 µM), while all compounds in this series were 
more potent than primaquine (IC50 = 0.643 µM). Moreover, the PA-824-aminoquinoline 
hybrids exhibited additive antiplasmodial activity while the PA-824-primaquine hybrids 
showed antagonism. Also, these derivatives were more active in the TB assays than the 
standard drugs, kanamycin, chloroquine and primaquine, while three of them were more 
efficacious than streptomycin, another standard TB drug. In the antimycobacterial evaluation, 
both the PA-824-aminoquinoline and PA-824-primaquine hybrids showed antagonistic effect. 
More interestingly, these compounds appear to be more selective towards the parasite and 
bacteria than the mammalian cell-lines used.  
 
Also, the β-lactams showed IC50 values in the low micromolar range against K1 strain, with 
compound 4.22c (IC50 = 0.209 µM), the most active in this series, showing comparable 
activity to chloroquine (IC50 = 0.213 µM). The one limitation of these β-lactams was their 
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Summary, Conclusions and Recommendations 
5.1 Summary and Conclusions 
The main objective of this study was to design a series of compounds around the tetrazole 
moiety utilizing known anti-malarial and anti-TB pharmacophores or bioactiphores, which 
possess in vitro and/or in vivo antiplasmodial and antimycobacterial potency. Specifically, 
these bioactiphores included deoxyamodiaquine, chloroquine-like, primaquine, 4-arylamino 
quinoline and PA-824 scaffolds. 
 
A limited number of derivatives of each bioactiphore were synthesized from the modified 
TMSN3-Ugi multi-component reaction (MCR) strategy, followed by evaluation in vitro for 
antiplasmodial and antimycobacterial activity. Furthermore, these derivatives were profiled in 
silico for solubility, permeability and metabolic stability among others. Aqueous solubility of 
key compounds from each series was determined experimentally to corroborate or negate 
these in silico predictions. Below is the summary of the results from each series: 
 
(i) In the deoxyamodiaquine series, the t-butyl protected tetrazole compounds 3.9b-c and 
3.9k with IC50 values ranging from 0.006 to 0.012 µM showed superior antiplasmodial 
activity than both amodiaquine (IC50 = 0.02689 µM) and chloroquine (IC50 = 0.0360 µM) in 
the K1 strain. In addition, two of the de-tert-butylated compounds 3.10b (IC50 = 0.054µM) 
and 3.10c (IC50 = 0.049 µM) exhibited comparable activities to the reference drugs. 
Similarly, compounds 3.9a-f, 3.9k and 3.10c (IC50 values ranging from 0.040 to 0.194 µM) 
were all more potent than amodiaquine (IC50 = 0.4007 µM) in the W2 strain, while only one 
compound, 3.9k (IC50 = 0.040 µM), was more active than chloroquine (IC50 = 0.0591 µM) on 
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Moreover, these compounds also exhibited encouraging antimycobacterial activity against 
drug-sensitive H37Rv M. tuberculosis strain, with compounds 3.9a, 3.9c-f inhibiting over 
90% of the replicating bacteria with MICs in the 14.1- 63.7 µM range. In addition, 
compounds 3.9d (MIC90 = 7.6 µM) and 3.9k (MIC90 = 14.1 µM) were also more efficacious 
than amodiaquine (MIC90 = 56.9 µM). Against the non-replicating bacteria, compounds 3.9a 
(MIC90 = 118.7 µM), 3.9c (MIC90 = 74 µM) and 3.9k (MIC90 = 15.1 µM) were the most 
active, and all had over 70% inhibitory effect on the bacteria. Also, these derivatives showed 
acceptable cytotoxicty with selective indices greater than 1000. The experimentally 
determined aqueous solubility of key compounds in this series corroborated the results 
obtained from the in silico solubility predictions; that is, the de-tert-butylated compounds 
were more soluble than the t-butyl protected analogues.  
 
(ii) Among the chloroquine-like compounds, 3.15a4 (IC50 = 0.0004 µM) was 13-times more 
active than chloroquine (IC50 = 0.0052 µM) in the 3D7 strain. On the other hand, 6 (3.15a1, 
3.12a3- 3.15a7) out of the 14 compounds tested against K1 strain showed greater activity 
than chloroquine, with 3.15a5 (IC50 = 0.001 µM) exhibiting a 36-fold improved activity over 
chloroquine (IC50 = 0.036 µM). Moreover, compounds 3.15a2, 3.15a3, 3.15a5, and 3.15c 
showed favourable resistance index against K1, suggesting a reduced potential to develop 
cross-resistance with chloroquine. Against the W2 strain, almost all the compounds tested 
were more active than chloroquine (IC50 = 0.059 µM), the exception being 3.15a1 (IC50 = 
0.069 µM) which had comparable activity to this reference drug. In terms of SAR, the 
compound with the shortest ethylene spacer, 3.15a1, was less efficacious than those with the 
longer carbon spacers (3.15b and 3.15c) on all strains tested. 
  
In the antimycobacterial evaluation, the para-substituted phenyl ring was highly preferred in 
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growth of the bacteria with MICs in the low micromolar range (5.6 to 14.3 µM). In addition, 
the elongation of the alkyl side-chain, going from n=1 to n=3, reduced the activity by 2-fold; 
3.15a1 (n=1, MIC90 = 20.9 µM), 3.15b (n=2, MIC90 = 29.0 µM) and 3.15c (n=3, MIC90 = 
47.8 µM). Against the non-replicating bacteria, the para-substituted phenyl-based 
compounds also exhibited superior antimycobacterial activity than the unsubstituted 
analogues. However, there was no clear trend that could be deduced regarding the elongation 
of the alkyl side-chain. Furthermore, compounds 3.15a3 (MIC90 = 13.5 µM) and 3.15a4 
(MIC90 = 24.0 µM) were more potent than moxifloxacin (MIC90 = 31.1 µM) in this assay, a 
standard TB drug. In terms of cytotoxicity, almost all the compounds in this series showed 
acceptable cytotoxicity on mammalian cell-lines having values closer to or greater than 100 
µM.  
 
(iii) In the primaquine series, the most active compound 3.19d (IC50 = 1.311 µM) was 2-fold 
less active than the primaquine (IC50 = 0.615 µM). Also, none of these compounds showed 
any activity against the M. tuberculosis H37Rv strain. Furthermore, these compounds showed 
unfavourable cytotoxicity profile towards mammalian cell-lines. 
 
(iv) The 4-arylamino quinoline derivatives did not show any significant activity against both 
K1 and W2 strains. Against the 3D7 strain the most active compound 4.12d (IC50 = 0.647 
µM) was 924-fold less active than quinine. Also, quinine derivatives were significantly more 
active than their mefloquine counterparts. In this series there were only two compounds, 
4.12b and 4.12d that exhibited antimycobacterial activity. Compound 4.12b had an MIC90 of 
123.2 µM against the non-replicating bacteria, while 4.12d inhibited 98% of the replicating 
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(v) Among the PA-824 derivatives, the PA-824-aminoquinoline hybrids were the most active 
against the K1 strain, with compounds 4.19d (IC50 = 0.100 µM) and 4.19f (IC50 = 0.164 µM) 
exhibiting better activity than both chloroquine (IC50 = 0.213 µM) and primaquine (IC50 = 
0.643 µM). Also, 4.19d (IC50 = 0.100 µM) was more active than its parent compound 3.13a 
(IC50 = 0.298 µM) and the equimolar combination of parent compounds (4.18a:3.13a) (IC50 = 
0.303 µM), indicating an additive activity. Among these hybrids, compounds with 2- and 4-
carbon spacer were more active than one containing a 3-carbon spacer. In contrast to the PA-
824-aminoquinoline hybrids, the two PA-824-primaquine hybrids [4.19g (IC50 = 2.042 µM) 
and 4.19h (IC50 = 0.985 µM)], which were tested as 1:1 diastereomeric mixtures, were less 
active than both primaquine (IC50 = 0.643 µM) and chloroquine (IC50 = 0.213 µM) on the K1 
strain. Furthermore, these hybrids exhibited an antagonistic effect on antiplasmodial activity. 
Against the cultured T. b. brucei parasite, most compounds in this series showed poor 
activity. 
 
Similarly, these PA-824 derivatives showed potent antimycobacterial activity against the 
replicating M. tuberculosis bacteria in the 7 and 14 day assays, with MICs ranging from 0.25 
to 1.25 µM. Furthermore, all these compounds were more active than Kanamycin (MIC90 = 
3.125 µM), a standard TB drug, and the two antimalarial drugs, chloroquine (MIC90 > 160 
µM) and primaquine (MIC90 = 80 µM), in both assays. However, the majority of these 
compounds appeared to lose their 7 day efficacy when incubated for longer periods except 
compound 4.19d, and this was postulated to be the result of degradation and precipitation in 
the assay media. The PA-824-aminoquinoline hybrids exhibited MICs in the range of 0.313-
0.625 µM, where an increase in the length of the alkyl side-chain was accompanied by 
reduction in activity in both assays. Moreover, these PA-824-aminoquinoline hybrids (4.19d-
f) were less efficacious than their parent compound, nitroimidazooxazine 4.18a. Similarly, 
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nitroimidazooxazine 4.18a-b parent compounds showed superior activity than the 
corresponding hybrids. Thus, hybridisations in both cases of antimycobacterial evaluation 
indicate an antagonistic effect, suggesting that hybridisation in this instance does not yield 
any beneficial outcome. The selective indices of the most active compounds in this series 
were closer to or greater than 100, indicating that these compounds are more selective 
towards the pathogens. Aqueous solubility of these compounds did not appear to be playing a 
significant role on antiplasmodial activity. However, on the antimycobacterial activity, good 
solubility was accompanied by improved activity. 
 
(vi) The β-lactam series possessed antiplasmodial activity against the K1 strain with IC50 
values in the low micro-molar range. Compound 4.22c (IC50 = 0.209 µM) was the most 
active in this series and had comparable activity to chloroquine (IC50 = 0.213 µM). However, 
none of these β-lactams showed any significant inhibitory activity against the T. b. brucei 
parasite and against the drug sensitive M. tuberculosis H37Rv strain. Furthermore, these 
compounds showed notable cytotoxicity against mammalian cell-lines..  
 
In conclusion, a number of new derivatives that possessed potent antiplasmodial and/or 
antimycobacterial activity which have a potential to be anti-malarial or antimycobacterial 
agents were identified from this study. These first generation compounds provide interesting 
starting point for further derivatization and optimization, provided their shortcomings are 
addressed.  
 
5.2 Recommendations for future work 
Since a number of potent compounds were identified in this study, the following future 
studies are proposed: (i) In vitro ADME profiling including metabolite identification and (ii) 
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mechanistic details of these new derivatives by investigating the inhibition of the β-haematin 
formation amongst others.  
 
Also, in vitro and in vivo drug metabolism and pharmacokinetic (DMPK), and in vivo 
efficacy studies should ideally be undertaken as well. The in silico predicted physico-
chemical properties such as the Blood Brain-Barrier (BBB) penetration should also be 
determined experimentally to corroborate these predictions. Lastly, whenever possible, the 

















6.1 Chemical reagents and Solvents 
All chemical reagents used were supplied by either Sigma-Aldrich
®
 or Merck and were used 
without further purification. Unless otherwise stated, all the solvents used were anhydrous 
and were purchased from Sigma-Aldrich, with the exception of THF and diethyl ether which 
were dried by appropriate techniques. Chromatographic solvents such as Ethyl acetate, 
dichloromethane and Hexane were purchased from Kimix or Protea Chemicals and were 
distilled prior to use. HPLC grade methanol, acetonitrile and formic acid (98 – 100%) were 
purchased from Sigma-Aldrich. Ultra filtered water was purified by a Millipore Synergy 
water purification system and was used as such. 
 
6.2 Chromatography Purification 
Thin layer chromatography (TLC) was carried out on a Merck PF254 aluminium-backed pre-
coated silica gel plates and viewed under ultraviolet (UV) light or visualized using iodine 
vapour. Product purification on the flash column chromatography was carried out using 
Merck Kieselgel 60: 70 – 230 mesh.  
 
Preparative HPLC separations were performed on a modular Waters HPLC system consisting 
of a 2767 sample manager, 2545 quaternary gradient pump, 1500 series column heater and a 
2998 photodiode array detector (PDA) with a Prep 2998 flow-cell. Sample solutions for 
purification were prepared at ca. 100 mg/mL in 50% methanol. Injection volumes ranged 
between 50 L and 1 mL, the mobile phase flow rate was 20 mL/min for all purifications and 
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an aqueous solution of 0.1% formic acid, was mixed on-line with mobile phase B, a 0.1% 
formic acid solution in methanol. 
 
6.3 Physical and spectroscopic characterization 
Melting points were determined on a Reichert-Jung Thermovar hot-stage microscope and are 
uncorrected. Microanalyses were determined using a Fisons EA 1180 CHNO-S instrument. 
Low-resolution mass spectra were obtained by flow-injection (5 mM NH4 formate pH3 in 
H2O:ACN, no column used) on a AB SCIEX 4000 QTRAP Hybrid triple quadrupole linear 
ion trap mass spectrometer, coupled with an Agilent 1200 Rapid Resolution (600 bar) HPLC 
system consisting of a binary pump, degasser, auto sampler and temperature controlled 
column compartment. Infra-red spectra were recorded on a PerkinElmer Spectrum 100 FT-IR 
spectrometer in the 4000 – 450 cm
-1
 range, with samples either as dichloromethane solution 
or as KBr discs. 
 
NMR spectra were recorded on Bruker 400 MHz or Varian Unity 400 MHz and/or Varian 
Mercury 300 MHz spectrometers, all chemical shifts are reported in ppm and were referenced 
using solvent signals (2.50 and 39.4 ppm for DMSO-d6 and 7.6 and 77.0 ppm for CDCl3). 
Chemical shifts (δ) are recorded in parts per million (ppm). Coupling constants, J, are 
measured in Hertz (Hz) and rounded off to one decimal place. Abbreviations used in the 
assignment of the 
1
H NMR spectra are as follows: br (broad), d (doublet), dd (doublet of 
doublets), m (multiplets), s (singlet) and t (triplet). 
13
C NMR chemical shifts are listed 
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6.4 Experimental details 
General procedure for the synthesis of 4-aminoquinoline-phenyl alcohols 3.7a-c.
  
 
4,7-Dichloroquinoline (1.0 eq) (3.6) and various aminobenzyl alcohols (1.0 eq) (3.5a-c) were 
refluxed in EtOH (25 ml) at 85-90 °C for 3 hrs. The resulting mixture was allowed to cool to 
room temperature, basified to pH 8 by drop-wise addition of ice-cold ammonium hydroxide 
solution (25%). The resulting precipitates were collected by filtration, washed with water (2 x 
50 ml), ice-cold ethanol (2 x 30 ml) and allowed to further dry on standing in the fume-hood 
overnight to afford crude products. Product 3.7a was purified by column chromatography 
eluting with 20% methanol: DCM mixture while products 3.7b and 3.7c were purified eluting 






As a cream-colored powder (1.94 g, 88%); m. p. 241-243 °C 
(lit.
1
 247- 250 °C), Rf (MeOH: DCM, 20:80%) 0.19; δH (400 
MHz; DMSO-d6) 9.07 (1H, s, NH), 8.47 (1H, d, J 5.6 Hz, 
H2), 8.45 (1H, d, J 9.2 Hz, H5), 7.89 (1H, d, J 2.0 Hz, H8), 
7.57 (1H, dd, J 9.2 and 2.0 Hz, H6), 7.37 (1H, t, J 7.8 Hz, H10), 7.34 (1H, s, H12), 7.24 (1H, 
d, J 7.8 Hz, H11), 7.11 (1H, d, J 7.8 Hz, H9), 6.93 (1H, d, J 5.6 Hz, H3), 5.21 (1H, t, J 5.6 






As a yellow solid (0.37 g, 25%); m. p. 185-188 °C (lit.
1
 194- 
197 °C), Rf (MeOH: DCM, 5:95%) 0.28;δH (300 MHz; 
DMSO-d6) 8.79 (1H, br s, NH), 8.39 (2H, m, H2 and H5), 
7.89 (1H, d, J 2.0 Hz, H8), 7.62 (1H, m, H11), 7.57 (1H, dd, J 
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As a pale-yellow powder (0.58 g, 30%); m. p. 155-157 °C , 
Rf (MeOH: DCM, 5:95%) 0.33; δH (400 MHz; DMSO-d6) 
9.04 (1H, s, NH), 8.45 (1H, d, J 5.6 Hz, H2), 8.43 (1H, d, J 
9.2 Hz, H5), 7.89 (1H, d, J 2.0 Hz, H8), 7.57 (1H, dd, J 9.2 
and 2.0 Hz, H6), 7.39 (2H, d, J 8.4 Hz, H10 and H11), 
7.32 (2H, d, J 8.4 Hz, H9 and H12), 6.86 (1H, d, J 5.6 Hz, H3), 5.17 (1H, t, J 5.4 Hz, OH), 
4.52 (2H, d, J 5.4 Hz, H13); δC (101 MHz; DMSO-d6) 152.0, 149.6, 149.4, 147.7, 143.8, 





General procedure for the synthesis of 4-aminoquinoline-phenyl aldehydes 3.8a-c.
 
 
SO3.Pyr (2.0 eq) was added to a stirred solutions of benzyl alcohols 3.7a-c (1.0 eq) and Et3N 
(4.0 eq) in anhydrous DMSO (5 ml) under nitrogen at 26°C. The resulting mixtures were 
further stirred at this temperature for 3 days, extracted with EtOAc (5 x 50 ml). The extracts 
were washed with water (10 ml) and brine (10 ml), dried over MgSO4 and solvent evaporated 
in vacuo and the obtained crude products purified by chromatography to give the desired 






As a pale-yellow powder (0.20 g, 84.4%); m. p. 182- 184 
°C (lit.
1
 182- 184 °C), Rf (EtOAc: Hexane, 70:30%) 
0.25; δH (400 MHz; DMSO-d6) 10.03 (1H, s, H13), 9.29 
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9.2 Hz, H5), 7.94 (1H, d, J 1.8 Hz, H8), 7.93 (1H, s, H12), 7.70 (4H, m, H9, H10, H11 and 






As a yellow solid (0.481 g, 87%); m. p. 158- 160 °C (lit.
13
 
164- 166 °C), Rf (DCM: MeOH, 95:5%) 0.28; δH (400 MHz; 
DMSO-d6) 10.27 (1H, br s, NH), 10.10 (1H, s, H13), 8.61 
(1H, d, J 5.2 Hz, H2), 8.31 (1H, d, J 9.2 Hz, H5),7.99 (1H, d, 
J 1.2 Hz, H8), 7.96 (1H, dd, J 9.2 and 1.2 Hz, H6), 7.57 (3H, 






As a pale-yellow solid (0.39 g, 19%); Rf (DCM: MeOH, 
95:5%) 0.31; δH (400 MHz; DMSO-d6) 11.01 (1H, br s, 
NH), 10.03 (1H, s, H13), 8.65 (1H, d, J 5.4 Hz, H2), 8.54 
(1H, d, J 9.1 Hz, H5), 8.05 (1H, d, J 2.1 Hz, H8), 7.82 (2H, 
2 x d, J 8.4 Hz, H10 and H11), 7.56 (1H, dd, J 9.1 and 2.1 




 of the aldehyde 4c as an HCl salt. 
A stirred methanolic mixture of 4,7-dichloroquinoline (1.0 eq) and 4-aminobenzaldehyde
1
 
(1.0 eq) was treated with 2M HCl (4 ml) and refluxed at 90 °C. After 30 minutes a thick 
yellow precipitate appeared and heating was continued at a low setting for 3 hrs and the 
resultant mixture was allowed to cool to room temperature. The yellow solid was filtered, 
washed with ice-cold methanol, then ether and dried on the vacuum line over a period of 6 














 for the synthesis of deoxyamodiaquine-tetrazoles 3.9a-k. 
Aldehydes 3.8a-c (0.5 mmol) and an amine
ǂ
 (1.0 mmol) were stirred in anhydrous methanol 
at 25 °C for 1 hr. Thereafter TMSN3 (1.0 mmol) was added, followed by the addition of the t-
butyl or ethylmorpholine isocyanide (1.0 mmol) and the resulting mixture stirred at this 
temperature for 24 hrs. The solvent was removed in vacuo to afford a crude product which 
was purified by column chromatography and HPLC to afford tertazoles 3.9a-k.  
 
N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(dimethylamino)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9a (TK1) 
 
As a yellow solid (185 mg, 86%); m. p. 200- 202 
°C, Rf (EtOAc, 100%) 0.46; IR νmax (DCM)/cm
-1
 
3431 (N-H), 1610 (Ar C=C), 1372 (N=N), 1322 
(C=N); δH (400 MHz; DMSO-d6) 9.12 (1H, s, 
NH), 8.46 (1H, d, J 5.2 Hz, H2), 8.43 (1H, d, J 9.0 Hz, H5), 7.90 (1H, s, H8), 7.57 (1H, d, J 
9.0 Hz, H6), 7.49 (1H, s, H12), 7.43 (1H, t, J 7.8 Hz, H10), 7.33 (1H, d, J 7.8 Hz, H9), 7.23 
(1H, d, J 7.8 Hz, H11), 6.87 (1H, d, J 5.2 Hz, H3), 5.50 (1H, s, H13), 2.27 (6H, s, 2 x H15), 
1.68 (9H, s, 3 x H14); δC (101 MHz; DMSO-d6) 154.0, 151.7, 149.5, 147.7, 140.0, 137.5, 
133.8, 129.0, 127.5, 125.0, 124.8, 124.3, 123.4, 122.0, 118.2, 101.7, 62.8, 61.3, 41.6 (2C) and 
29.4 (3C); MS (ESI) m/z 435.8 (M
+
) and 458.4 (M
+
+Na), (Found: C, 60.63, H, 6.16, N, 22.14 






                                                 
ǂ














amine, 3.9b (TK2) 
 
As a yellow solid (81 mg, 25%); m. p. 111- 112 
°C, Rf (EtOAc: Hex, 70:30%) 0.19; IR νmax 
(DCM)/cm
-1
 3455 (N-H), 1606 (Ar C=C), 1374 
(N=N), 1324 (C=N); δH (400 MHz; DMSO-d6) 
9.10 (1H, s, NH), 8.46 (1H, d, J 5.2 Hz, H2), 8.41 (1H, d, J 9.0 Hz, H5), 7.90 (1H, d, J 1.6 
Hz,, H8), 7.57 (1H, dd, J 9.0 and 1.6 Hz, H6), 7.40 (1H, t, J 7.9 Hz, H10), 7.32 (1H, s, H12), 
7.31 (1H, d, J 7.9 Hz, H9), 7.08 (1H, d, J 7.9 Hz, H11), 6.86 (1H, d, J 5.2 Hz, H3), 5.74 (1H, 
s, H13), 2.73 (4H, 2 x q, J 7.0 Hz, 2 x H15), 1.68 (9H, s, 3 x H14), 0.92 (6H, t, J 7.0Hz, 2 x 
H16); δC (101 MHz; DMSO-d6) 154.5, 151.6, 149.5, 147.7, 140.0, 139.2, 133.8, 129.0, 
127.5, 124.8, 124.7, 124.3, 123.2, 121.7, 118.2, 101.7, 60.0, 59.9, 44.1 (2C), 29.3 (3C) and 
13.9 (2C); m/z 391.80 [M
+
-N(CH2CH3)2, 100%]; LCMS m/z 464.1 (M
+
) and 486.2 (M
+
+Na), 
(Found: C, 61.75, H, 7.40, N, 19.49 %; C25H30ClN7.1.5H2O Requires C, 61.15, H, 6.97, N, 
19.97%), HPLC purity: 98.7%; tr’=4.59 min. 
 
N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(pyrrolidin-1-yl)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9c (TK3) 
 
As a yellow-crystalline powder (200 mg, 87%); 
m. p. 90- 92 °C, Rf (EtOAc, 100%) 0.38; IR νmax 
(DCM)/cm
-1
 3426 (N-H), 1608 (Ar C=C), 1374 
(N=N), 1329 (C=N); δH (400 MHz; DMSO-d6) 
9.12 (1H, s, NH), 8.46 (1H, d, J 5.2 Hz, H2), 8.42 (1H, d, J 9.0 Hz, H5), 7.90 (1H, d, J 1.8 
Hz, H8), 7.59 (1H, s, H12), 7.57 (1H, dd, J 9.0 and 1.8 Hz, H6), 7.42 (1H, t, J 7.8 Hz, H10), 
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m, H15a), 2.45 (2H, m, H15b), 1.69 (9H, s, 3 x H14), 1.67 (4H, m, 2 x H16); δC (101 MHz; 
DMSO-d6) 154.8, 151.7, 149.5, 147.7, 140.1, 138.5, 133.8, 129.1, 127.5, 124.8, 124.7, 124.3, 
123.1, 121.9, 118.2, 101.8, 61.3, 60.9, 50.1 (2C), 29.5 (3C) and 22.8 (2C); MS (ESI) m/z 
461.9 (M
+
), (Found: C, 62.26, H, 6.70, N, 20.72 %; C25H28ClN7.H2O Requires C, 62.56, H, 
6.30, N, 20.43%), HPLC purity: 99.0%; tr’=4.46 min. 
 
N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(piperidin-1-yl)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9d (TK4) 
 
As a white solid (131 mg, 55%); m. p. 136- 138 
°C, Rf (EtOAc, 100%) 0.64; IR νmax (DCM)/cm
-1
 
3422 (N-H), 1608 (Ar C=C), 1374 (N=N), 1327 
(C=N); δH (400 MHz; DMSO-d6) 9.12 (1H, s, 
NH), 8.46 (1H, d, J 5.6 Hz, H2), 8.43 (1H, d, J 9.0 Hz, H5), 7.90 (1H, d, J 1.8 Hz, H8), 7.57 
(1H, dd, J 9.0 and 1.8 Hz, H6),7.52 (1H, s, H12), 7.42 (1H, t, J 7.8 Hz, H10), 7.32(1H, d, J 
7.8 Hz, H9), 7.23 (1H, d, J 7.8 Hz, H11), 6.85 (1H, d, J 5.6 Hz, H3), 5.46 (1H, s, H13), 2.61 
(2H, m, H15a), 2.33 (2H, m, H15b), 1.66 (9H, s, 3 x H14), 1.43 (4H, m, 2 x H16), 1.33 (2H, 
m, H17); δC (101 MHz; DMSO-d6) 153.9, 151.7, 149.5, 147.7, 139.9, 137.1, 133.8, 128.9, 
127.5, 125.2, 124.8, 124.3, 123.5, 121.8, 101.8, 79.0, 63.2, 61.5, 50.3 (2C), 29.4 (3C), 25.7 
(2C) and 23.9; MS (ESI) m/z 476.0 (M
+
), (Found: C, 62.93, H, 6.86, N, 19.79 %; 
C25H30ClN7.H2O Requires C, 63.21, H, 6.53, N, 19.85%), HPLC purity: 99.5%; tr’=4.56 min. 
 
N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(piperazinn-1-yl)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9e (TK5) 
 
As a yellow crystalline solid (78 mg, 19% ), m.p.  
140- 144 °C, Rf (DCM: MeOH, 95: 05%) 0.48; IR 
νmax (DCM)/cm
-1
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(N=N), 1325 (C=N); δH (400 MHz; DMSO-d6) 8.57 (1H, s, NH), 8.26 (1H, d, J 6.3 Hz, H2), 
8.21 (1H, d, J 9.0 Hz, H5), 7.80 (1H, d, J 1.6, H8), 7.64 (1H, s, H12), 7.41 (2H, m, H10 and 
H11), 7.35 (1H, dd, J 9.0 and 1.6 Hz, H6), 7.25 (1H, d, J 7.9 Hz, H9), 6.70 (1H, d, J 5.6 Hz, 
H3), 5.38 (1H, s, H13), 3.52 (2H, m, H16a), 3.37 (2H, t, J 4.9 Hz, H16b), 2.81 (1H, m, 
H15a1), 2.67 (1H, m, H15a2), 2.46 (2H, m, H15b), 1.76 (9H, s, 3 x H14), δC (101 MHz; 
DMSO-d6) 153.4, 152.0, 145.3, 142.6, 138.8, 138.3, 136.8, 130.0, 127.2, 127.1, 124.8, 124.2, 
123.6, 122.7, 116.7, 100.8, 64.4, 61.9, 50.3, 49.8, 45.7, 40.1 and 30.4 (3C); MS (ESI) m/z 
477.5 (M
+
); HPLC purity: 99.5%; tr’=4.47 min. 
 
N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(morpholino)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9f (TK6) 
 
As a yellow-crystalline powder (127 mg, 53%); 
m. p. 166-168 °C, Rf (EtOAc, 100%) 0.29; IR νmax 
(DCM)/cm
-1
 3288 (N-H), 1611 (Ar C=C), 1372 
(N=N), 1327 (C=N), 1112 (C-O-C); δH (400 
MHz; DMSO-d6) 9.13 (1H, s, NH), 8.47 (1H, d, J 5.2 Hz, H2), 8.42 (1H, d, J 9.0 Hz, H5), 
7.90 (1H, d, J 2.0 Hz, H8), 7.57 (1H, dd, J 9.0 and 2.0 Hz, H6), 7.56 (1H, s, H12), 7.44 (1H, 
t, J 7.8 Hz, H10), 7.33 (1H, d, J 7.8 Hz, H9), 7.27 (1H, d, J 7.8 Hz, H11), 6.87 (1H, d, J 5.2 
Hz, H3), 5.53 (1H, s, H13), 3.55 (4H, br m, 2 x H16), 2.66 (2H, t, J 5.6 Hz, H15a), 2.40 (2H, 
t, J 5.6 Hz, H15b), 1.69 (9H, s, 3 x H14); δC (101 MHz; DMSO-d6) 153.8, 151.7, 149.5, 
147.7, 140.2, 136.6, 133.8, 129.1, 127.5, 125.1, 124.8, 124.4, 123.4, 122.0, 118.3, 101.9, 66.2 
(2C), 62.9, 61.5, 50.0 (2C) and 29.5 (3C); MS (ESI) m/z 478.0 (M
+
); (Found: C, 58.98, H, 
6.60, N, 18.60 %; C25H28ClN7O.2H2O Requires C, 58.42, H, 6.27, N, 19.07%), HPLC purity: 
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7-Chloro-N-{3-[(dimethylamino)(1-(2-morpholinoethyl)-1H-tetrazol-5-
yl)methyl]phenyl}quinolin-4-amine, 3.9g (TK7) 
 
As a thick yellow oil (100 mg, 35%); Rf (DCM: 
MeOH, 95: 05%) 0.32, IR νmax (DCM)/cm
-1
 
3413 (N-H), 1607 (Ar C=C), 1372 (N=N), 1331 
(C=N), 1116 (C-O-C); δH (400 MHz; CDCl3) 
8.54 (1H, d, J 5.5 Hz, H2), 8.04 (1H, d, J 2.0 
Hz, H8), 8.00 (1H, d, J 9.0 Hz, H5), 7.50 (1H, s, H12), 7.45 (1H, dd, J 9.0 and 2.0 Hz, H6), 
7.43 (1H, t, J 7.8 Hz, H10), 7.35 (1H, d, J 7.8 Hz, H9), 7.24 (1H, d, J 7.8 Hz, H11), 6.95 (1H, 
d, J 5.5 Hz, H3), 5.03 (1H, s, H13), 4.54 (2H, m, H14), 3.60 (4H, t, J 4.6 Hz, 2 x H17), 2.75 
(2H, m, H15), 2.45 (4H, t, J 4.6 Hz, 2 x H16), 2.31 ( 6H, s, 2 x H18); δC (101 MHz; CDCl3) 
154.3, 150.8, 150.3, 147.8, 139.9, 136.0, 135.1, 129.9, 128.1, 126.5, 125.4, 123.0, 122.4, 
121.8, 118.0, 102.5, 66.7 (2C), 64.9, 57.4, 53.7 (2C), 45.2 and 42.8 (2C), MS (ESI) m/z 493.0 
(M
+
); HPLC purity: 97.5%; tr’=4.16 min. 
 
N-{3-[(diethylamino)-(1-(2-morpholinoethyl)-1H-tetrazol-5-yl)methyl]phenyl}-7-
chloroquinolin-4-amine, 3.9h (TK8) 
 
As a white paste (95 mg, 32%); Rf (DCM: 
MeOH, 95: 05%) 0.38, IR νmax (DCM)/cm
-1
 
3422 (N-H), 1609 (Ar C=C), 1374 (N=N), 
1325 (C=N), 1116 (C-O-C); δH (400 MHz; 
CDCl3) 8.79 (1H, s, NH), 8.55 (1H, d, J 5.3 
Hz, H2), 8.01 (1H, d, J 2.1 Hz, H8), 7.90 (1H, d, J 9.0 Hz, H5), 7.45 (1H, dd, J 9.0 and 2.1 
Hz, H6), 7.38 (2H, m, H10 and H12), 7.30 (1H, d, J 7.9 Hz, H9), 7.18 (1H, d, J 7.9 Hz, H11), 
6.97 (1H, d, J 5.3 Hz, H3), 5.41 (1H, s, H13), 4.51 (2H, m, H14), 3.69 (2H, t, J 4.7 Hz, 
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(2H, m, H16a), 2.43 (2H, m, H16b), 1.04 (6H, t, J 7.1 Hz,  2 x H19); δC (101 MHz; CDCl3) 
154.3, 151.7, 149.7, 147.3, 140.1, 137.8, 135.5, 129.7, 128.9, 126.3, 125.2, 123.0, 122.1, 
121.4, 118.5, 102.7, 66.8 (2C), 59.6, 57.3, 53.4 (2C), 45.4, 44.0 (2C) and 13.0 (2C), MS 
(ESI) m/z 521.0 (M
+
); HPLC purity: 98.9%; tr’=4.29 min. 
 
7-Chloro-N-{3-[1-(2-morpholinoethyl)-1H-tetrazol-5-yl)(pyrrolidin-1-
yl)methyl]phenyl}quinolin-4-amine, 3.9i (TK9) 
 
As a white paste (130 mg, 40%); Rf (DCM: 
MeOH, 95: 05%) 0.39, IR νmax (DCM)/cm
-1
 
3422 (N-H), 1606 (Ar C=C), 1370 (N=N), 
1325 (C=N), 1119 (C-O-C); δH (400 MHz; 
CDCl3) 8.51 (1H, d, J 5.5 Hz, H2), 8.04 (1H, 
d, J 1.8 Hz, H8), 7.98 (1H, d, J 8.8 Hz, H5), 7.47 (1H, s, H12), 7.46 (1H, dd, J 8.8 and 1.8 
Hz, H6), 7.40 (1H, t, J 7.8 Hz, H10), 7.33 (2H, m, H9 and H11), 6.94 (1H, d, J 5.5 Hz, H3), 
5.06 (1H, s, H13), 4.53 (2H, m, H14), 3.61 (4H, t, J 4.6 Hz, 2 x H17), 2.81 (2H, m, H15), 
2.66 (2H, m, H18a), 2.50 (2H, m, H18b), 2.44 (4H, t, J 4.6 Hz, 2 x H16) 1.83 (4H, m, 2 x 
H19); δC (101 MHz; CDCl3) 155.1, 150.4, 150.3, 148.0, 140.1, 138.7, 136.2, 130.0, 127.8, 
126.6, 124.6, 122.3, 122.1, 122.0, 118.0, 102.5, 66.7 (2C), 63.7, 57.0, 53.6 (2C), 52.4 (2C), 
45.1 and 23.5 (2C), MS (ESI) m/z 519.0 (M
+
); HPLC purity: 98.2%; tr’=4.08 min. 
 
N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(dimethylamino)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9j (TK10) 
 
As a yellow paste (45 mg, 12%); Rf (DCM: MeOH, 95: 05%) 
0.51, IR νmax (DCM)/cm
-1
 3422 (N-H), 1607 (Ar C=C), 1368 
(N=N), 1325 (C=N); δH (400 MHz; DMSO-d6) 9.82 (1H, s, 
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7.84 (1H, d, J 8.9 Hz, H5), 7.61 (1H, d, J 7.9 Hz, H12), 7.49 (1H, dd, J 2.1 and 8.9 Hz, H6), 
7.37 (1H, t, J 7.8 Hz, H10), 7.13 (1H, d, J 5.3 Hz, H3), 6.98 (1H, t, J 7.8 Hz, H11), 6.60 (1H, 
d, J 7.6 Hz, H9), 5.61 (1H, s, H13), 2.55 (6H, s, 2 x H15), 1.55 (9H, s, 3 x H14); δC (101 
MHz; DMSO-d6) 151.8, 149.3, 147.0, 146.8, 139.8, 129.8, 129.5, 128.9, 127.8, 126.5, 123.5, 
121.4, 120.8, 120.7, 102.0, 101.9, 61.6, 59.6, 40.9 (2C) and 29.6 (3C); MS (ESI) m/z 436.2 
(M
+
); HPLC purity: 98.2%; tr’=6.87 min. 
 
N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(dimethylamino)methyl]phenyl}-7-Chloroquinolin-4-
amine, 3.9k (TK11) 
 
As a yellow solid (101 mg, 16%); m. p. 165- 
168 °C, Rf (DCM: MeOH, 90: 10%) 0.35; IR 
νmax (KBr)/cm
-1
 3500 (N-H), 1611 (Ar C=C), 
1374 (N=N), 1323 (C=N);, δH (300 MHz; 
DMSO-d6) 9.53 (1H, s, NH), 8.40 (1H, d, J 5.4 
Hz, H2), 8.20 (1H, d, J 9.0 Hz, H5), 7.81 (1H, d, J 2.2 Hz, H8), 7.67 (2H, d, J 7.0 Hz, 2 x 
H9), 7.56 (2H, d, J 6.9 Hz, 2 x H10), 7.53 (1H, dd, J 9.0 and 2.2 Hz, H6), 6.73 (1H, d, J 5.4 
Hz, H3), 5.54 (1H, s, H11), 2.31 (6H, s, 2 x H13), 1.74 (9H, s, 3 x H12); δC (75 MHz; 
DMSO-d6) 153.9, 151.3, 148.9, 147.3, 141.2, 139.4, 138.3, 136.5, 133.2, 129.9, 127.3, 125.0, 
124.4, 123.6, 119.8, 117.4, 100.4, 62.4, 61.3, 41.4 (2C) and 29.4 (3C); MS (ESI) m/z 436.4 
(M
+
); HPLC purity: 99.5%; tr’=7.21 min. 
 
General procedure for the synthesis of de-tert-butylated deoxyamodiaquine-tetrazoles 
3.10a-f. 
 
A solution of the tert-butylated tetrazole 3.9a-f (0.58 mmol) in 32% HCl acid (10 ml) was 
refluxed at 120 °C for 4-8 hrs. On complete consumption of the starting material, as shown 
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and the pH adjusted to 12 by the addition of 5% NaHCO3. The resultant mixture was washed 
with EtOAc (2 x 100 ml), aqueous layer neutralized to pH 7 by drop-wise addition of 32% 
HCl acid and allowed to stand in the fume hood overnight. The precipitate which had formed 
was filtered and washed with cold Et2O to afford a crude product which was purified by 





 As an off-white powder (129 mg, 59%); m. p. 
174- 176 °C, Rf (DCM: MeOH: NH4OH; 90: 9.7: 
0.3%) 0.17; IR νmax (KBr)/cm
-1
 3341 (N-H), 1588 
(Ar C=C), 1370 (N=N), 1329 (C=N);  δH (400 
MHz; DMSO-d6) 9.12 (1H, br s, NH), 8.45 (1H, 
d, J 9.1 Hz, H5), 8.42 (1H, d, J 5.4 Hz, H2), 7.87 (1H, d, J 2.2 Hz, H8), 7.58 (1H, s, H12), 
7.54 (1H, dd, J 9.1 and 2.2 Hz, H6), 7.33 (1H, t, J 7.6 Hz, H10), 7.26 (1H, d, J 7.6 Hz, H9), 
7.21 (1H, d, J 7.6 Hz, H11), 6.89 (1H, d, J 5.4 Hz, H3), 4.82 (1H, s, H13), 2.14 (6H, s, 2 x 
H14); δC (101 MHz; DMSO-d6) 159.8, 151.7, 149.4, 148.0, 142.5, 139.5, 133.7, 128.4, 
127.4, 124.6 (2C), 124.4, 123.2, 121.1, 118.2, 101.5, 66.7 and 42.8 (2C); MS (ESI) m/z 380.4 
(M
+
); (Found: C, 51.77, H, 5.83, N, 24.24%; C19H18ClN7.H2O.NH4HCO2 Requires C, 52.12, 





As a pale-yellow powder (99 mg, 40%), m. p. 185- 
187 °C, Rf (DCM: MeOH: NH4OH; 90: 9.7: 0.3%) 
0.11; IR νmax (KBr)/cm
-1
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C=C), 1374 (N=N), 1325 (C=N); δH (400 MHz; DMSO-d6) 9.20 (1H, br s, NH), 8.47 (1H, d, 
J 5.4 Hz, H2), 8.43 (1H, d, J 9.0 Hz, H5), 7.91 (1H, d, J 2.2 Hz, H8), 7.59 (1H, s, H12), 7.58 
(1H, dd, J 9.0 and 2.2 Hz, H6), 7.45 (1H, t,  J 7.8 Hz, H10), 7.32 (2H, 2 x d, J 7.8 Hz, H9 and 
H11), 6.91 (1H, d, J 5.4 Hz, H3), 5.61 (1H, s, H13), 2.79 (2H, q, J 7.1 Hz, H14a), 2.64 (2H, 
q, J 7.1 Hz, H14b), 1.05 (6H, t, J 7.1 Hz, 2 x H15); δC (101 MHz; DMSO-d6) 157.2, 152.2, 
149.8, 148.4, 140.9, 134.5, 130.0, 128.0, 125.5, 125.0, 124.9, 123.2, 122.8, 118.9, 102.6, 
61.1, 55.3, 44.3 (2C) and 11.1 (2C); MS (ESI) m/z 408.6 (M
+
+H); (Found: C, 56.94, H, 6.05, 
N, 24.04%; C21H22ClN7.NH4HCO2 Requires C, 56.11, H, 5.78, N, 23.79%); HPLC purity: 





 As a pale-yellow powder (134 mg, 55%), m. p. 
189- 192 °C, Rf (DCM: MeOH: NH4OH; 90: 9.7: 
0.3%) 0.14; IR νmax (KBr)/cm
-1
 3360 (N-H), 1601 
(Ar C=C), 1373 (N=N), 1325 (C=N); δH (400 
MHz; DMSO-d6) 9.16 (1H, br s, NH), 8.48 (1H, d, J 5.3 Hz, H2), 8.43 (1H, d, J 9.1 Hz, H5), 
7.91 (1H, d, J 2.0 Hz, H8), 7.65 (1H, s, H12), 7.58 (1H, dd, J 9.1 and 2.0 Hz, H6), 7.45 (1H, 
t, J 7.8 Hz, H10), 7.38 (1H, d, J 7.8 Hz, H9), 7.33 (1H, d, J 7.8 Hz, H11), 6.92 (1H, d, J 5.3 
Hz, H3), 5.49 (1H, s, H13), 2.85 (4H, t, J 6.2 Hz, 2 x H14), 1.84 (4H, t, J 6.2 Hz, 2 x H15); 
δC (101 MHz; DMSO-d6) 157.8, 151.7, 149.3, 147.6, 140.4, 138.3, 133.9, 129.6, 127.4, 
124.9, 124.4, 124.1, 122.4, 122.2, 118.3, 102.1, 64.2, 52.2 (2C) and 22.8 (2C); MS (ESI) m/z 
406.3 (M
+
); (Found: C, 54.05, H, 6.01, N, 22.45%; C21H20ClN7.H2O.NH4HCO2 Requires C, 

















As a yellow powder (84 mg, 39%); m. p. 193- 195 
°C, Rf (DCM: MeOH: NH4OH; 90: 9.7: 0.3%) 
0.16; IR νmax (KBr)/cm
-1
 3381 (N-H), 1609 (Ar 
C=C), 1374 (N=N), 1322 (C=N); δH (300 MHz; 
DMSO-d6) 9.09 (1H, br s, NH), 8.47 (1H, d, J 5.4 Hz, H2), 8.43 (1H, d, J 9.0 Hz, H5), 7.90 
(1H, d, J 2.2 Hz, H8), 7.57 (1H, dd, J 9.0 and 2.2 Hz, H6),7.55 (1H, s, H12), 7.43 (1H, t, J 
7.8 Hz, H10), 7.30 (1H, d, J 7.8 Hz, H9), 7.24 (1H, d, J 7.8 Hz, H11), 6.89 (1H, d, J 5.4 Hz, 
H3), 5.24 (1H, s, H13), 2.57 (2H, m, H14a), 2.45 (2H, m, H14b), 1.58 (4H, m, 2 x H15), 1.41 
(2H, t, J 7.4 Hz, H16); δC (75 MHz; DMSO-d6) 156.9, 151.6, 149.3, 148.9, 147.8, 140.2, 
138.4, 133.4, 129.2, 127.4, 124.8, 124.3 (2C), 122.6, 121.8, 102.0, 65.0, 51.3 (2C), 24.6 (2C) 
and 23.2; MS (ESI) m/z 420.1 (M
+
); (Found: C, 56.06, H, 5.96, N, 22.45%; 
C22H22ClN7.0.5H2O.NH4HCO2 Requires C, 56.15, H, 5.74, N, 22.78%); HPLC purity: 
96.4%; tr’=4.38 min. 
 
N-{3-[(morpholino) (1H-tetrazol-5-yl)methyl]phenyl}-7-Chloroquinolin-4-amine, 3.10f 
(TK6B3) 
 
 As a yellow powder (170 mg, 45%); m. p. 190- 
192 °C, Rf (DCM: MeOH: NH4OH, 90: 9.7: 0.3%) 
0.10; IR νmax (KBr)/cm
-1
 3340 (N-H), 1587 (Ar 
C=C), 1371 (N=N), 1320 (C=N); δH (300 MHz; 
DMSO-d6) 8.46 (1H, d, J 5.4 Hz, H2), 8.41 (1H, d, J 9.0 Hz, H5), 7.90 (1H, d, J 2.2 Hz, H8), 
7.54 (1H, dd, J 9.0 and 2.2 Hz, H6), 7.51 (1H, s, H12), 7.38 (1H, t, J 7.8 Hz, H10), 7.28 (1H, 
d, J 7.8 Hz, H9), 7.22 (1H, d, J 7.8 Hz, H11), 6.88 (1H, d, J 5.2 Hz, H3), 5.05 (1H, s, H13), 
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DMSO-d6) 156.9, 151.4, 149.1, 147.9, 140.2, 138.6, 133.9, 129.3, 127.2, 124.8, 124.4, 124.1, 
122.4, 121,8, 118.2, 101.9, 65.9 (2C), 64.6 and 51.0 (2C); MS (ESI) m/z 422.2 (M
+
); (Found: 
C, 54.60, H, 5.46, N, 23.53%; C21H20ClN7O.NH4HCO2 Requires C, 54.49, H, 5.20, N, 
23.11%); HPLC purity: 99.4%; tr’=4.47 min. 
 
General procedure for the synthesis of 4-aminoquinoline-amines 3.13a-c. 
4,7-Dichloroquinoline (1.0 eq) (3.6) and the respective diamine (3.12a-c) (5.0 eq) were 
heated neat at 80 °C for 1 hr without stirring and then at 135 °C for 4 hrs with stirring. The 
resulted mixtures were allowed to cool to room temperature, 10% NaOH (60 ml) added and a 
portion of products precipitated, and collected by filtration. These were then washed with 
distilled water and ice-cold ethanol to afford white or yellow powdery products. Excess 
products that remained in the aqueous solution were extracted with hot EtOAc (3 x 100 ml), 
washed with distilled water and dried over MgSO4. Solvents were removed in vacuo to obtain 




As a white powder (1.47 g, 65%); m. p. 138- 140 °C (lit.
2
 
137- 139 °C); Rf (NH3: MeOH, 2:98%) 0.20; δH (400 
MHz; CD3OD) 8.37 (1H, d, J 5.6 Hz, H2), 8.13 (1H, d, J 
9.2 Hz, H5), 7.79 (1H, d, J 2.0 Hz, H8), 7.42 (1H, dd, J 9.2 





As a white-crystalline powder (1.59 g, 66%); m. p. 
120-122 °C (lit.
2
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2:98%) 0.21; δH (400 MHz; CD3OD) 8.36 (1H, d, J 5.6 Hz, H2), 8.09 (1H, d, J 8.8 Hz, H5), 
7.78 (1H, d, J 2.4 Hz, H8), 7.40 (1H, dd, J 8.8 and 2.4 Hz, H6), 6.54 (1H, d, J 5.6 Hz, H3), 




As a pale-yellow powder (1.78 g, 70%); m. p. 40-41 
°C (lit.
2
 43- 47 °C); Rf (NH3: MeOH, 2:98%) 0.22; δH 
(300 MHz; CD3OD) 8.30 (1H, d, J 5.7, H2), 8.05 (1H, 
d, J 9.0, H5), 7.73 (1H, d, J 2.1, H8), 7.34 (1H, dd, J 
9.0 and 2.1, H6), 6.44 (1H, d, J 5.7, H3), 3.30 (2H, t, J 7.2, H9), 2.76 (2H, t, J 7.2, H12), 1.75 




for the synthesis of chloroquine-like tetrazoles  
 
Quinoline diamines 3.13a-c (1.35 mmol) and an aromatic aldehydes (1.35 mmol) were stirred 
in anhydrous methanol at 26 °C for 5 minutes. Thereafter, TMSN3 (1.35 mmol) was added, 
followed by the addition of tert-butyl isocyanide (1.35 mmol) and the resulting mixture was 
then stirred for 24 hrs. The solvent was removed in vacuo to afford crude tetrazole products 
3.15a1-5 (n=1), 3.15b (n=2) and 3.15c (n=3).  
 
N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(phenyl)methylamino]ethyl}-7-chloroquinolin-4-
amine, 3.15a1 (TK900A) 
 
Purified by column chromatography (on silica 
gel; elution with DCM: MeOH; 95:05) to yield 
the desired product 3.15a1 (382 mg, 65%) as a 
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(DCM: MeOH, 95: 05%) 0.38; IR νmax (DCM)/cm
-1
 1602 (Ar C=C), 1370 (N=N), 1330 
(C=N), 1277 (C-N); δH (400 MHz; CDCl3) 8.47 (1H, d, J 5.6 Hz, H2), 8.11 (1H, d, J 9.0 Hz, 
H5), 7.98 (1H, d, J 2.1 Hz, H8), 7.43 (1H, dd, J 9.0 and 2.1 Hz, H6), 7.33 (3H, m, 2 x H13 
and H14), 7.23 (2H, 2 x d, J 7.9 Hz, 2 x H12), 6.80 (1H, br s, NH), 6.30 (1H, d, J 5.6 Hz, 
H3), 5.40 (1H, s, H11), 3.35 (2H, m, H9), 3.15 (1H, m, H10a), 2.99 (1H, m, H10b), 1.58 (9H, 
s, 3 x H15); δC (101 MHz; CDCl3) 155.7, 151.0, 150.4, 147.4, 138.4, 135.7, 129.3 (2C), 
128.8, 128.0 (2C), 127.1, 125.8, 122.4, 117.1, 98.6, 61.8, 59.1, 45.7, 42.7 and 29.9 (3C); MS 
(ESI) m/z 436.1 (M
+
); HPLC purity: 98.5%; tr’=6.59 min. 
 
N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(4-methoxyphenyl)methylamino]ethyl}-7-
chloroquinolin-4-amine, 3.15a2 (TK900B) 
 
Purified by column chromatography (on silica 
gel; elution with DCM: MeOH; 95:05) to yield 
the desired product 3.15a2 (358 mg, 57%) as a 
pale-yellow crystalline solid; m. p. 75- 77 °C, Rf 
(DCM: MeOH, 95: 05%) 0.48; IR νmax 
(DCM)/cm
-1
 1610 (Ar C=C), 1371 (N=N), 1329 (C=N), 1241 (C-O Ester); δH (400 MHz; 
CDCl3) 8.49 (1H, d, J 5.4 Hz, H2), 8.04 (1H, d, J 9.0 Hz, H5), 7.96 (1H, d, J 2.2 Hz, H8), 
7.44 (1H, dd, J 9.0 and 2.2 Hz, H6), 7.13 (2H, d, J 8.8 Hz, 2 x H13), 6.85 (2H, d, J 8.8 Hz, 2 
x H12), 6.40 (1H, br s, NH), 6.33 (1H, d, J 5.4 Hz, H3), 5.33 (1H, s, H11), 3.78 (3H, s, 
OCH3), 3.36 (2H, m, H9), 3.12 (1H, m, H10a), 2.98 (1H, m, H10b), 1.59 (9H, s, 3 x H14); δC 
(101 MHz; CDCl3) 159.8, 155.9, 151.7, 150.2, 147.5, 137.8, 130.5, 129.2 (2C), 128.3, 125.5, 
122.0, 117.4, 114.6 (2C), 98.9, 61.7, 58.5, 55.3, 45.7, 42.5 and 29.9 (3C); MS (ESI) m/z 
465.9 (M
+
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N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(p-tolyl)methylamino]ethyl}-7-chloroquinolin-4-
amine, 3.15a3 (TK900C) 
 
Purified by column chromatography (on silica 
gel; elution with DCM: MeOH; 95:05) to yield 
the desired product 3.15a3 (371 mg, 61%) as a 
pale-yellow crystalline solid; m. p. 80- 82 °C, Rf 
(DCM: MeOH, 95: 05%) 0.33; IR νmax 
(DCM)/cm
-1
 1612 (Ar C=C), 1366 (N=N), 1325 (C=N), 1265 (C-N); δH (400 MHz; CDCl3) 
8.45 (1H, d, J 5.5 Hz, H2), 8.09 (1H, d, J 9.0 Hz, H5), 7.97 (1H, d, J 2.1 Hz, H8), 7.44 (1H, 
dd, J 9.0 and 2.1 Hz, H6), 7.14 (2H, d, J 8.3 Hz, 2 x H13), 7.09 (2H, d, J 8.3 Hz, 2 x H12), 
6.66 (1H, br s, NH), 6.31 (1H, d, J 5.5 Hz, H3), 5.36 (1H, s, H11), 3.36 (2H, m, H9), 3.14 
(1H, m, H10a), 2.98 (1H, m, H10b), 2.32 (3H, s, H14), 1.58 (9H, s, 3 x H15); δC (101 MHz; 
CDCl3) 155.7, 151.6, 150.3, 147.8, 138.9, 135.5, 135.1, 129.2 (2C), 128.3, 127.8 (2C), 125.5, 
122.0, 117.4, 98.9, 61.8, 58.8, 45.7, 42.5, 29.9 (3C) and 21.1; MS (ESI) m/z 450.3 (M
+
), 
HPLC purity: 99.5%; tr’=6.92 min. 
 
N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(3,4-dichlorophenyl)methylamino]ethyl}-7-
chloroquinolin-4-amine, 3.15a4 (TK900D) 
 
Purified by column chromatography (on silica 
gel; elution with DCM: MeOH; 95:05) to yield 
the desired product 3.15a4 (73 mg, 11%) as a 
pale-yellow crystalline solid; m. p. 68- 71 °C, 
Rf (DCM: MeOH, 95: 05%) 27; IR νmax 
(DCM)/cm
-1
 1583(Ar C=C), 1373 (N=N), 1333 (C=N), 1245 (C-N); δH (400 MHz; CDCl3) 
8.55 (1H, d, J 5.3 Hz, H2), 7.97 (1H, d, J 2.1 Hz, H8), 7.94 (1H, d, J 9.0 Hz, H5), 7.46 (1H, 
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dd, J 8.2 and 2.5 Hz, H12), 6.35 (1H, d, J 5.4 Hz, H3), 6.09 (1H, br s, NH), 5.33 (1H, s, 
H11), 3.38 (2H, m, H9), 3.09 (1H, m, H10a), 2.95 (1H, m, H10b), 1.63 (9H, s, 3 x H15); δC 
(101 MHz; CDCl3) 154.8, 151.7, 150.0, 148.9, 138.5, 135.1, 133.6, 133.3, 131.2, 130.1, 
128.6, 127.1, 125.7, 121.6, 117.4, 99.0, 61.8, 58.0, 46.0, 42.4 and 29.9 (3C); MS (ESI) m/z 
504.3 (M
+
); HPLC purity: 99.2%; tr’=7.79 min. 
 
N-{2-[(1-tert-butyl-1H-tetrazol-5-yl)(4-chlorophenyl)methylamino]ethyl}-7-
chloroquinolin-4-amine, 3.15a5 (TK900E) 
 
Purified by column chromatography (on silica 
gel; elution with DCM: MeOH; 95:05) to yield 
the desired product 3.15a5 (180 mg, 28%) as a 
pale-yellow crystalline solid; m. p. 79- 81 °C, Rf 
(DCM: MeOH, 95: 05%) 0.37; IR νmax 
(DCM)/cm
-1
 1579 (Ar C=C), 1375 (N=N), 1319 (C=N), 1269 (C-N); δH (400 MHz; CDCl3) 
8.51 (1H, d, J 5.3 Hz, H2), 7.98 (1H, d, J 9.0 Hz, H5), 7.96 (1H, d, J 2.1 Hz, H8), 7.44 (1H, 
dd, J 9.0 and 2.1 Hz, H6), 7.33 (2H, d, J 8.5 Hz, 2 x H13), 7.19 (2H, d, J 8.5 Hz, 2 x H12), 
6.35 (1H, d, J 5.3 Hz, H3), 6.21 (1H, br s, NH), 5.37 (1H, s, H11), 3.39 (2H, m, H9), 3.13 
(1H, m, H10a), 2.99 (1H, m, H10b), 1.62 (9H, s, 3 x H14); δC (101 MHz; CDCl3) 155.3, 
151.8, 150.0, 149.0, 136.9, 135.1, 134.9, 129.5 (2C), 129.3 (2C), 128.6, 125.6, 121.7, 117.4, 
99.0, 61.8, 58.4, 45.9, 42.4 and 30.0 (3C); MS (ESI) m/z 470.4 (M
+
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N-{3-[(1-tert-butyl-1H-tetrazol-5-yl)(phenyl)methylamino]propyl}-7-chloroquinolin-4-
amine, 3.15b (TK910) 
 
Purified by column chromatography (on 
silica gel; elution with DCM: MeOH; 95:05) 
to yield the desired product 3.15b (291 mg, 
51%) as a pale-yellow crystalline solid; m. 
p. 68- 70 °C, Rf (DCM: MeOH, 95: 05%) 
0.38; IR νmax (DCM)/cm
-1
 1607 (Ar C=C), 
1372 (N=N), 1329 (C=N), 1278 (C-N); δH (400 MHz; CDCl3) 8.48 (1H, d, J 5.6 Hz, H2), 
7.93 (1H, d, J 2.1 Hz, H8), 7.40 (3H, m, H5 and 2 x H13), 7.31 (3H, m, 2 x H14 and H15), 
7.03 (1H, dd, J 9.0 and 2.1 Hz, H6), 6.30 (1H, d, J 5.6 Hz, H3), 5.31 (1H, s, H12), 3.44 (2H, 
t, J 5.9 Hz, H9), 2.95 (1H, m, H11a), 2.99 (1H, m, H11b), 1.96 (2H, m, H10), 1.59 (9H, s, 3 x 
H16); δC (101 MHz; CDCl3) 155.2, 150.9, 150.7, 147.7, 138.2, 135.3, 129.4 (2C), 128.9, 
128.1 (2C), 127.3, 125.9, 122.1, 117.1, 98.1, 61.6, 59.5, 47.9, 43.8, 30.0 (3C) and 27.3; MS 
(ESI) m/z 450.7 (M
+
+H); HPLC purity: 96.5%; tr’=6.15 min. 
 
N-{4-[(1-tert-butyl-1H-tetrazol-5-yl)(phenyl)methylamino]butyl}-7-chloroquinolin-4-
amine, 3.15c (TK920) 
 
Purified by column chromatography (on silica 
gel; elution with DCM: MeOH; 95:05) to 
yield the desired product 3.15c (282 mg, 51%) 
as a pale-yellow crystalline solid; m. p. 64- 66 
°C, Rf (DCM: MeOH, 95: 05%) 0.39; IR νmax 
(KBr)/cm
-1
 1609 (Ar C=C), 1372 (N=N), 1326 (C=N), 1276 (C-N); δH (400 MHz; CDCl3) 
8.34 (1H, d, J 5.8 Hz, H2), 7.90 (1H, d, J 2.1 Hz, H8), 7.74 (1H, d, J 9.0 Hz, H5), 7.31 (3H, 
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Hz, H3), 5.26 (1H, s, H13), 3.33 (2H, t, J 6.8 Hz, H9), 2.62 (2H, m, H12), 1.83 (2H, m, H10), 
1.68 (2H, m, H11), 1.61 (9H, s, 3 x H17); δC (101 MHz; CDCl3) 155.6, 151.2, 149.1, 146.2, 
138.6, 135.9, 129.1 (2C), 128.5, 128.0 (2C), 126.2, 125.6, 122.2, 116.7, 98.4, 61.4, 59.2, 
47.3, 43.0, 30.0 (3C), 27.3 and 26.0; MS (ESI) m/z 464.3 (M
+
); HPLC purity: 95.9%; tr’=5.84 
min. 
 
General procedure for the synthesis of de-tert-butylated chloroquine-like tetrazoles 
3.16a1-5, 3.16b and 3.16c. 
 
The procedure used in the synthesis of the de-tert-butylated deoxyamodiaquine tetrazole 
3.10a-f was followed, chloroquine-based tetrazoles 3.15a1-5, 3.15b and 3.15c (0.46 mmol) 
were refluxed in 32% HCl (10 ml) for a period of 4 to 8 hours to give the desired de-tert-
butylated products, 3.16a1-5, 3.16b and 3.16c, after purification by column chromatography 





As a -yellow powder (15 mg, 8%), m. p. 144- 
148 °C, Rf (DCM: MeOH: NH4OH; 
95:0.9:01%) 0.12; IR νmax (KBr)/cm
-1
 1600 (Ar 
C=C), 1372 (N=N), 1330 (C=N); δH (400 MHz; 
CDCl3) 8.49 (1H, d, J 9.0 Hz, H5), 8.34 (1H, d, 
J 5.4 Hz, H2), 7.76 (1H, d, J 2.1 Hz, H8), 7.68 (1H, br m, NH), 7.40 (3H, m, H6, 2 x H13), 
7.20 (2H, 2 x d, J 7.2 Hz, 2 x H12), 7.14 (1H, t, J 7.2 Hz, H14), 6.40 (1H, d, J 5.4 Hz, H3), 
5.09 (1H, s, H11), 3.29 (2H, m, H9), 2.79 (1H, m, H10a), 2.75 (1H, m, H10b); δC (101 MHz; 










Chapter 6: Experimental  
199 
123.8, 117.4, 98.4, 59.0, 45.7, and 42.9, MS (ESI) m/z 379.9 (M
+






 As a pale-yellow solid (68 mg, 38%), m. p. 
171- 173 °C, Rf (DCM: MeOH: NH4OH; 
95:0.9:01%) 0.18; IR νmax (KBr)/cm
-1
 1615 (Ar 
C=C), 1370 (N=N), 1328 (C=N), 1240 (C-O 
Ester); δH (400 MHz; CDCl3) 8.38 (1H, d, J 5.5 
Hz, H2), 8.30 (1H, d, J 9.0 Hz, H5), 7.78 (1H, d, J 2.2 Hz, H8), 7.45 (1H, dd, J 9.0 and 2.2 
Hz, H6), 7.41 (2H, d, J 8.7 Hz, 2 x H13), 6.87 (2H, d, J 8.7 Hz, 2 x H12), 6.46 (1H, d, J 5.5 
Hz, H3), 5.40 (1H, s, H11), 3.72 (3H, s, OCH3), 3.43 (2H, t, J 6.6 Hz, H9), 2.87 (2H, t, J 6.6 
Hz, H10); δC (101 MHz; CDCl3) 159.1, 158.7, 151.0, 150.2, 148.0, 133.7, 132.8, 129.6 (2C), 
126.6, 124.3, 124.0, 117.2, 113.7 (2C), 98.6, 57.1, 55.0, 43.9 and 40.2; MS (ESI) m/z 410.1 
(M
+




 As a pale-yellow crystalline powder (54 mg, 
31%), m. p. 150- 153 °C, Rf (DCM: MeOH: 
NH4OH; 95:0.9:01%) 0.28; IR νmax (KBr)/cm
-1
 
1610 (Ar C=C), 1376 (N=N), 1327 (C=N); δH 
(400 MHz; CDCl3) 8.40 (1H, d, J 5.6 Hz, H2), 
8.26 (1H, d, J 9.0 Hz, H5), 7.80 (1H, d, J 2.2 Hz, H8), 7.47 (1H, dd, J 9.0 and 2.2 Hz, H6), 
7.37 (2H, d, J 8.3 Hz, 2 x H13), 7.14 (2H, d, J 8.3 Hz, 2 x H12), 6.49 (1H, d, J 5.6 Hz, H3), 
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δC (101 MHz; CDCl3) 156.2, 155.4, 142.7, 139.1, 138.4, 137.8, 129.7, 129.4 (2C), 128.9 
(2C), 126.7, 126.3, 118.8, 115.6, 98.6, 55.3, 43.5, 40.5 and 20.6; MS (ESI) m/z 494.4 (M
+
); 
HPLC purity: 98.0%; tr’=6.19 min. 
N-{2-[(3,4-dichlorophenyl)(1H-tetrazol-5-yl)methylamino]ethyl}-7-chloroquinolin-4-
amine, 3.16a4 (TK900DB3) 
 
As a yellow powder (77 mg, 58%), m. p. 124- 
1127 °C, Rf (DCM: MeOH: NH4OH; 
95:0.9:01%) 0.21; IR νmax (KBr)/cm
-1
 1598 (Ar 
C=C), 1368 (N=N), 1328 (C=N); δH (400 MHz; 
CDCl3) 8.49 (1H, d, J 9.1 Hz, H5), 8.44 (1H, d, 
J 6.4 Hz, H2), 7.90 (1H, d, J 1.8 Hz, H8), 7.76 (1H, d, J 1.9 Hz, H14), 7.61 (2H, m,H6 and 
H13), 7.44 (1H, dd, J 8.3 and 1.9 Hz, H12), 6.68 (1H, d, J 6.4 Hz, H3), 5.48 (1H, s, H11), 
3.55 (2H, t, J 6.3 Hz, H9), 2.89 (2H, t, J 6.3 Hz, H10); δC (101 MHz; CDCl3) 158.5, 152.8, 
146.7, 143.2, 140.6, 135.6, 130.3, 130.2, 128.1, 124.9 (2C), 122.7, 122.6, 125.7, 116.3, 98.6, 
56.1, 44.5 and  42.3; MS (ESI) m/z 449.9 (M
+




As a pale-yellow powder (47 mg, 27%), m. p. 
152- 155 °C, Rf (DCM: MeOH: NH4OH; 
95:0.9:01%) 0.13; IR νmax (KBr)/cm
-1
 1620 (Ar 
C=C), 1378 (N=N), 1325 (C=N); δH (400 MHz; 
CDCl3) 8.28 (1H, d, J 9.1 Hz, H5), 8.25 (1H, d, 
J 6.7 Hz, H2), 7.79 (1H, d, J 1.9 Hz, H8), 7.58 (1H, dd, J 9.1 and 1.9 Hz, H6), 7.37 (2H, d, J 
8.4 Hz, 2 x H13), 7.19 (2H, d, J 8.4 Hz, 2 x H12), 6.61 (1H, d, J 6.7 Hz, H3), 5.23 (1H, s, 
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151.0, 149.9, 146.7, 138.0, 134.3, 132.5, 129.9 (2C), 128.3 (2C), 125.6, 124.6, 124.3, 117.0, 
98.6, 56.9, 44.3 and 41.3; MS (ESI) m/z 414.1 (M
+





 As a pale-yellow powder (91 mg, 52%), m. 
p. 99- 102 °C, Rf (DCM: MeOH: NH4OH; 
95:0.9:01%) 0.22; IR νmax (KBr)/cm
-1
 1608 
(Ar C=C), 1374 (N=N), 1327 (C=N); δH 
(300 MHz; CDCl3) 8.40 (1H, d, J 5.5 Hz, 
H2), 8.40 (1H, d, J 9.1 Hz, H5), 7.79 (1H, d, J 2.0 Hz, H8), 7.55 (3H, m, 2 x H13), 7.44 (1H, 
dd, J 9.1 and 2.0 Hz, H6), 7.35 (3H, m, 2 x H14 and H15), 6.49 (1H, d, J 5.5 Hz, H3), 5.57 
(1H, s, H12), 3.33 (2H, t, J 6.3 Hz, H9), 2.83 (2H, t, J 6.2 Hz, H11), 1.96 (2H, m, H10), δC 
(75 MHz; CDCl3) 158.5, 150.7, 150.2, 147.8, 137.7, 133.5, 128.1 (2C), 128.0 (2C), 127.8, 
126.4, 124.0, 123.9, 117.0, 98.4, 57.9, 45.6, 44.3 and 25.6; MS (ESI) m/z 394.0 (M
+
); HPLC 




As a pale-yellow powder (98 mg, 72%), m. 
p. 113- 116 °C, Rf (DCM: MeOH: NH4OH; 
95:0.9:01%) 0.25; IR νmax (KBr)/cm
-1
 1605 
(Ar C=C), 1370 (N=N), 1324 (C=N); δH 
(400 MHz; CDCl3) 8.39 (1H, d, J 5.6 Hz, H2), 8.27 (1H, d, J 9.0 Hz, H5), 7.79 (1H, d, J 2.2 
Hz, H8), 7.55 (2H, m, 2 x H15), 7.47 (1H, dd, J 9.0 and 2.2 Hz, H6), 7.35 (3H, m, 2 x H14 
and H16), 6.49 (1H, d, J 5.6 Hz, H3), 5.60 (1H, s, H13), 3.27 (2H, t, J 7.0 Hz, H9), 2.76 (2H, 
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147.8, 136.3, 133.7, 128.6 (2C), 128.3 (2C), 126.5, 124.1, 124.0, 117.1, 98.6, 57.9, 54.7, 
45.6, 41.7, 24.9 and 23.5; MS (ESI) m/z 408.0 (M
+
); HPLC purity: 97.6%; tr’=5.89 min. 
 
Synthesis of Primaquine-based tetrazoles
4
  
Similar to the procedure used in the synthesis of chloroquine-like compounds, primaquine-
based tetrazoles were obtained from the multi-component reaction of a racemic Primaquine 
diphosphate (3.17) (1.1 mmol) in triethylamine (4.0 eq), aromatic aldehydes (1.1 mmol) 
TMSN3 (1.1 mmol) and tert-butyl isocyanide (1.1 mmol) as unresolved racemic (1:1) mixture 
of diastereomers (3.19a-e) in poor to moderate yields. 
 
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(phenyl)methylamino]pentan-2-yl}-6-
methoxyquinolin-8-amine, 3.17a (TK1000A) 
 
Product 3.19a (108.4 mg, 21%) is obtained as a thick 
yellow oil; Rf (DCM: Acetone, 95: 05%) 0.50; IR νmax 
(DCM)/cm
-1
 1615 (Ar C=C), 1385 (N=N), 1315 
(C=N), 1266 (C-N), 1254 (C-O Ester); δH (300 MHz; 
CDCl3) 8.47 (1H, m, H2), 7.88 (1H, dd, J 8.3 and 1.6 
Hz, H4), 7.25 (6H, m, ArH and H3), 6.29 (1H, d, J 2.3 Hz, H7), 6.23 (1H, d, J 2.5 Hz, H5), 
5.99 (1H, t, J 8.6 Hz, NH), 5.22 (1H, d, J 6.7 Hz, H14), 3.85 (3H, s, OCH3), 3.56 (1H, m, 
H9), 2.53 (2H, m, H13), 1.63 (4H, m, H11 and H12), 1.55 (9H, d, J 4.04 Hz, 3 x H18), 1.25 
(3H, d, J 6.4 Hz, H10); δC (75 MHz; CDCl3) 159.5, 155.7, 145.0, 144.2, 138.9, 135.4, 134.7, 
129.9, 128.9 (2C), 128.2, 128.0 (2C), 121.8, 96.6, 91.6, 61.2, 59.0, 55.2, 55.1, 47.9, 34.2, 
30.0 (3C), 26.5 and 20.5; MS (ESI) m/z 474.1 (M
+
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N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(methoxyphenyl)methylamino]pentan-2-yl}-6-
methoxyquinolin-8-amine, 3.19b (TK1000B) 
 
Product 3.19b (219.6 mg, 40%) is obtained as a yellow 
oil; Rf (DCM: Acetone, 95: 05%) 0.54; IR νmax 
(DCM)/cm
-1
 1615 (Ar C=C), 1387 (N=N), 1269 
(C=N), 1266 (C-N), 1217 (C-O Ester); δH (400 MHz; 
CDCl3) 8.50 (1H, m, H2), 7.91 (1H, dd, J 8.3 and 1.8 
Hz, H4), 7.29 (1H, dd, J 8.2 and 4.2 Hz, H3), 7.18 (2H, 
m, 2 x H16), 6.83 (2H, m, 2 x H15), 6.32 (1H, d, J 1.7 Hz, H7), 6.26 (1H, d, J 1.7 Hz, H5), 
6.03 (1H, m, NH), 5.20 (1H, d, J 9.0 Hz, H14), 3.85 (3H, d, J 1.4 Hz, OCH3), 3.77 (3H, d, J 
1.0 Hz, H17), 3.61 (1H, m, H9), 2.54 (2H, m, H13), 1.67 (4H, m, H11 and H12), 1.57 (9H, d, 
J 5.3 Hz, 3 x H18), 1.28 (3H, d, J 6.4 Hz, H10); δC (101 MHz; CDCl3) 159.4, 155.9, 145.1, 
144.2 (2C), 135.4, 134.7 (2C), 131.0, 129.9, 129.2 (2C), 121.8, 114.3 (2C), 96.6, 91.6, 61.1, 
58.3, 55.2, 47.9 (2C), 34.2, 30.0 (3C), 26.5 and 20.5; MS (ESI) m/z 504.6 (M
+
+H); HPLC 
purity: 99.5%; tr’=16.62 min. 
 
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(p-tolyl)methylamino]pentan-2-yl}-6-
methoxyquinolin-8-amine, 3.19c (TK1000C) 
 
Product 3.19c (265.9 mg, 50%) is obtained as a thick 
yellow oil; Rf (DCM: Acetone, 95: 05%) 0.51; IR νmax 
(DCM)/cm
-1
 1617 (Ar C=C), 1390 (N=N), 1325 
(C=N), 1260 (C-N), 1232 (C-O Ester); δH (400 MHz; 
CDCl3) 8.53 (1H, m, H2), 7.93 (1H, dd, J 8.3 and 1.7 
Hz, H4), 7.31 (1H, dd, J 8.3 and 4.2 Hz, H3), 7.12-7.18 (4H, m, 2 x H16 and 2 x H15), 6.34 
(1H, d, J 2.4 Hz, H7), 6.28 (1H, d, J 2.5 Hz, H5), 6.04 (1H, m, NH), 5.29 (1H, d, J 8.2 Hz, 










Chapter 6: Experimental  
204 
1.69 (4H, m, H11 and H12), 1.60 (9H, d, J 5.4 Hz, 3 x H18), 1.25 (3H, d, J 6.4 Hz, H10); δC 
(101 MHz; CDCl3) 159.5, 155.9, 145.1, 144.2 (2C), 138.0, 135.9, 135.2, 134.7, 129.9, 129.6 
(2C), 127.9 (2C), 121.8, 96.6, 91.6, 61.2, 58.7, 55.2, 47.9, 34.2, 30.1 (3C), 26.5, 21.0 and 
20.5; MS (ESI) m/z 488.2 (M
+
); HPLC purity: 99.4%; tr’=17.14 min. 
 
N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(3,4-dichlorophenyl)methylamino]pentan-2-yl}-6-
methoxyquinolin-8-amine, 3.19d (TK1000D) 
 
Product 3.19d (100.5 mg, 17%) is obtained as a thick 
yellow oil; Rf (DCM: Acetone, 95: 0.5%) 0.29; IR νmax 
(DCM)/cm
-1
 1609 (Ar C=C), 1383 (N=N), 1330 
(C=N), 1264 (C-N), 1245 (C-O Ester); δH (400 MHz; 
CDCl3) 8.53 (1H, m, H2), 7.94 (1H, dd, J 8.3 and 1.6 
Hz, H4), 7.42 (1H, d, J 2.1 Hz, H15), 7.42 (1H, d, J 2.1 Hz, H16), 7.38 (1H, s, H17), 7.32 
(1H, dd, J 8.2 and 4.2 Hz, H3), 6.35 (1H, d, J 1.9 Hz, H7), 6.28 (1H, d, J 2.2 Hz, H5), 6.03 
(1H, m, NH), 5.22 (1H, d, J 9.6 Hz, H14), 3.91 (3H, d, J 1.4 Hz, OCH3), 3.62 (1H, m, H9), 
2.56 (2H, m, H13), 1.69 (4H, m, H11 and H12), 1.63 (9H, d, J 12.1 Hz, 3 x H18), 1.25 (3H, 
d, J 6.4 Hz, H10); δC (101 MHz; CDCl3) 159.5, 155.0, 145.0, 144.3, 139.1, 135.4, 134.7, 
132.6, 130.8, 130.1, 130.0, 129.9, 127.3, 121.8, 96.6, 91.6, 61.3, 57.8, 55.2, 47.9, 34.0, 33.7, 
30.0 (3C), 26.5 and 20.8; LCMS m/z 542.0 (M
+
) and 556.3 (MH
+
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N-{5-[(1-tert-butyl-1H-tetrazol-5-yl)(4-chlorophenyl)methylamino]pentan-2-yl}-6-
methoxyquinolin-8-amine, 3.19e (TK1000E) 
 
Product 3.19e (228.5 mg, 41%) is obtained as a thick 
yellow oil; Rf (DCM: Acetone, 95: 0.5%) 0.52; IR 
νmax (DCM)/cm
-1
 1630 (Ar C=C), 1380 (N=N), 1335 
(C=N), 1278 (C-N), 1246 (C-O Ester);δH (400 MHz; 
CDCl3) 8.52 (1H, dd, J 4.2 and 1.6 Hz, H2), 7.93 (1H, 
dd, J 8.4 and 1.6 Hz, H4), 7.26- 7.42 (5H, m, ArH and H3), 7.35 (1H, d, J 2.4 Hz, H7), 6.28 
(1H, d, J 2.4 Hz, H5), 6.03 (1H, m, NH), 5.24 (1H, d, J 12.0 Hz, H14), 3.90 (3H, d, J 2.2 Hz, 
OCH3), 3.63 (1H, m, H9), 2.55 (2H, m, H13), 1.68 (4H, m, H11 and H12), 1.60 (9H, d, J 6.1 
Hz, 3 x H17), 1.30 (3H, d, J 6.4 Hz, H10); δC (101 MHz; CDCl3) 159.5, 155.4, 145.0, 144.2 
(2C), 137.4, 135.4, 134.7, 134.2, 129.9, 129.4 (2C), 129.1 (2C), 121.8, 96.6, 91.6, 61.3, 58.2, 
55.2, 47.8, 34.1, 30.0 (3C), 26.5 and 20.6; MS (ESI) m/z 508.3 (M
+
); HPLC purity: 99.7%; 
tr’=17.44 min. 
 
Synthesis of the Quinine-nucleus,
5,6




In a 25 ml ethanolic solution of p-anisidine (4.3) (2.97 g, 24.1 mmol) 
were added Meldrum’s acid (4.4) (4.02 g, 27.9 mmol) followed by 
triethyl orthoformate (4.24 ml, 25.4 mmol) and the resultant mixture 
refluxed at 100 °C for 4 hrs. Theafter the mixture was cooled to room 
temperature and a white precipitate formed and was filtered, washed with 
ice cold ethanol to afford the title compound (4.5) (5.34 g, 80%) as a 
white powder and was used without further purification; δH (400 MHz; CDCl3) 11.18 (1H, d, 
J 13.9 Hz, NH), 8.56 (1H, d J 13.9 Hz, H3), 7.25 (2H, m, H1), 7.01 (2H, m, H2), 3.88 (3H, s, 














Product 4.5 (5.25 g, 18.9 mmol) was added in portions to 
Dowtherm A (35 ml) at 255 °C. The resultant mixture was 
heated for 20 minutes and allowed to cool to room temperature 
and diluted with diethyl ether (15 m). A precipitate which 
formed was filtered, washed with ice cold diethyl ether and dried in the vacuum line for 3 hrs 
to afford the desired product 4.6 (4.05 g, 90%) as an off-white powder which was used 
without further purification; δH (300 MHz; DMSO-d6) 11.62 (1H, br s, OH), 7.80 (1H, d, J 
7.3 Hz, H2), 7.52 (1H, d, J 3.0 Hz, H5), 7.49 (1H, d, J 9.0 Hz, H8), 7.49 (1H, dd, J 9.0 and 
3.0 Hz, H7), 5.98 (1H, d, J 7.3 Hz, H3), 3.83 (3H, s, OCH3); m/z 175.01 [M
+
 , 100%]. 
 
4-Bromo-6-Methoxyquinoline, 4.7 
To a mixture of 4.6 (1.60 g, 9.2 mmol) in anhydrous DMF (5 
ml) was added PBr3 (1 ml, 10.6 mmol) drop-wise over a 5 
minutes period. The resultant dark brown solution was stirred 
for a further 5 minutes under N2 atmosphere before a brown 
precipitate formed. The precipitated mixture was further stirred for 2 hrs, quenched with 
water and pH adjusted to 10. The precipitate is then filtered, washed with ice cold water. The 
crude brown precipitate is purified by column chromatography (on silica gel; elution with 
EtOAc: Hex; 50:50) to give an off-white solid (1.65 g, 75%); δH (300 MHz; CDCl3) 8.52 
(1H, d, J 3.6 Hz, H2), 8.02 (1H, dd, J 6.6 and 0.9 Hz, H7), 7.65 (1H, d, J 3.6 Hz, H3), 7.39 
(2H, m, H5 and H8), 3.99 (3H, s, OCH3); m/z 238.8 [M
+




To a solution of n-BuLi (2.5 M, 3.5 ml, 6.3 mmol) in 
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solution of 4.7 (3.00 g, 12.6 mmol) in diethyl ether (35 ml), a thick yellow suspension 
appeared and the mixture was stirred further for 30 minutes at -78 °C. Anhydrous DMF (10 
ml) was then added, the resultant orange mixture was stirred for 3 hrs at -78 °C. The reaction 
was quenched with water (250 ml), diethyl ether (300 ml) was added and the organic phase 
separated, washed with NH4Cl (150 ml), saturated Na2S2O3 (150 ml) and brine (150 ml) and 
dried over anhydrous Na2SO4. The solvent was removed in vacuo to afford a crude product 
which was purified by column chromatography (on silica gel; elution with EtOAc: Hex; 
50:50) to give a pale-yellow solid (4.8) (1.92 g, 86%); δH (300 MHz; CDCl3) 10.41 (1H, s, 
CHO), 9.01 (1H, d, J 4.3 Hz, H2), 8.44 (1H, d, J 2.8 Hz, H5), 8.07 (1H, d, J 9.3 Hz, H8), 7.72 
(1H, d, J 4.3 Hz, H3), 7.44 (1H, dd, J 9.3 and 2.8 Hz, H7), 3.99 (3H, s, OCH3); m/z 187.01 
[M
+
 , 28%]. 
 







Phosphorus oxybromide (8.0 g, 28 mmol, 8.0 eq) in an oven-
dried round bottom flask was heated at 75 °C until the solid 
melted. Thereafter, commercially available 2,8-
bis(trifluoromethyl)quinolin-4-ol (4.9) (1.0 g, 3.5 mmol, 1.0 
eq) was added gradually to the molten solid and the mixture was further heated at 150 °C for 
2 hrs. Upon cooling to room temperature, ice-cold water was added (50 ml) to the resultant 
mixture resulting in the formation of a yellow precipitate which was filtered, dried on a 
vacuum pump for 4 hrs. The obtained pale-yellow powder (4.10) (0.95 g, 78%) was pure 
enough for use in the subsequent step without further purification; δH (400 MHz; CDCl3) 8.55 















4-bromo-2,8-bis(trifluoromethyl)quinoline (4.10) (0.85 g, 2.35 
mmol) was dissolved in dry THF (10 ml) and cooled to -78 °C. 
To the flask was added n-BuLi (2.5 M in hexane; 7.05 mmol, 
2.9 ml, 3 eq) at once and the resultant blue solution was stirred 
at this temperature for 30 minutes. Thereafter, anhydrous DMF (1 ml, 11.75 mmol, 5.0 eq) 
was added drop-wise and the resultant solution was further stirred for 2 hrs at -78 °C. On 
complete consumption of the starting material the solution was poured into a separatory 
funnel containing 1:1 ethyl acetate:brine mixture and the aqueous layer was further extracted 
three times with ethyl acetate. The combined organic extract was washed with NH4Cl (20 
ml), saturated Na2S2O3 (20 ml) and water (150 ml), and dried over anhydrous MgSO4. The 
solvent was removed in vacuo to afford an oily crude product (0.35 g) which was purified by 
column chromatography (on silica gel; elution with EtOAc: Hex; 30:70) to give a pale-yellow 
paste (4.11) (0.20 g, 29%) which showed a presence of impurities on the 
1
H NMR and was 
used as such in the next step; δH (300 MHz; CDCl3) 10.47 (1H, s, CHO), 9.32 (1H, d, J 7.2 
Hz, H7), 8.29 (1H, d, J 7.4 Hz, H5), 8.23 (1H, s, H3), 7.93 (1H, t, J 7.6 Hz, H6);  
 
Synthesis of Quinine- and Mefloquine-based tetrazoles  
 
Aldehydes 4.8 and 4.11 (1.6 mmol) with various amines (2.12 mmol) were stirred in 
anhydrous methanol at 26 °C for 5 minutes. Thereafter, TMSN3 (2.12 mmol) was added, 
followed by the addition of tert-butyl isocyanide (2.12 mmol) and the resulting mixture was 
then stirred for 24 hrs. The solvent was removed in vacuo to afford crude tetrazole products 
















Purified by column chromatography (on silica gel; elution 
with EtOAc: Hex; 50:50) to yield the desired product 4.12a 
(235 mg, 65%) as a white solid; m. p. 101- 103 °C, Rf 
(EtOAc: Hex, 50: 50%) 0.41; IR νmax (DCM)/cm
-1
 1621 (Ar 
C=C), 1374 (N=N), 1318 (C=N), 1278 (C-N), 1230 (C-O 
Ester); δH (400 MHz; CDCl3) 8.64 (1H, d, J 4.5 Hz, H2), 8.07 (1H, d, J 9.2 Hz, H8), 7.67 
(1H, d, J 2.7 Hz, H5), 7.43 (1H, dd, J 9.2 and 2.7 Hz, H7), 6.89 (1H, d, J 4.5 Hz, H3), 6.13 
(1H, s, H9), 3.99 (3H, s, OCH3), 2.48 (6H, s, 2 x H10), 1.56 (9H, s, 3 x H11); δC (101 MHz; 
CDCl3) 158.4, 152.5, 147.2, 144.8, 140.6, 131.8, 127.9, 122.0, 121.4, 102.6, 61.3, 60.5, 55.5, 
41.3 (2C) and 30.1 (3C); MS (ESI) m/z 341.3 (M
+





Purified by column chromatography (on silica gel; elution 
with DCM: MeOH; 95:05) to yield the desired product 
4.12b (312 mg, 80%) as a pale-yellow solid; m. p. 118- 121 
°C, Rf (DCM: MeOH, 95: 05%) 0.59; IR νmax (DCM)/cm
-1
 
1619 (Ar C=C), 1376 (N=N), 1316 (C=N), 1290 (C-N), 
1236 (C-O Ester); δH (300 MHz; CDCl3) 8.60 (1H, d, J 4.6 Hz, H2), 8.05 (1H, d, J 9.2 Hz, 
H8), 7.86 (1H, d, J 2.8 Hz, H5), 7.42 (1H, dd, J 9.2 and 2.8 Hz, H7), 6.60 (1H, d, J 4.6 Hz, 
H3), 6.30 (1H, s, H9), 3.98 (3H, s, OCH3), 2.89 (4H, m, 2 x H10), 1.52 (9H, s, 3 x H12), 0.91 
(6H, t, J 5.4 Hz, 2 x H11); δC (75 MHz; CDCl3) 158.6, 153.1, 147.2, 145.1, 142.6, 131.7, 
127.9, 122.5, 122.4, 102.6, 62.1, 58.6, 55.9, 46.3 (2C), 30.1 (3C) and 15.3 (2C); MS (ESI) 
m/z 369.3 (M
+















Purified by column chromatography (on silica gel; elution 
with DCM: MeOH; 95:05) to yield the desired product 
4.12c (179 mg, 46%) as a thick brown oil; Rf (DCM: 
MeOH, 95: 05%) 0.61; IR νmax (DCM)/cm
-1
 1618 (Ar 
C=C), 1372 (N=N), 1309 (C=N), 1279 (C-N), 1238 (C-O 
Ester); δH (400 MHz; CDCl3) 8.62 (1H, d, J 4.5 Hz, H2), 8.05 (1H, d, J 9.2 Hz, H8), 7.90 
(1H, d, J 2.4 Hz, H5), 7.43 (1H, dd, J 9.2 and 2.4 Hz, H7), 6.79 (1H, d, J 4.5 Hz, H3), 6.16 
(1H, s, H9), 4.03 (3H, s, OCH3), 3.01 (2H, m, H10a), 2.50 (2H, m, H10b), 1.59 (9H, s, 3 x 
H12), 1.44 (4H, m, 2 x H11); δC (101 MHz; CDCl3) 158.2, 152.6, 147.3, 145.0, 140.3, 131.7, 
128.0, 122.0, 121.7, 102.7, 62.8, 61.3, 55.5, 50.3 (2C), 30.1 (3C) and 26.8 (2C); MS (ESI) 
m/z 367.2 (M
+





Purified by column chromatography (on silica gel; elution 
with DCM: MeOH; 95:05) to yield the desired product 
4.12d (179 mg, 87%) as a light brown solid; m. p. 117- 119 
°C, Rf (DCM: MeOH, 95: 05%) 0.39; IR νmax (DCM)/cm
-1
 
1617 (Ar C=C), 1374 (N=N), 1314 (C=N), 1260 (C-N), 
1241 (C-O Ester); δH (400 MHz; CDCl3) 8.65 (1H, d, J 4.5 Hz, H2), 8.06 (1H, d, J 9.2 Hz, 
H8), 7.73 (1H, d, J 2.2 Hz, H5), 7.42 (1H, dd, J 9.2 and 2.2 Hz, H7), 7.06 (1H, d, J 4.6 Hz, 
H3), 6.29 (1H, s, H9), 4.00 (3H, s, OCH3), 3.14 (2H, m, H10a), 2.45 (2H, m, H10b), 1.80 
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153.6, 147.5, 144.8, 140.9, 131.8, 127.7, 121.4 (2C), 102.3, 61.3, 57.2, 55.5, 49.5 (2C), 30.1 
(3C), 29.9 and 24.2 (2C); MS (ESI) m/z 381.5 (M
+





Purified by column chromatography (on silica gel; elution 
with DCM: MeOH; 95:05) to yield the desired product 
4.12e (117 mg, 56%) as a pale-yellow solid; m. p. 140- 144 
°C, Rf (DCM: MeOH, 95: 05%) 0.32; IR νmax (DCM)/cm
-1
 
1619 (Ar C=C), 1374 (N=N), 1318 (C=N), 1275 (C-N), 
1223 (C-O Ester); δH (300 MHz; CDCl3) 8.62 (1H, d, J 4.5 Hz, H2), 8.04 (1H, d, J 9.2 Hz, 
H8), 7.81 (1H, d, J 2.7 Hz, H5), 7.41 (1H, dd, J 9.2 and 2.7 Hz, H7), 6.93 (1H, d, J 4.5 Hz, 
H3), 6.12 (1H, s, H9), 3.99 (3H, s, OCH3), 3.00 (2H, m, H10a), 2.45 (2H, m, H10b), 2.38 
(2H, m, H11a), 2.31 (2H, m, H11b), 2.20 (3H, s, H12), 1.56 (9H, s, 3 x H13); δC (75 MHz; 
CDCl3) 158.3, 152.4, 147.4, 145.0, 140.0, 131.9, 127.9, 122.3, 121.8, 102.6, 61.4, 61.0, 55.6 
(3C), 49.5 (2C), 46.0 and 30.2 (3C); MS (ESI) m/z 396.1 (M
+
); HPLC purity: 98.9%; tr’=5.38 
min. 
 
4-[(1-tert-butyl-1H-tetrazol-5-yl)(morpholino)methyl]-6-methoxyquinoline, 4.12f (TK506) 
 
Purified by column chromatography (on silica gel; elution 
with DCM: MeOH; 95:05) to yield the desired product 
4.12f (302 mg, 75%) as a pale-yellow solid; m. p. 110- 112 
°C, Rf (DCM: MeOH, 95: 05%) 0.45; IR νmax (DCM)/cm
-1
 
1619 (Ar C=C), 1372 (N=N), 1321 (C=N), 1276 (C-N), 
1239 (C-O Ester); δH (400 MHz; CDCl3) 8.65 (1H, d, J 4.5 Hz, H2), 8.08 (1H, d, J 9.2 Hz, 
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H3), 6.15 (1H, s, H9), 4.02 (3H, s, OCH3), 3.67 (2H, m, H11a), 3.57 (2H, m, H11b), 3.06 
(2H, m, H10a), 2.54 (2H, m, H10b), 1.58 (9H, s, 3 x H13); δC (101 MHz; CDCl3) 158.4, 
152.3, 147.3, 145.0, 139.1, 132.0, 127.7, 122.3, 121.6, 102.6, 67.4 (2C), 61.4, 61.2, 55.6, 49.8 
(2C) and 30.2 (3C); MS (ESI) m/z 383.3 (M
+
+H); HPLC purity: 93.8%; tr’=8.35 min. 
 
[2,8-bis(trifluoromethyl)quinolin-4-yl](tert-butyl-1H-tetrazol-5-yl)-N,N-
dimethylmethanamine, 4.13a (TK710) 
 
Purified by column chromatography (on silica gel; elution with 
EtOAc: Hex; 50:50) to yield the desired product 4.13a as a white 
powder (20 mg, 22%); m. p. 171- 173 °C, Rf (EtOAc: Hex, 50: 
50%) 0.35; IR νmax (DCM)/cm
-1
 1602 (Ar C=C), 1423 (N=N), 
1314 (C=N), 1271 (C-N), 1090 (C-F); δH (400 MHz; CDCl3) 
8.70 (1H, d, J 8.5 Hz, H7), 8.23 (1H, d, J 7.1 Hz, H5), 7.84 (1H, t, J 7.9 Hz, H6), 7.40 (1H, s, 
H3), 6.29 (1H, s, H8), 2.46 (6H, s, 2 x H9), 1.62 (9H, s, 3 x H10); δC (101 MHz; CDCl3) 
151.4, 145.2, 144.2, 129.4, 129.3, 129.2, 128.2, 128.1, 127.8, 124.8, 122.0, 118.0, 61.6, 60.3, 
41.3 (2C) and 30.2 (3C); MS (ESI) m/z 447.2 (M
+
+H); HPLC purity: 98.9%; tr’=8.60 min. 
 
N-{[2,8-bis(trifluoromethyl)quinolin-4-yl](tert-butyl-1H-tetrazol-5-yl)metyhyl}-N-
ethylethanamine, 4.13b (TK720) 
 
Purified by column chromatography (on silica gel; elution with 
EtOAc: Hex; 50:50) to yield the desired product 4.13b as a 
yellow solid (13.3 mg, 22%) as a light-brown solid; m. p. 76- 78 
°C, Rf (EtOAc: Hex, 50: 50%) 0.35; IR νmax (DCM)/cm
-1
 1602 
(Ar C=C), 1424 (N=N), 1309 (C=N), 1279 (C-N), 1112 (C-F); 
δH (400 MHz; CDCl3) 8.82 (1H, d, J 8.6 Hz, H7), 8.23 (1H, d, J 7.2 Hz, H5), 7.84 (1H, t, J 
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x H11), 0.93 (6H, t, J 7.2 Hz, 2 x H10); δC (101 MHz; CDCl3) 152.5, 146.6, 143.1, 129.4, 
129.3, 129.2, 128.4, 128.0, 127.8, 124.8, 122.1, 118.1, 61.9, 58.4, 45.8 (2C), 30.2 (3C) and 
14.7 (2C); MS (ESI) m/z 475.4 (M
+
+H); HPLC purity: 95.3%; tr’=8.93 min. 
 
General procedure for the synthesis of de-tert-butylated quinine-based tetrazoles 4.14a-f  
 
The procedure used in the synthesis of the de-tert-butylated deoxyamodiaquine tetrazole 
3.10a-f was followed, quinine-based tetrazoles 4.13a-f (0.51 mmol) were refluxed in 32% 
HCl (10 ml) to give the desired products, 4.14a-f, after purification by column 
chromatography (on silica gel; elution with DCM: MeOH: NH4OH; 95:0.5:01). 
 
(6-methoxyquinolin-4-yl)-N,N-dimethyl(1H-tetrazol-5-yl)methanamine, 4.14a (TK501B3) 
 
As a pale-yellow solid (55 mg, 33%); m. p. 159- 162 °C, Rf 
(DCM: MeOH: NH4OH; 95:0.9:01%) 0.12; IR νmax 
(KBr)/cm
-1
 1588 (Ar C=C), 1369 (N=N), 1314 (C=N), 
1276 (C-O Ester), 1245(C-O Ester); δH (400 MHz; DMSO-
d6) 8.65 (1H, d, J 4.5 Hz, H2), 7.86 (1H, d, J 9.2 Hz, H8), 
7.82 (1H, d, J 2.8 Hz, H5), 7.76 (1H, d, J 4.5 Hz, H3), 7.33 (1H, dd, J 9.2 and 2.8 Hz, H7), 
5.37 (1H, s, H9), 3.87 (3H, s, OCH3), 2.14 (6H, s, 2 x H10); δC (101 MHz; DMSO-d6) 159.5, 
156.4, 147.3, 146.0, 143.9, 130.6, 127.7, 120.9, 120.5, 103.7, 63.3, 55.2 and 43.2 (2C); MS 
(ESI) m/z 285.1 (M
+





















As a yellow solid (26 mg, 15%); m. p. 168- 171 °C, Rf 
(DCM: MeOH: NH4OH; 95:0.9:01%) 0.11; IR νmax 
(KBr)/cm
-1
 1600 (Ar C=C), 1368 (N=N), 1319 (C=N), 
1269 (C-N), 1225 (C-O Ester); δH (400 MHz; DMSO-d6) 
8.61 (1H, d, J 4.5 Hz, H2), 7.91 (1H, d, J 2.8 Hz, H5), 7.86 
(1H, d, J 9.2 Hz, H8), 7.52 (1H, d, J 4.5 Hz, H3), 7.32 (1H, dd, J 9.2 and 2.8 Hz, H7), 5.87 
(1H, s, H9), 3.85 (3H, s, OCH3), 2.63 (2H, q, J 7.1 Hz, H10a), 2.27 (2H, q, J 7.1 Hz, H10b), 
0.91 (6H, t, J 7.1 Hz, 2 x H11); δC (100 MHz; DMSO-d6) 159.6, 156.6, 147.8, 146.1, 144.6, 
131.1, 127.8, 122.1, 121.2, 104.4, 58.8, 55.8, 44.3 (2C) and 13.5 (2C); MS (ESI) m/z 313.2 
(M
+
+H); HPLC purity: 96.7%; tr’=7.38 min. 
 
6-methoxy-4-[(pyrrolidin-1-yl)(1H-tetrazol-5-yl)methyl]quinoline, 4.14c (TK503B3)  
 
As a light-brown solid (22 mg, 13%); m. p. 211- 214 °C; 
Rf (DCM: MeOH: NH4OH; 95:0.9:01%) 0.09; IR νmax 
(KBr)/cm
-1
 1579(Ar C=C), 1366 (N=N), 1326 (C=N), 1274 
(C-N), 1215 (C-O Ester); δH (300 MHz; DMSO-d6) 8.66 
(1H, d, J 4.4 Hz, H2), 7.96 (1H, d, J 2.6 Hz, H8), 7.84 (1H, 
d, J 9.2 Hz, H5), 7.79 (1H, d, J 4.4 Hz, H3), 7.30 (1H, dd, J 9.2 and 2.6 Hz, H7), 5.40 (1H, s, 
H9), 3.86 (3H, s, OCH3), 2.54 (2H, m, H10a), 2.35 (2H, m, H10b), 1.65 (4H, m, 2 x H11); δC 
(75 MHz; DMSO-d6) 159.0, 156.2, 147.2, 146.5, 130.3, 130.1, 129.1, 127.2, 120.3, 103.7, 
61.9, 58.5, 51.6 (2C) and 23.0 (2C); MS (ESI) m/z 311.4 (M
+
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6-methoxy-4-[(piperidin-1-yl)(1H-tetrazol-5-yl)methyl]quinoline, 4.14d (TK504B3) 
 
As a pale-yellow crystalline solid (49 mg, 28%); m. p. 131- 
134 °C, Rf (DCM: MeOH: NH4OH; 95:0.9:01%) 0.10; IR 
νmax (KBr)/cm
-1
 1630 (Ar C=C), 1368 (N=N), 1309 (C=N), 
1251 (C-N), 1223 (C-O Ester);δH (300 MHz; DMSO-d6) 
8.62 (1H, d, J 4.5 Hz, H2), 7.99 (1H, d, J 2.8 Hz, H5), 7.85 
(1H, d, J 9.2 Hz, H8), 7.69 (1H, d, J 4.5 Hz, H3), 7.31 (1H, dd, J 9.2 and 2.8 Hz, H7), 5.43 
(1H, s, H9), 3.88 (3H, s, OCH3), 2.45 (2H, m, H10a), 2.25 (2H, m, H10b), 1.44 (4H, m, 2 x 
H11), 1.35 (2H, m, H12); δC (101 MHz; DMSO-d6) 159.2, 156.1, 147.1, 145.9, 143.9, 130.3, 
127.8, 120.8, 120.4, 104.0, 63.5, 55.0, 51.6 (2C), 25.8 (2C) and 24.0; MS (ESI) m/z 325.1 
(M
+





As a cream-coloured solid (58 mg, 34%); m. p. 176- 179 
°C, Rf (DCM: MeOH: NH4OH; 95:0.9:01%) 0.12; IR νmax 
(KBr)/cm
-1
 1590 (Ar C=C), 1368 (N=N), 1299 (C=N), 
1259 (C-N), 1219 (C-O Ester);δH (400 MHz; DMSO-d6) 
8.60 (1H, d, J 4.5 Hz, H2), 7.96 (1H, d, J 2.5 Hz, H5), 7.81 
(1H, d, J 9.2 Hz, H8), 7.68 (1H, d, J 4.5 Hz, H3), 7.27 (1H, dd, J 9.2 and 2.5 Hz, H7), 5.36 
(1H, s, H9), 3.84 (3H, s, OCH3), 2.46 (2H, m, H10a), 2.39 (2H, m, H10b), 2.26 (4H, m, 2 x 
H11), 2.09 (3H, s, H12); δC (100 MHz; DMSO-d6) 159.5, 156.3, 147.4, 145.6, 144.0, 130.5, 
127.7, 120.9, 120.8, 103.9, 63.2, 55.3, 55.0 (3C), 50.5 and 45.6; MS (ESI) m/z 340.4 (M
+
+H); 
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6-methoxy-4-[morpholino(1H-tetrazol-5-yl)methyl]quinoline, 4.14f (TK506B3) 
 
As a light-brown solid (37 mg, 21%); m. p. 137- 140 °C, Rf 
(DCM: MeOH: NH4OH; 95:0.9:01%) 0.23; IR νmax 
(KBr)/cm
-1
 1598 (Ar C=C), 1368 (N=N), 1330 (C=N), 
1273 (C-N), 1220 (C-O Ester);δH (300 MHz; DMSO-d6) 
8.64 (1H, d, J 4.5 Hz, H2), 8.03 (1H, d, J 2.8 Hz, H5), 7.85 
(1H, d, J 9.2 Hz, H8), 7.74 (1H, d, J 4.5 Hz, H3), 7.32 (1H, dd, J 9.2 and 2.8 Hz, H7), 5.44 
(1H, s, H9), 3.90 (3H, s, OCH3), 3.56 (4H, m, 2 x H11), 2.44 (2H, m, H10a), 2.29 (2H, m, 
H10b); δC (75 MHz; DMSO-d6) 158.9, 156.3, 147.2, 145.1, 144.0, 130.4, 127.7, 121.0, 
120.6, 104.0, 66.4 (2C), 63.4, 55.2 and 51.2 (2C); MS (ESI) m/z 327.3 (M
+
+H); HPLC purity: 
99.1%; tr’=6.66 min. 
 
Synthesis of nitroimidazole-based tetrazoles and hybrids 
Synthesis of p, m and o-(bromomethyl)benzaldehydes
9
, 4.16a-c 
Solutions of commercially available p-, m- and o-(bromomethly)benzonitrile (4.15a-c) (10.2 
mmol) in dry toluene (30 ml) was cooled to 0 °C in an ice-bath under an inert N2 atmosphere. 
A 1.5 M solution of DIBAL-H in toluene (15.3 mmol) was then added drop-wise over a 
period of 30 minutes and the resultant solution was then allowed to further stir for 1 hour at 0 
°C. Thereafter, CHCl3 (20 ml) and 2M HCl (25 ml) were added and mixture stirred for 12 
hours at room temperature. The organic layer was separated and washed twice with water, 
dried over MgSO4 and solvent removed vacuo to give the desired products (4.16a-c) pure 




Obtained as a thick-colourless oil (1.25 g, 68%); Rf (EtOAc: Hex, 50: 
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Obtained as a yellow paste (1.86 g, 85%); Rf (EtOAc: Hex, 50: 
50%) 0.41; δH (400 MHz; CDCl3) 9.96 (1H, s, CHO), 7.84 (1H, s, 
H5), 7.74 (1H, d, J 7.6 Hz, H4), 7.60 (1H, d, J 7.6 Hz, H2), 7.45 




Obtained as white flakes (1.65 g, 80%); Rf (EtOAc: Hex, 50: 50%) 
0.45; δH (300 MHz; CDCl3) 10.01 (1H, s, CHO), 7.87 (2H, d, J 6.3 
Hz, 2 x H3), 7.55 (2H, d, J 6.3 Hz, 2 x H2), 4.51 (2H, s, H1). 
 
Synthesis of 2-nitroimidazo-oxazine aldehydes
10
, 4.18a-b 
At 0 °C, under N2 atmosphere, NaH (60% mineral oil, 1.3 eq) was added to the stirred 
solution of p, m and o-(bromomethyl)benzaldehydes (1.2 eq) (4.16a-c) and (S)-2-nitro-6,7-
dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-ol (4.17) (1.0 eq) in anhydrous DMF (5 ml). The 
resultant mixture was maintained at this temperature for 30 minutes, allowed to warm to 
room temperature and stirred further for 12 hrs. On completion of the reaction as seen on the 
TLC, the solvent was removed in vacuo by azeotropic distillation of toluene to afford crude 
products 4.18a-b (m- and p-based products). The o-(bromomethyl)benzaldehyde reaction did 


















Purified by column chromatography (on silica gel; elution with 
DCM: MeOH; 95:05) to yield the desired product 4.18a (91 mg, 
46%) as pale-yellow flakes; m. p. 145- 148 °C, Rf (DCM: MeOH, 
95: 05%) 0.27; IR νmax (DCM)/cm
-1
 1699 (C=O), 1579 (Ar C=C), 
1548 (NO2), 1266 (C-O Ether); δH (400 MHz; DMSO-d6) 9.99 
(1H, s, CHO), 8.02 (1H, s, H1), 7.89 (2H, d, J 8.1 Hz, 2 x H7), 
7.52 (2H, d, J 8.1 Hz, 2 x H6), 4.77 (2H, dd, JAB 13.2 Hz, H5), 4.49 (1H, dt, J 2.6 and 12.1 
Hz, H3), 4.48 (1H, d, J 11.9 Hz, H4a), 4.28 (3H, m, H2 and H4b); δC (101 MHz; DMSO-d6) 
193.1, 147.6, 145.2, 136.0, 130.0 (2C), 128.2 (2C), 127.1, 118.4, 69.6, 68.4, 62.9 and 47.2; 
MS (ESI) m/z 304.1 (M
+
+H), HPLC purity: 98.9%; tr’=6.98 min.  
 
4-{[(S)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yloxy]methyl}benzaldehyde, 
4.18b (PA-2A2 or PA-10A) 
 
Purified by column chromatography (on silica gel; elution with 
DCM: MeOH; 95:05) to yield the desired product 4.18b (131 mg, 
78%) as yellow flakes; m. p. 129- 132 °C, Rf (DCM: MeOH, 95: 
05%) 0.22; IR νmax (DCM)/cm
-1
 1685 (C=O), 1569 (Ar C=C), 1538 
(NO2), 1245 (C-O Ether); δH (400 MHz; DMSO-d6) 10.01 (1H, s, 
CHO), 7.99 (1H, s, H1), 7.83 (2H, m, H8 and H9), 7.65 (1H, t, J 7.7 
Hz, H7), 7.60 (1H, d, J 7.7 Hz, H6), 4.76 (2H, dd, JAB 12.9 Hz, H5), 4.66 (1H, dt, J 4.7 and 
11.9 Hz, H3), 4.49 (1H, d, J 11.6 Hz, H3a), 4.28 (3H, m, H2 and H3b); δC (101 MHz; 
DMSO-d6) 192.8, 148.3, 143.2, 138.3, 135.9, 133.3, 129.0, 128.8, 127.9, 117.7, 68.9, 67.7, 
66.5 and 46.5; MS (ESI) m/z 304.2 (M
+
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Towards the synthesis of nitroimidazo-oxazine-tetrazole derivatives
4
, 4.19a-h 
The 2-nitroimidazo-oxazine aldehyde, 4.18a (0.099 mmol) and anvarious amine (including 4-
amino-7chloroquinoline diamines)
§
 (0.207 mmol) were stirred in anhydrous methanol as a 
suspension at 26 °C for 5 minutes. Thereafter, TMSN3 (0.207 mmol) was added, followed by 
the addition of tert-butyl isocyanide (0.207 mmol) and the resulting mixture was then stirred 
at 40 °C for 12 hrs. Thereafter, the solvent was removed in vacuo to afford the crude 
tetrazoles which were purified by column chromatography (on silica gel; elution with DCM: 
MeOH; 95:05) to give the desired products, 4.19a-h, in low to excellent yields.  
 
(4-{[(S)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yloxy]methyl}phenyl)(1-tert-
butyl-1H-tetrazol-5-yl)-N,N-dimethylmethanamine, 4.19a (PA-3A) 
 
As a yellow solid (25 mg, 46%); m. p. 68- 72 °C, Rf (DCM: 
MeOH, 95: 05%) 0.32; IR νmax (DCM)/cm
-1
 1588 (Ar C=C), 
1566 (NO2), 1368 (N=N), 1340 (C=N), 1284 (C-O Ether); δH 
(400 MHz; CDCl3) 7.42 (2H, d, J 8.0 Hz, 2 x H7), 7.37 (1H, 
d, J 12.9 Hz, H1), 7.27 (2H, d, J 8.0 Hz, 2 x H6), 5.19 (1H, s, 
H8), 4.72 (1H, m, H3), 4.59 (2H, m, H5), 4.35 (1H, d, J 12.1 
Hz, H4a), 4.17 (3H, m, H2 and H4b), 2.29 (6H, s, 2 x H9), 1.69 (9H, s, 3 x H10); δC (101 
MHz; CDCl3) 154.3, 147.2, 136.9, 136.0, 130.1 (2C), 127.6 (2C), 127.0, 115.0, 70.7, 67.4, 
66.7, 65.0, 63.2, 47.5; 42.4 (2C) and 30.2 (3C); MS (ESI) m/z 457.3 (M
+
), HPLC purity: 





                                                 
§
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N-(4-{[((S)-6,7-dihydro-2-nitro-5H-imidazo[2,1-b][1,3]oxazin-6-yloxy)methyl]pheny}(1-
tert-butyl-1H-tetrazol-5-yl)methyl)-N-dimethylmethanamine, 4.19b (PA-4A) 
 
As a pale-yellow solid (30.2 mg, 63%); m. p. 48- 50 °C, Rf 
(DCM: MeOH, 95: 05%) 0.46; IR νmax (DCM)/cm
-1
 1601 (Ar 
C=C), 1536 (NO2), 1378 (N=N), 1340 (C=N), 1260 (C-O 
Ether); δH (400 MHz; CDCl3) 7.37 (1H, d, J 15.0 Hz, H1), 
7.25 (4H,m, 2 x H6 and 2 x H7), 5.61 (1H, s, H8), 4.72 (1H, 
m, H3), 4.59 (2H, m, H5), 4.34 (1H, d, J 12.3 Hz, H4a), 4.16 
(3H, m, H2 and H4b), 2.78 (2H, q, J 7.1 Hz, H9a), 2.65 (2H, q, J 7.1 Hz, H9b), 1.66 (9H, s, 3 
x H11), 0.95 (6H, t, J 7.1 Hz, 2 x H10); δC (101 MHz; CDCl3) 154.7, 147.1, 138.0, 136.4, 
136.3, 129.7 (2C), 127.5 (2C), 127.4, 114.9, 70.8, 67.4, 67.3, 60.6, 47.5; 44.8 (2C), 30.3 (3C) 
and 14.1 (2C); MS (ESI) m/z 485.4 (M
+
+H), HPLC purity: 98.9%; tr’=8.06 min.  
 
(S)-6-{4-[(1-tert-butyl-1H-tetrazol-5-yl)(pyrrolidin-1-yl)methyl]benzyloxy}-6,7-dihydro-2-
nitro-5H-imidazo[2,1-b][1,3]oxazine, 4.19c (PA-5A) 
 
As a yellow solid (21 mg, 44%); m. p. 58- 61 °C, Rf (DCM: 
MeOH, 95: 05%) 0.39; IR νmax (DCM)/cm
-1
 1604 (Ar C=C), 
1520 (NO2), 1380 (N=N), 1360 (C=N), 1263 (C-O Ether); δH 
(300 MHz; CDCl3) 7.50 (2H, d, J 8.1 Hz, 2 x H7), 7.37 (1H, 
d, J 6.7 Hz, H1), 7.26 (2H, d, J 8.1 Hz, 2 x H6), 5.20 (1H, s, 
H8), 4.72 (1H, m, H3), 4.62 (2H, m, H5), 4.34 (1H, d, J 12.1 
Hz, H4a), 4.17 (3H, m, H2 and H4b), 2.59 (2H, m, H9a), 2.49 (2H, m, H9b), 1.79 (4H, m, 2 
x H10), 1.68 (9H, s, 3 x H11); δC (75 MHz; CDCl3) 155.5, 147.2, 136.1, 127.4, 123.1, 121.9 
(2C), 119.2 (2C), 118.3, 79.9, 67.4, 63.2, 53.0, 52.2, 52.1, 41.2 (2C), 30.2 (3C) and 24.6 
(2C); MS (ESI) m/z 483.4 (M
+















4-amine, 4.19d (PA-6A) 
 
As a pale-yellow solid (27 mg, 65%); m. p. 87- 89 °C, 
Rf (DCM: MeOH, NH4OH, 94: 5.5: 0.5%) 0.16; IR 
νmax (DCM)/cm
-1
 1610 (Ar C=C), 1550 (NO2), 1390 
(N=N), 1369 (C=N), 1250 (C-O Ether); δH (400 MHz; 
DMSO-d6) 8.35 (1H, d, J 5.4 Hz, H2’), 8.20 (1H, d, J 
9.1 Hz, H5’), 7.99 (1H, d, J 4.3 Hz, H1), 7.77 (1H, d, J 
2.2 Hz, H8’), 7.43 (3H, m, 2 x H7 and H6’), 7.26 (2H, 
d, J 8.1 Hz, 2 x H6), 7.18 (1H, t, J 5.3 Hz, NH), 6.43 (1H, d, J 5.4 Hz, H3’), 5.53 (1H, s, H8), 
4.63 (3H, m, H3 and H5), 4.46 (1H, d, J 11.9 Hz, H4a), 4.23 (3H, m, H2 and H4b), 3.35 (2H, 
m, H9), 4.30 (1H, br m, NH), 2.78 (2H, m, H10), 1.62 (9H, s, 3 x H11); δC (101 MHz; 
DMSO-d6) 158.2, 155.8, 151.7 (2C), 149.9, 148.9, 146.5, 138.6, 137.1, 133.2, 128.1 (2C), 
127.5 (2C), 127.4 (2C), 123.9, 123.8, 117.8, 98.6, 69.2, 67.7, 66.3, 55.8 46.6, 45.1; 42.5 and 
29.2 (3C); MS (ESI) m/z 633.5 (M
+




4-amine, 4.19e (PA-7A) 
 
As a pale-yellow solid (20 mg, 47%); m. p. 95- 99 
°C, Rf (DCM: MeOH, NH4OH, 94: 5.5: 0.5%) 
0.35; IR νmax (DCM)/cm
-1
 1613 (Ar C=C), 1576 
(NO2), 1369 (N=N), 1387 (C=N), 1265 (C-O 
Ether); δH (400 MHz; CDCl3) 8.45 (1H, d, J 5.3 
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2 x H7, 2 x H6, H1 and H5’), 7.15 (1H, br s, NH), 6.95 (1H, dd, J 9.0 and 2.2 Hz, H6’), 6.29 
(1H, d, J 5.3 Hz, H3’), 5.30 (1H, s, H8), 4.73 (1H, m, H3), 4.63 (2H, dd, J 12.1 and 3.5Hz, 
H5), 4.36 (1H, d, J 12.1 Hz, H4a), 4.18 (3H, m, H2 and H4b), 3.41 (2H, m, H9), 2.88 (1H, m, 
H11a), 2.79 (1H, m, H11b), 1.92 (2H, m, H10), 1.53 (9H, s, 3 x H12); δC (101 MHz; CDCl3) 
156.7, 155.2, 152.0 (2C), 150.2, 149.0, 147.0, 144.1, 143.7, 138.3, 137.4, 134.4, 128.4 (2C), 
128.3, 128.2, 124.8, 122.1, 117.4, 98.4, 70.5, 67.2, 67.1, 61.6, 59.0, 47.8, 47.4; 43.5 and 29.8 
(3C); MS (ESI) m/z 647.4 (M
+




4-amine, 4.19f (PA-8A) 
 
As a pale-yellow solid (37 mg, 85%); m. p. 82- 86 
°C, Rf (DCM: MeOH, NH4OH, 94: 5.5: 0.5%) 
0.32; IR νmax (DCM)/cm
-1
 1619 (Ar C=C), 1555 
(NO2), 1388 (N=N), 1360 (C=N), 1248 (C-O 
Ether); δH (400 MHz; CDCl3) 8.48 (1H, d, J 5.4 
Hz, H2’), 7.92 (1H, d, J 2.0 Hz, H8’), 7.57 (1H, 
dd, J 9.2 and 2.0 Hz, H6’), 7.33 (1H, d, J 6.5 Hz, 
H1), 7.24 (5H, m, 2 x H7, 2 x H6 and H5’), 6.37 (1H, d, J 5.4 Hz, H3’), 5.48 (1H, m, NH), 
5.27 (1H, s, H8), 4.67 (1H, m, H3), 4.60 (2H, m, H5), 4.32 (1H, d, J 11.7 Hz, H4a), 4.12 (3H, 
m, H2 and H4b), 3.32 (2H, m, H12), 2.62 (2H, m, H9), 1.83 (2H, m, H11), 1.69 (2H, m, 
H10), 1.61 (9H, s, 3 x H13); δC (101 MHz; CDCl3) 157.4, 155.5, 151.9 (2C), 149.9, 149.8, 
138.9, 137.1, 137.0, 128.6, 128.5, 128.3 (2C), 128.1, 128.0, 125.1, 121.2, 115.0, 99.0, 70.6, 
67.3, 67.2, 66.9, 66.8, 58.8, 47.5, 42.9, 30.1 (3C), 27.4 and 26.3; MS (ESI) m/z 661.5 (M
+
), 















methoxyquinolin-8-amine, 4.19g (PA-9A) 
 
As a thick-yellow oil (55 mg, 83%; 1:1 
diastereomeric mixture); Rf (DCM: MeOH, 
95: 05%) 0.48; IR νmax (DCM)/cm
-1
 1601 (Ar 
C=C), 1539 (NO2), 1388 (N=N), 1338 (C=N), 
1238 (C-O Ester); δH (300 MHz; CDCl3) 8.59 
(1H, s, H1), 8.50 (1H, dd, J 4.2 and 1.6 Hz, 
H2’), 7.91 (1H, dd, J 8.3 and 1.6 Hz, H4’), 
7.36 (1H, dd, J 8.7 and 4.4 Hz, H3’), 7.31 (2H, m, H7), 7.22 (2H, m, H6), 6.32 (1H, d, J 2.5 
Hz, H7’), 6.24 (1H, t, J 2.8 Hz, H5’), 6.01 (1H, br m, NH), 5.24-5.26 (1H, 2 x s, H8), 4.68 
(1H, d, J 12.2 Hz, H3), 4.57 (2H, m, H5), 4.31 (1H, d, J 12.4 Hz, H4a), 4.12 (3H, m, H2 and 
H4b), 3.88 (3H, s, OCH3), 3.57 (1H, m, H12), 2.56 (2H, m, H9), 1.64 (4H, m, H10 and H11), 
1.59-1.60 (9H, 2 x s, 3 x H14), 1.27 (3H, d, J 6.3 Hz, H13); δC (75 MHz; CDCl3) 159.5, 
155.6, 145.0, 144.3, 143.8, 139.7, 136.6, 134.8, 129.9, 128.5 (2C), 128.2, 128.1 (2C), 127.4, 
121.8, 114.9, 96.6, 91.6, 70.6, 67.3, 67.2, 66.4, 58.5, 55.2, 47.9; 47.5, 47.4, 34.2, 29.8 (3C), 
26.5 and 20.6; MS (ESI) m/z 671.6 (M
+




methoxyquinolin-8-amine, 4.19h (PA-11A) 
 
As a thick-yellow oil (140 mg, 79%; 1:1 
diastereomeric mixture); Rf (DCM: MeOH, 
95: 05%) 0.52; IR νmax (DCM)/cm
-1
 1610 (Ar 
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(C=N), 1228 (C-O Ester); δH (400 MHz; CDCl3) 8.50 (1H, s, H1), 8.49 (1H, dd, J 4.2 and 1.7 
Hz, H2’), 7.90 (1H, dd, J 8.3 and 1.6 Hz, H4’), 7.32 (1H, s, H9), 7.31 (2H, m, H3’ and H8), 
7.20 (2H, m, H6 and H7), 6.32 (1H, d, J 2.5 Hz, H7’), 6.24 (1H, dd, J 6.8 and 2.7 Hz, H5’), 
5.99 (1H, br m, NH), 5.25-5.27 (1H, 2 x s, H10), 4.66 (1H, m, H3), 4.54 (2H, m, H5), 4.26 
(1H, m, H4a), 4.09 (3H, m, H2 and H4b), 3.86-3.87 (3H, 2 x s, OCH3), 3.59 (1H, m, H14), 
2.55 (2H, m, H11), 1.72 (9H, s, 3 x H16), 1.66 (4H, m, H12 and H13), 1.27-1.29 (3H, 2 x d, J 
5.9 and 6.3 Hz, H15); δC (101 MHz; CDCl3) 159.5, 155.7, 145.0, 144.2, 139.7, 137.5, 135.3, 
134.8, 129.9, 129.2, 128.1, 127.6, 127.5, 127.0, 121.9, 115.1, 96.7, 91.6, 70.9, 67.7, 66.5, 
66.4, 58.6, 55.2, 47.9; 47.8, 47.4, 34.3, 29.9 (3C), 26.5 and 20.6; MS (ESI) m/z 671.9 
(M
+




 for the synthesis of 4-aminoquinoline-imines 4.21a-g. 
Quinoline diamine 3.13a-c (1.0 mmol) and various aldehydes (1.0 mmol) were stirred in 
anhydrous methanol at room temperature for 24 hrs, thereafter solvent removed in vacuo to 
afford crude imines 4.21a-g which were further dried under vacuum for 4 hrs. Imines in 
general are known to be unstable and they tend to break down is silica hence these were 





As a cream-coloured powder (0.39 g, 65%); δH (300 
MHz; DMSO-d6) 8.42 (1H, d, J 5.4 Hz, H2), 8.36 (1H, 
s, H1’), 8.25 (1H, d, J 9.0 Hz, H5), 7.78 (1H, d, J 2.4 
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J 1.5 and 3.3 Hz, H5’), 7.44 (1H, dd, J 9.0 and 2.3 Hz, H6), 7.43 (2H, m, 2 x H4’), 6.61 (1H, 
d, J 5.4 Hz, H3), 3.91 (2H, m, H9), 3.61 (2H, m, H10); m/z 309.85 (MH
+







As a cream-coloured powder (0.28 g, 72.3%); δH 
(300 MHz; DMSO-d6) 8.42 (1H, d, J 5.2 Hz, H2), 
8.37 (1H, s, H1’), 8.22 (1H, d, J 8.8 Hz, H5), 7.78 
(1H, d, J 1.8 Hz, H8), 7.74 (2H, d, J 2.2 Hz, 2 x 
H3’), 7.48 (2H, d, J 2.2 Hz, 2 x H4’), 7.41 (1H, dd, J 8.8 and 2.0 Hz, H6), 7.17 (1H, t, J 0.8 
Hz, NH), 6.60 (1H, d, J 5.2 Hz, H3), 3.91 (2H, t, J 5.6 Hz, H9), 3.63 (2H, m, H10); m/z 
342.66 (M
+




As a cream-coloured solid (0.22 g, 57.9%); δH 
(400 MHz; DMSO-d6) 8.42 (1H, d, J 5.2 Hz, 
H2), 8.35 (1H, s, H1’), 8.22 (1H, d, J 9.2 Hz, 
H5), 7.91 (1H, s, H5’), 7.78 (1H, d, J 2.4 Hz, 
H8), 7.67 (2H, d, J 2.1 Hz, H3’ and H4’), 7.40 (1H, dd, J 9.2 and 2.4 Hz, H6), 7.19 (1H, br s, 
NH), 6.59 (1H, d, J 5.2 Hz, H3), 3.91 (2H, t, J 6.2 Hz, H9), 3.65 (2H, m, H10); m/z 378.73 
(M
+






As a pale-yellow solid (0.17 g, 49%); δH (300 
MHz; DMSO-d6) 8.65 (1H, d, J 5.0 Hz, H2), 
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7.92 (1H, d, J 2.3 Hz, H8), 7.77 (2H, d, J 2.5 Hz, 2 x H3’), 7.67 (2H, d, J 2.5 Hz, 2 x H4’), 
7.45 (1H, dd, J 9.0 and 2.4 Hz, H6), 7.29 (1H, s, NH), 6.65 (1H, d, J 5.4 Hz, H3), 3.91 (2H, t, 




As a pale-yellow solid (0.21 g, 59%); δH (400 MHz; 
DMSO-d6) 8.41 (1H, d, J 5.4 Hz, H2), 8.39 (1H, d, J 
9.2 Hz, H5), 8.29 (1H, s, H1’), 8.24 (1H, d, J 1.5 Hz, 
H8), 7.83 (2H, d, J 7.3 Hz, 2 x H3’), 7.78 (1H, dd, J 
9.o and 1.6 Hz, H6), 7.33 (1H, br m, NH), 7.21 (2H, d, J 7.3 Hz, 2 x H4’), 6.59 (1H, d, J 5.4 




As a pale-yellow paste (0.11 g, 39%); δH (400 
MHz; DMSO-d6) 8.39 (2H, d, J 5.6 Hz, H2 
and H1’), 8.28 (1H, d, J 9.0 Hz, H5), 7.96 (1H, 
d, J 2.0 Hz, H8), 7.75 (1H, dd, J 9.0 and 2.0 
Hz, H6), 7.45 (5H, m, ArH), 7.37 (1H, br m, NH), 6.49 (1H, d, J 5.6 Hz, H3), 3.71 (2H, t, J 




As a yellow paste (0.25 g, 79%); δH (400 
MHz; DMSO-d6) 8.37 (1H, d, J 5.1 Hz, H2), 
8.34 (1H, s, H1’), 8.27 (1H, d, J 9.1 Hz, H5), 
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7.44 (5H, m, ArH), 7.32 (1H, br m, NH), 6.47 (1H, d, J 5.1 Hz, H3), 3.61 (2H, t, J 5.7 Hz, 




 for the synthesis of 4-aminoquinoline- β-lactams 4.22a-g  
Imines 4.21a-g (1.0 eq) and Et3N (3.0 eq) were stirred in dry DCM (5 ml) at -78 °C under 
inert N2 atmosphere, followed by drop-wise addition of the methoxy acetyl chloride (1.5 eq) 
in dry DCM (2 ml). The resulting mixtures were allowed to warm to room temperature and 
further stirred overnight. Thereafter, saturated NaHCO3 was added to the mixture and the 
organic layer extracted with DCM, washed with brine and water, dried over MgSO4 and 
solvent removed in vacuo to yield crude products, which were purified by column 
chromatography to obtain the desired β-lactams 4.22a-g. The synthesized β-lactams were 









1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-3-methoxy-4-phenylazetidin-2-one, 4.22a (BL1) 
 
As a white solid (55 mg, 30%); m. p. 142- 146 °C, Rf 
(DCM: MeOH, 95: 0.5%) 0.21; IR νmax (DCM)/cm
-1
 
1744 (C=O), 1620 (Ar C=C), 1264 (C-O Ester); δH (400 
MHz; CDCl3) 8.49 (1H, d, J 5.4 Hz, H2), 8.00 (1H, d, J 
2.1 Hz, H8), 7.84 (1H, d, J 9.0 Hz, H5), 7.42 (1H, dd, J 
9.0 and 2.1 Hz, H6), 7.35 (5H, m, ArH), 6.26 (1H, d, J 5.4 Hz, H3), 4.97 (1H, d, J 4.4 Hz, 
H1’), 4.74 (1H, d, J 4.4 Hz, H2’), 3.54 (2H, m, H9), 3.46 (2H, m, H10), 3.12 (3H, s, H6’); δC 
(101 MHz; CDCl3) 168.9, 151.5, 149.8, 148.8, 135.3, 133.2, 129.1, 128.7 (2C), 128.4, 128.3 
(2C), 125.8, 121.9, 117.3, 98.5, 85.4, 63.3, 58.2, 42.4 and 41.1; MS (ESI) m/z 382.1 (M
+
), 
















As a pale-yellow solid (20.3 mg, 14%); m. p. 135- 138 
°C, Rf (DCM: MeOH, 95: 0.5%) 0.14; IR νmax 
(DCM)/cm
-1
 1740 (C=O), 1598 (Ar C=C), 1265 (C-O 
Ester); δH (400 MHz; CDCl3) 8.46 (1H, d, J 5.3 Hz, H2), 
7.95 (1H, d, J 1.9 Hz, H8), 7.85 (1H, d, J 9.0 Hz, H5), 
7.39 (1H, dd, J 9.0 and 1.9 Hz, H6), 7.31 (2H, d, J 8.5 Hz, 2 x H4’), 7.24 (2H, d, J 8.5 Hz, 2 
x H3’), 6.47 (1H, br s, NH), 6.24 (1H, d, J 5.3 Hz, H3), 4.77 (1H, d, J 4.3 Hz, H1’), 4.72 (1H, 
d, J 4.3 Hz, H2’), 3.54 (1H, m, H10a), 3.47 (3H, m, H9 and H10b), 3.13 (3H, s, H6’); δC (101 
MHz; CDCl3) 168.7, 151.2, 150.0, 148.4, 135.4, 135.1, 131.2, 129.7 (2C), 128.9 (2C), 128.0, 
125.9, 122.0, 117.2, 98.5, 85.4, 62.6, 58.3, 42.3 and 41.0; MS (ESI) m/z 416.1 (M
+
), HPLC 





As a pale-yellow solid (17.3 g, 4%); m. p. 152- 156 °C, Rf 
(DCM: MeOH, 95: 0.5%) 0.16; IR νmax (DCM)/cm
-1
 1739 
(C=O), 1601 (Ar C=C), 1277 (C-O Ester); δH (400 MHz; 
CDCl3) 8.45 (1H, d, J 5.6 Hz, H2), 7.96 (1H, d, J 2.1 Hz, 
H8), 7.89 (1H, d, J 9.0 Hz, H5), 7.39 (3H, m, ArH), 7.16 
(1H, dd, J 9.0 and 2.1 Hz, H6), 6.74 (1H, br s, NH), 6.25 
(1H, d, J 5.6 Hz, H3), 4.78 (1H, d, J 4.4 Hz, H1’), 4.74 (1H, d, J 4.4 Hz, H2’), 3.49 (2H, m, 
H9), 3.43 (2H, m, H10), 3.18 (3H, s, H6’); δC (101 MHz; CDCl3) 168.6, 150.5, 150.1, 147.2, 
136.0, 133.7, 133.2, 130.6, 130.4, 127.6, 127.0, 126.2, 126.1, 122.2, 117.0, 98.3, 85.5, 62.1, 
58.6, 42.2 and 41.0; MS (ESI) m/z 450.3 (M
+















As a yellow solid (44.6 mg, 9%); m. p. 144- 147 °C, Rf 
(DCM: MeOH, 95: 0.5%) 0.21; IR νmax (DCM)/cm
-1
 
1746 (C=O), 1610 (Ar C=C), 1267 (C-O Ester);δH (400 
MHz; CDCl3) 8.48 (1H, d, J 5.5 Hz, H2), 7.98 (1H, s, 
H8), 7.84 (1H, d, J 8.9 Hz, H5), 7.41 (1H, d, J 9.0, H6), 
7.24 (2H, d, J 8.6 Hz, 2 x H4’), 6.86 (2H, d, J 8.6 Hz, 2 x H3’), 6.45 (1H, br s, NH), 6.25 
(1H, d, J 5.5 Hz, H3), 4.74 (1H, d, J 4.4 Hz, H1’), 4.71 (1H, d, J 4.4 Hz, H2’), 3.79 (3H, s, 
H5’), 3.52 (2H, t, J 4.6 Hz, H9), 3.47 (1H, m, H10a), 3.41 (1H, m, H10b), 2.92 (3H, s, H6’); 
δC (101 MHz; CDCl3) 169.0, 160.3, 151.1, 150.1, 148.3, 135.5, 129.7 (2C), 127.9, 125.9, 
124.8, 122.0, 117.2, 114.1 (2C), 98.4, 85.3, 62.9, 58.2, 55.3, 42.5 and 40.9; MS (ESI) m/z 
412.1 (M
+
), HPLC purity: 95.6%; tr’=8.43 min.  
 
1-[2-(7-Chloroquinolin-4-ylamino)ethyl]-3-methoxy-4-p-tolylazetidin-2-one, 4.22e (BL5) 
 
As a yellow solid (21 mg, 6%); m. p. 78- 82 °C, Rf 
(DCM: MeOH, 95: 0.5%) 0.31; IR νmax (DCM)/cm
-1
 
1744 (C=O), 1604 (Ar C=C), 12652 (C-O Ester); δH 
(400 MHz; CDCl3) 8.49 (1H, d, J 1.3 Hz, H8), 8.04 
(1H, d, J 5.7 Hz, H2), 7.88 (1H, d, J 9.0 Hz, H5), 7.41 
(1H, dd, J 9.0 and 1.3 Hz Hz, H6), 7.20 (2H, d, J 8.0 Hz, 2 x H4’), 7.14 (2H, d, J 8.0 Hz, 2 x 
H3’), 6.78 (1H, br s, NH), 6.24 (1H, d, J 5.7 Hz, H3), 4.77 (1H, d, J 4.3 Hz, H1’), 4.73 (1H, 
d, J 4.3 Hz, H2’), 3.52 (2H, m, H9), 3.47 (2H, m, H10), 3.13 (3H, s, H6’), 2.35 (3H, s, H5’); 
δC (101 MHz; CDCl3) 169.0, 150.7, 150.1, 147.1, 139.1, 136.0, 129.4 (2C), 128.9, 128.4 
(2C), 126.8, 126.1, 122.3, 117.0, 98.2, 85.3, 63.1, 58.2, 42.5, 40.9 and 21.6; MS (ESI) m/z 
396.2 (M
+
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 1-[3-(7-Chloroquinolin-4-ylamino)propyl]-3-methoxy-4-phenylazetidin-2-one, 4.22f (BL6) 
 
As a yellow paste (19.6 mg, 5%); Rf (DCM: MeOH, 
95: 0.5%) 0.41; IR νmax (DCM)/cm
-1
 1745 (C=O), 
1609 (Ar C=C), 1269 (C-O Ester); δH (300 MHz; 
CDCl3) 8.50 (1H, d, J 5.4 Hz, H2), 7.95 (1H, d, J 
2.0 Hz, H8), 7.84 (1H, d, J 9.0 Hz, H5), 7.40 (1H, 
m, H6), 7.36 (5H, m, ArH), 6.36 (1H, d, J 5.4 Hz, H3), 6.08 (1H, br s, NH), 4.73 (1H, d, J 4.4 
Hz, H1’), 4.70 (1H, d, J 4.4 Hz, H2’), 3.49 (3H, s, H6’), 3.43 (2H, m, H11), 3.18 (2H, m, 
H9), 1.80 (1H, m, H10a), 1.64 (1H, m, H10b); δC (75 MHz; CDCl3) 169.2, 155.2, 147.5, 
140.1, 136.8, 136.2, 129.0, 128.7, 128.5, 128.1, 126.6, 125.9, 124.3, 122.1, 117.5, 98.5, 85.1, 
61.9, 57.8, 42.1, 40.5 and 26.7; MS (ESI) m/z 396.7 (M
+
+H),  HPLC purity: 97.2%; tr’=9.06 
min.  
 
1-[4-(7-Chloroquinolin-4-ylamino)butyl]-3-methoxy-4-phenylazetidin-2-one, 4.22g (BL7) 
 
As a yellow solid (28 mg, 9%); m. p. 86- 89 °C, 
Rf (DCM: MeOH, 95: 0.5%) 0.31; IR νmax 
(DCM)/cm
-1
 1739 (C=O), 1599 (Ar C=C), 1258 
(C-O Ester); δH (400 MHz; CDCl3) 8.39 (1H, d, 
J 9.0 Hz, H5), 8.28 (1H, d, J 5.6 Hz, H2), 8.05 
(1H, s, H8), 7.92 (1H, br s, NH), 7.36 (6H, m, H6 and ArH), 6.39 (1H, d, J 5.6 Hz, H3), 4.76 
(1H, d, J 4.3 Hz, H1’), 4.73 (1H, d, J 4.3 Hz, H2’), 3.44 (4H, m, H9 and H12), 3.09 (3H, s, 
H6’), 1.92 (2H, m, H10), 1.72 (2H, m, H11); δC (101 MHz; CDCl3) 167.7, 153.5, 145.6, 
142.7, 137.7, 133.5, 128.8, 128.5 (2C), 128.4, 126.7, 126.2, 124.1, 123.1, 116.3, 98.1, 85.4, 
62.4, 58.1, 43.2, 40.9, 25.6 and 25.1; MS (ESI) m/z 410.5 (M
+
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6.5 Procedures for biological evaluation 
6.5.1 In vitro Antiplasmodial assays:11 3D7 and K1 strains (London School of 
Hygiene and Tropical Medicine, UK) 
 
Two clones of P. falciparum were used: (a) the 3D7 clone of NF54 which is known to be 
sensitive to all anti-malarials, (b) the K1 strain originating from Thailand that is resistant to 
chloroquine and pyrimethamine, but sensitive to mefloquine. The cultures are naturally, 
asynchronous (65-75% ring stage) and were maintained in continuous log phase growth in 
RPMI 1640 supplemented with 5% washed human A+ erythrocytes , 25mM HEPES, 32nM 
NaHCO3  and AlbuMAXII (lipid rich bovine serum albumin) (GIBCO, Grand Island, NY) 
(CM). All cultures and assays were conducted at 37
o
C under an atmosphere of 5% CO2 and 
5% O2, with a balance N2. These assays were performed in various stages i.e. the primary and 
secondary screens. 
 
Drug sensitivity assays 
Stock drug solutions were prepared in 100% DMSO (dimethylsulfoxide) at 20 mg/ml unless 
otherwise suggested by the supplier. The compound is further diluted to the appropriate 
concentration using complete medium RPMI1640 supplemented with 15nM cold 
hypoxanthine and AlbuMAXII. 
 
Assays were performed in sterile 96-well microtitre plates, each plate containing 100 μl of 
parasite culture (0.5% parasitemia, 2.5% hematocrit). The test compounds were tested in 
triplicate and parasite growth compared to the control and blank (uninfected erythtocytes) 
wells. After 24h of incubation at 37°C, 3.7Bq of [
3
H]hypoxanthine was added to each well 
[1]. Cultures were incubated for a further 24 h before they were harvested onto glass-fiber 
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counter. The results were recorded as counts per minute (CPM) per well at each compound 
concentration, control and blank wells. Percentage inhibition was calculated from comparison 
to blank and control wells, and IC50 values calculated using GraphPad Prism 4.0. 
 
Primary Screen 
The primary screen used the 3D7 strain. The test compounds were tested at 6 concentrations 
(30, 10, 3, 1, 0.3, and 0.1µg/mL). Compounds that did not affect parasite growth at 10µg/mL 
are considered inactive, between 10 and 11µg/mL are designated as partially active and if 
<1µg/mL the compound was classified as active and was further evaluated by three-fold 
serial dilutions in a repeat test. 
 
Secondary Screen  
In this screen both 3D7 and K1 were used. The test drug was diluted 3-fold over at 12 
different concentrations with an appropriate starting concentrations based on the primary 
screen. The IC50 values were determined by sigmoidal dose response analysis using Microsoft 
XLFit (IDBS, UK). For each assay, the IC50 values for each parasite line were determined 
against CQ and other standard compounds appropriate for the assay.  
 
6.5.2 In vitro Antiprotozoan and cytotoxicity assays: T.b. brucei rhodesiense 
STIB900, K1 and L6 mammalian cell-line (Swiss Tropical and Public Health 
Institute, Switzerland) 
 
Activity against Trypanosoma brucei rhodesiense STIB900
12,13,14 
 
This stock was isolated in 1982 from a human patient in Tanzania and after several mouse 
passages was cloned and adapted to axenic culture conditions (Baltz et al 1985) Minimum 
Essential Medium (50 µl) supplemented with 25 mM HEPES, 1g/l additional glucose, 1% 
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15% heat inactivated horse serum were added to each well of a 96-well microtiter plate. 
Serial drug dilutions of eleven three-fold dilution steps covering a range from 100 to 0.002 
μg/ml were prepared. Then, 4x10
3
 bloodstream forms of T. b. rhodesiense STIB 900 in 50 µl 
was added to each well and the plate incubated at 37 °C under a 5 % CO2 atmosphere for 70 
h. 10 µl Alamar Blue (resazurin, 12.5 mg in 100 ml double-distilled water)
 
was then added to 
each well and incubation continued for a further 2–4 h (Raz et al 1997). Then the plates were 
read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave 
length of 588 nm. The IC50 values were calculated by linear regression (Huber 1993) from 
the sigmoidal dose inhibition curves using SoftmaxPro software (Molecular Devices 
Cooperation, Sunnyvale, CA, USA). 
 
Activity against K1 strain of P. falciparum,
11,15
  
In vitro activity against erythrocytic stages of P. falciparum was determined using a 
3
H-
hypoxanthine incorporation assay, using the chloroquine and pyrimethamine resistant K1 
strain that originate from Thailand and the standard drug chloroquine (Sigma C6628). 
Compounds were dissolved in DMSO at 10 mg/mL and added to parasite cultures incubated 
in RPMI 1640 medium without hypoxanthine, supplemented with HEPES (5.94 g/l), 
NaHCO3 (2.1 g/l), neomycin (100 U/mL), Albumax
R
 (5 g/l) and washed human red cells A
+
 
at 2.5% haematocrit (0.3% parasitaemia). Serial drug dilutions of eleven three-fold dilution 
steps covering a range from 100 to 0.002 μg/ml were prepared. The 96-well plates were 
incubated in a humidified atmosphere at 37 °C; 4% CO2, 3% O2, 93% N2. After 48 h 50 μl of 
3
H-hypoxanthine (=0.5 μCi) was added to each well of the plate. The plates were incubated 
for a further 24 h under the same conditions. The plates were then harvested with a 
Betaplate™ cell harvester (Wallac, Zurich, Switzerland), and the red blood cells transferred 
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plastic foil with 10 mL of scintillation fluid, and counted in a Betaplate™ liquid scintillation 
counter (Wallac, Zurich, Switzerland). IC50 values were calculated from sigmoidal inhibition 
curves by linear regression using Microsoft Excel. 
 
In vitro cytotoxicity with L-6 cells
16,17
 
Assays were performed in 96-well microtiter plates, each well containing 100 l of RPMI 
1640 medium supplemented with 1% L-glutamine (200mM) and 10% fetal bovine serum, 
and 4000 L-6 cells (a primary cell line derived from rat skeletal myoblasts). Serial drug 
dilutions of eleven three-fold dilution steps covering a range from 100 to 0.002 μg/mL were 
prepared. After 70hours of incubation the plates were inspected under an inverted microscope 
to assure growth of the controls and sterile conditions. 10l of Alamar Blue was then added 
to each well and the plates incubated for another 2 hours. Then the plates were read with a 
Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, 
CA, USA) using an excitation wave length of 536 nm and an emission wave length of 588 
nm. The IC50 values were calculated by linear regression (Huber 1993) from the sigmoidal 
dose inhibition curves using SoftmaxPro software (Molecular Devices Cooperation, 
Sunnyvale, CA, USA). 
 
6.5.3 In vitro Antiplasmodial assays:18,19
 
W2 strain (Department of Medicine, San 
Francisco General Hospital, University of San Francisco) 
 
The protocol to this assay is as described by Rosenthal, et al,
18
 1996. The W2 (CQ resistant) 
strain of P. falciparum (1% parasitemia, 2% hematocrit), were cultured in 0.5ml of medium 
in 48-well culture dishes. Stock solutions of inhibitors (10mM) in DMSO were added to 
cultured parasites to a final concentration of 20µM. From the 48-well plates, 125µM of 
culture was transferred to two 96-well plates (duplicates). Serial dilutions (1%) of inhibitors 










Chapter 6: Experimental  
235 
were maintained at 37
o
C for 2 days after which the parasites were washed and fixed with 1% 
formaldehyde in PBS. After 2 days parasitemia was measured by flow cytometry using the 
DNA stain YOYO-1 as a marker of cell survival. 
 
6.5.4 In vitro Antimycobacterial evaluation:20,21,22
 
MABA and LORA Assays 
(Institute of Tuberculosis Research, College of Pharmacy, Univirsity of Chicago) 
 
MIC vs. replicating M. tuberculosis H37Rv. 
All compounds were evaluated for MIC vs. M. tuberculosis H37Rv (ATCC 27294) using the 
microplate Alamar Blue assay (MABA) as previously described
20
 except that we now use 
7H12 media (3) (instead of 7H9 + glycerol + casitone + OADC). In the case of compounds 
exhibiting significant background fluorescence, luciferase reporter strains of M. tuberculosis 
H37Rv were utilized as well as measurement of intracellular adenosine triphosphate. Cultures 
were incubated in 200 ul medium in 96-well plates for 7 days at 37C. Alamar Blue and 
Tween 80 are added and incubation continued for 24 hours at 37C. Fluorescence is 
determined at excitation/emission wavelengths of 530/590 nm, respectively. The MIC is 
defined as the lowest concentration effecting a reduction in fluorescence (or luminescence) of 
90% relative to controls. Six control compounds are run in each experiment including 
isoniazid, rifampin, moxifloxacin, streptomycin, PA-824 and metronidazole.  
 
Activity against non-replicating persistant (NRP) M. tuberculosis 
This Low Oxygen Recovery Assay (LORA)
21
 was designed to detect compounds which may 
have the potential for shortening the duration of therapy through (more) efficient killing of 
the non-replicating persistor (NRP) population. The assay involves 1) adaptation of M. 
tuberculosis to low oxygen through gradual, monitored, self-depletion of oxygen during 
culture in a sealed flask with slow stirring, 2) exposure for 10 days of the low-oxygen 
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environment using an Anoxomat system, thus precluding growth and 3) subsequent 
evaluation of M. tuberculosis viability as determined by the ability to recover. 
Recovery/viability is determined by the extent to which a luciferase-expressing strain can 
recover the ability to produce luminescence. This assay is HTS-compatible. Compounds such 
as isoniazid and ethambutol which are considered to be devoid of “sterilizing activity”, are 
inactive in this assay Confirmation of new classes with activity was made by immediate 
subculture (without recovery phase) onto solid, drug-free media and determination of colony 
forming units. While the rifamycins and the more potent fluoroquinolones, which do appear 
to eliminate some proportion of the persistor population and thus can affect treatment 
duration, are active, albeit at concentrations higher than the MICs for replicating cultures. 
Correlation between the cfu and luminescence readout has been good with the exception of 
the fluoroquinolone class for which luminescence underestimates absolute activity but not 
relative activity.  
 
Cytotoxicity Assay 
Compounds are routinely tested for cytotoxicity using VERO cells
22
. After 72 hours 
exposure, viability is assessed on the basis of cellular conversion of MTS into a soluble 
formazan product using the Promega CellTiter 96 Aqueous Non-Radioactive Cell 
Proliferation Assay.  Rifampin is included as a control. For compounds with IC50:MIC >10, 
cytotoxicity will be repeated, this time using the J774.1 macrophage cell line since these are 
used in the macrophage assay and are usually somewhat more sensitive than VERO cells. 
This is important for interpreting data from the macrophage assay. Since much more 
comparative data is available for VERO cells, the use these for primary cytotoxicity testing is 
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6.5.5 In vitro Antimycobacterial evaluation:23 7 and 14 day assays 
Culture preparation of the mycobacterium 
Mycobacterial tuberculosis H37Rv drug-sensitive strain was grown on Middlebrook 7H10 
(Merck) supplemented with 0.5% glycerol and 10% Middlebrook Oleic acid Dextros catalase 
(OADC) enrichment (Merck) for five days at 37 °C, without shaking. To prepare the 
suspension for inoculation, the cultures were vortexed, left for 45 seconds to allow heavy 
particles to settle, followed by dilution. 
 
Broth microdilution method assay 
The broth microdilution method allows a range of antibiotic concentrations to be tested, on a 
single 96-well (8 by 12) microtitre plate, to determine the minimum inhibitory concentration 
(MIC). Briefly, a 10 mL culture of M. tuberculosis is grown to an OD600 of 0.7. The culture 
is then diluted 1:500 in 7H9 media. In a 96- well microtitre plate, 50 μl of 7H9 media was 
added to all wells starting from Rows 2-12. In the first and last wells of Row 1, 100 μl of 7H9 
media was added as a control. The test compounds were added to Row 1 at a final 
concentration of 640 µM (stock concentration of 12.8 mM in DMSO, diluted to final 
concentration in 7H9 media). A serial dilution was prepared using a multichannel pipette by 
transferring 50 μl of the liquid in Row 1 to Row 2, followed by aspirating to mix. A 50 μl of 
the liquid in Row 2 was transferred to Row 3 and aspirated. The procedure was repeated until 
Row 12 was reached, where 50 μl of the liquid in Row 12 was discarded to bring the final 
volume in each well to 50 μl. 
 
Finally, the 50 μl of the diluted M. tuberculosis culture was added to all the wells starting 
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